7 000 844 E
Roche
|
Annual
Report
2009
Key figures
1 Key figures indexed to 2007 = 100. Figures for 2007 as in Annual Report 2008.
2 Before exceptional items. For a full index of Global Reporting Initiative (GRI)
3 Proposed by the Board of Directors. indicators used in the report see:
4 Development phase I to IV. www.roche.com/reporting_and_indices
5 For calculation of the Eco-Efficiency Rate see:
www.roche.com/environment
E
Roche
i
ance
Report
2009
09
Roche Annual R eport
F.HoPfufmbalnshn-eLda Roche Ltd
4070F BHaosfefml, aSnwnit-zear lRanodc
© 2010
All trademarks are legally protec ted.
www.roche.com
Excellence in Science
7 0 8 04060
00_Umschlag_ausgeschossen_ENGindd 1 29012010 14:20:50Key figures
1 Key figures indexed to 2007 = 100. Figures for 2007 as in Annual Report 2008.
2 Before exceptional items. For a full index of Global Reporting Initiative (GRI)
3 Proposed by the Board of Directors. indicators used in the report see:
4 Development phase I to IV. www.roche.com/reporting_and_indices
5 For calculation of the Eco-Efficiency Rate see:
www.roche.com/environment
00_L_Roche_AR09_ENG_Key figuresindd 1 29012010 14:20:10The year 2009 in brief
Group
• Group sales increase by 10% 1 to 49.1 billion Swiss francs (8% in Swiss francs; 7% in US dollars).
Both divisions gain market share.
• Operating profit before exceptional items increases by 14% (8% in Swiss francs) to 15.0 billion
Swiss francs due to strong sales growth and continuing productivity improvements; at the same time
investments in research and development increase by 12% to 9.9 billion Swiss francs.
• Effective 26 March 2009, Roche obtains full ownership of Genentech for a price of 47.0 billion US dollars,
or 52.7 billion Swiss francs. Genentech integration has been completed.
• Net income of 8.5 billion Swiss francs, down by 22% compared with the previous year due to exceptional
items relating to the Genentech transaction and integration.
• Excluding exceptional items, the Genentech transaction is already contributing to income:
income attributable to Roche shareholders increases by 9% to 9.8 billion Swiss francs.
• Core EPS at constant exchange rates 20% above 2008 (10% in Swiss francs).
• Board proposes a dividend increase of 20% to 6.00 Swiss francs, the 23rd consecutive year of
dividend growth; this would increase the payout ratio to 53%.
Pharmaceuticals
• Pharma sales grow by 11% (8% in Swiss francs; 8% in US dollars), almost twice the global market
growth rate, driven by leading cancer medications and Tamiflu (influenza medicine) as well as Lucentis
(ophthalmology medicine).
• Tamiflu sales grow sharply to 3.2 billion Swiss francs following substantially increased demand during
the pandemic influenza A(H1N1) virus (‘swine flu’) outbreak.
• Operating profit margin before exceptional items increases 1.2 percentage points at constant exchange
rates (+0.2 percentage points in Swiss francs).
• Strong R&D pipeline with ten new molecular entities in late-stage clinical testing; six new compounds
entered phase III clinical trials in 2009.
• Actemra approved in US for treatment of rheumatoid arthritis in January 2010.
Diagnostics
• Sales increase by 9% (4% in Swiss francs and 4% in US dollars) to 10.1 billion Swiss francs, more than
twice the market growth rate.
• Operating profit margin at constant exchange rates increases 0.4 percentage points (–0.4 percentage points
in Swiss francs).
Outlook
• Full-year 2010 sales for Pharmaceuticals and the Group expected to grow in the mid-single-digit range 2.
• Expected decrease of Tamiflu sales from 3.2 to 1.2 billion Swiss francs.
• Diagnostics sales expected to grow well ahead of market.
• Planned research and development expenses will decline slightly in 2010 compared to 2009.
• Roche confirms target of double-digit Core Earnings per Share growth 3 in 2010.
• Based on the strong operating free cash flow, Roche expects to reduce debt progressively and to return
to a net cash position by 2015 while maintaining its attractive dividend policy.
1 Unless otherwise stated, all growth rates are in local currencies.
2 Without Tamiflu sales.
3 At constant exchange rates.
Barring unforeseen events.
01_L_Roche_AR09_ENG_Highlightsindd 1 29012010 10:1403Pharmaceuticals pipeline | Focused on compounds
with first-in-class or best-in-class potential
Phase I Phase II Phase III Registration
Project ID Project/Product Indication Project ID Project/Product Indication Project ID Project/Product Indication Project ID Project/Product Indication
Oncology Oncology Oncology Oncology
RG4733 γ-secretase inh solid tumours RG435 Avastin multiple myeloma RG105 MabThera/Rituxan indolent NHL maint, 1st-line RG105* MabThera/Rituxan chronic lympocytic leukemia,
RG7160 anti-EGFR huMAb solid tumours RG435 Avastin metastatic melanoma RG340 Xeloda+Avastin adj colon cancer 1st-line
RG7167 CIF/MEK inh solid tumours RG1273 pertuzumab neoadj breast cancer, HER2+ RG340 Xeloda adj breast cancer RG105* MabThera/Rituxan chronic lympocytic leukemia,
RG7304 — solid tumours RG3502 trastuzumab-DM1 metastatic BC, HER2+, 3rd-line RG435 Avastin+MabThera diffuse large B cell lymphoma relapsed
RG7334 anti-PlGF MAb solid tumours RG3502 trastuzumab-DM1 metastatic BC, HER2+, 1st-line RG435 Avastin adj colon cancer RG340 Xeloda adj colon cancer, combo
RG7347 anti-NRP1 MAb solid tumours RG3616 hedgehog pathway inh basal cell carcinoma RG435 Avastin prostate cancer oxaliplatin
RG7112 MDM2 antag solid and hematologic tumours RG3616 hedgehog pathway inh colocrectal cancer RG435 Avastin adj breast cancer HER2+ RG435* Avastin mBC 1st-line combo docetaxel
RG3639 dulanermin cancer RG3616 hedgehog pathway inh ovarian cancer RG435 Avastin ovarian cancer, 1st-line RG435 Avastin mBC 1st-line combo standard
RG7420 MEK inh solid tumours RG7159 anti-CD20 huMAb non-Hodgkin’s lymphoma RG435 Avastin+Herceptin mBC, HER2+, 1st-line chemotherapies
RG7422 PI3 kinase inh solid and hematologic tumours RG3638 anti-MET huMAb metastatic NSCLC RG435 Avastin adj NSCLC RG597 Herceptin met gastric cancer HER2+
RG7321 PI3 kinase inh solid tumours RG7433 (ABT-263) solid and hematologic tumours RG435 Avastin met gastric cancer RG1415 Tarceva NSCLC 1st-line maintenance
RG7414 anti-EGFL7 MAb solid tumours CHU topoisomerase I inh gastric cancer RG435 Avastin adj breast cancer HER2–
CHU anti-Glypican MAb liver cancer RG435 Avastin adj BC, triple negative Inflammation and autoimmune disorders
Inflammation and autoimmune disorders RG435 Avastin mBC HER2–, combo hormonal RG105 MabThera/Rituxan rheumatoid arthritis, DMARD
Inflammation and autoimmune disorders RG667 palovarotene emphysema therapy inadequate responders
RG7413 anti-Beta7 rhuMAb ulcerative colitis RG3637 lebrikizumab asthma RG435 Avastin ovarian cancer platinum- RG3648* Xolair pediatric asthma
RG7416 anti-LT alpha MAb rheumatoid arthritis RG4930 OX40L huMAb asthma sensitive CHU eldecalcitol (ED-71) osteoporosis
BTI VAP-1 inflammatory diseases RG7415 rontalizumab systemic lupus erythematosus RG435 Avastin mBC, 2nd-line
RG3648 Xolair chronic idiopathic urticaria RG435 Avastin high-risk carcinoid Virology
Virology RG435 Avastin GBM, 1st-line RG127 Valcyte cytomegalovirus, extension
CHU serine palmitoyltrans- hepatitis C Virology RG597 Herceptin SC formulation, BC HER2+ of treatment
ferase inh RG3484 HPV16 immunotherapy cervical neoplasia RG597 Herceptin adj BC HER2+, 2-yr treatment
CHU nitazoxanide hepatitis C RG7128 nucleoside inh prodrug hepatitis C RG1273 pertuzumab mBC HER2+ Ophthalmology
RG7227 protease inh hepatitis C RG1415 Tarceva NSCLC EGFR mutation- RG3645 Lucentis retinal vein occlusion
Cardiovascular and metabolic diseases positive, 1st-line
RG7089 Y2R peptide agonist type 2 diabetes Cardiovascular and metabolic diseases RG1415 Tarceva adj NSCLC Others
RG1512 anti-P selectin huMAb peripheral vascular disease RG1439 aleglitazar cardiovascular risk reduction RG1415 Tarceva+Avastin NSCLC maint, 1st-line CHU Epogin (EPOCH) chemo-induced anemia
RG4929 11β-HSD inh type 2 diabetes RG7201 SGLT2 inh type 2 diabetes RG7159 anti-CD20 huMAb chronic lymphocytic leukemia
RG7234 11β-HSD inh type 2 diabetes RG7204 BRAF inh malignant melanoma
RG7273 ABCA1 inducer dyslipidemia Central nervous system RG3502 trastuzumab-DM1 mBC HER2+, 2nd-line
RG7376 CRAF inh polycystic kidney disease RG1594 ocrelizumab relapsing–remitting MS
RG7418 anti-oxLDL MAb secondary prevention RG1678 GLYT1 inh schizophrenia Inflammation and autoimmune disorders
of cardiovascular events RG3487 nicotinic α7 receptor Alzheimer’s disease RG105 MabThera/Rituxan ANCA-associated vasculitis
RG7426 (BHT-3021) type 1 diabetes agonist RG1569 Actemra/RoActemra JIA, systemic onset
RG7090 mGluR5 antag treatment-resistant depression RG1569 Actemra/RoActemra early rheumatoid arthritis
Central nervous system RG1594 ocrelizumab rheumatoid arthritis, PJD
RG1450 gantenerumab Alzheimer’s disease RG3648 Xolair asthma, add-on therapy
RG1578 mGluR2 antag depression
RG1662 GABA-A agonist Alzheimer’s disease Selected abbreviations Cardiovascular and metabolic diseases Legend
RG7010 IGF1 PEG amyotrophic lateral sclerosis adj adjuvant treatment inh inhibitor RG1583 taspoglutide type 2 diabetes Therapeutic protein, other biologic
RG7166 triple reuptake inh depression AMD age-related macular JIA juvenile idiopathic arthritis RG1658 dalcetrapib dyslipidemia Small molecule
degeneration MAb monoclonal antibody
RG7351 TAAR1 partial agonist depression Blue type First indication
antag antagonist maint maintenance treatment
RG7412 anti-amyloid β-peptide Alzheimer’s disease BC breast cancer m, met metastatic (cancer) Ophthalmology Black type Additional indications
MAb combo combined with MS multiple sclerosis RG3645 Lucentis diabetic macular edema
DMARD disease-modifying NHL non-Hodgkin’s lymphoma
EVO NMDA receptor antag treatment-resistant depression antirheumatic drug NSCLC non-small cell lung cancer RG3645 Lucentis AMD, high dose RG-No. Roche and/or Genentech managed
GBM glioblastoma multiforme PJD prevention of joint CHU Chugai managed
Ophthalmology HER2+ HER2-positive destruction Others BTI BioTie opt-in
HER2– HER2-negative r recombinant EVO Evotec
RG7417 anti-factor D MAb geographic atrophy HPV human papilloma virus SC subcutaneous RG3625 TNKase catheter clearance
hu humanised
Phase I Initial studies in healthy volunteers and possibly in patients
Phase II Efficacy, tolerability and dose-finding studies in patients
Phase III Large-scale studies in patients for statistical confirmation of safety
and efficacy
Registra- Marketing application(s) filed in EU, US and/or Japan
tion
* Approved EU
Current as of January 2010
00_Umschlag_ausgeschossen_ENG indd 2 29012010 14:20:50Our Business | Innovation is our
answer to medical challenges. Our daily
work is saving patients’ lives and helping
millions of people around the world
through excellence in science.
Focus on unsolved medical problems
For more than 110 years Roche has played a pioneer- These include cancers, viral infections, metabolic and
ing role in healthcare. Today, as the world leader in central nervous system disorders and inflammatory
in vitro diagnostics, we supply a wide range of diag- diseases. Roche is a pioneer in personalised health-
nostic instruments and tests for rapid and reliable care: we aim to fit treatments as closely as pos sible
disease detection and monitoring by doctors, labora- to patients’ needs — to make healthcare better, safer
tories and patients themselves. As the world’s largest and more cost-effective.
biotech company Roche has brought many highly
effective drugs to market and become the world’s
leading supplier of prescription drugs for cancer
treatment. Our daily work focuses on disease areas
where medical needs are great.
02_L_Roche_AR09_ENG_Table of Contentsindd 2 29012010 01:4705Contents
Key figures
Inside cover
Pharmaceuticals pipeline
Inside cover
1
The year 2009 in brief
4
Letter to Shareholders
10
Roche Group
11 Group results
12 Outlook
14 Group strategy
20
Pharmaceuticals
21 Pharmaceuticals Division in brief
22 Results
24 Sales review
30 Development highlights
36 Research and development
46
Diagnostics
47 Diagnostics Division in brief
49 Results
52 Business area highlights
57 Research and development
64
Corporate Governance, Remuneration Report
65 Corporate Governance
75 Remuneration Report
88
Corporate Responsibility
89 In brief
90 Responsible practices
97 Patients
1 04 People
112 Society
114 Safety, security, health and
environmental protection
121
Independent Assurance Report
122 GRI statement
02_L_Roche_AR09_ENG_Table of Contentsindd 3 29012010 01:47064
Roche Business Report 2009 Letter to Shareholders
Letter to Shareholders
Franz B. Humer
Dear Shareholders
Despitethesustainedglobalfinancialandeconomiccrisis,2009wasaverysuccessfulyearforRoche.Sales
inboththePharmaceuticalsandtheDiagnosticsDivisiongrewtwiceasfastasthemarket.Groupsales
increasedby10%inlocalcurrenciesto49.1billionSwissfrancs,mainlydrivenbyourleadingmedicines
totreatpatientswithcancer,viralinfections,age-relatedblindnessandotherseriousdiseases.Salesof
theinfluenzamedicineTamiflu,at3.2billionSwissfrancs,alsocontributedsignificantlytorevenuegrowth.
Operatingprofitbeforeexceptionalitemsgrewevenmorestronglythansales,advancing14%inlocal
currenciesto15.0billionSwissfrancs.
2009willberememberedasoneofthemostimportantyearsinyourcompany’slonghistory.Followingthe
mergeragreementwithGenentechinMarch2009andtherapidfinalisationofthetransaction,wewere
abletocompletetheintegrationbytheendoftheyear.BycombiningRocheandGenentechwearenotonly
increasingoperationalefficiencybutalsopromotinginternalknowledgetransfer.Wearecommittedto
strengtheningtheRocheGroup’sinnovativepowerinthelongtermandto providingpatientswithinno-
vativemedicinesthroughresearchofthehighestquality.
Excellentresearchisandwillremainabasicrequirementforthedevelopmentoftherapiesthataredecisive
forpatients’healthandqualityoflife.AfterconcludingtheGenentechintegrationwewillcontinueto
systematicallypursuediverseresearchapproachesforinnovativehealthcaresolutions.Thiscreatesscope
forcreativityandincreasesthechancesofdevisingsustainablemedicalandtherapeuticprogress.For
thisreasonGenentechResearchandEarlyDevelopmentwillcontinuetofunctionasanindependentunit.
03_L_Roche_AR09_ENG_Letter to Shareholdersindd 4 29012010 10:15:435
Severin Schwan
Inaddition,combiningtheactivitiesofthetwocompaniesintheareasofproductdevelopment,production
andsaleshasalreadygeneratedsignificantincreasesinproductivity.Ouraimistoachievepre-taxannual
savingsofapproximately1billionSwissfrancsby2011.
TheoperatingfreecashflowoftheGroupincreasedby27%to15.7billionSwissfrancsdespitesignificant
negativecurrencyeffects.Roche’sstrongoperatingperformanceisalsoclearlyreflectedinCoreEarnings
perShare,whichadvanced20%inlocalcurrencies(10%inSwissfrancs).
Asaresultofexceptionalcostsof2.7billionSwissfrancs,whichwereprimarilyintegration-related,
theGroup’soperatingprofitin2009declinedby5%inlocalcurrencies(12%inSwissfrancs)to12.3billion
Swissfrancs.Exceptionalitemsalsoimpactednetincome,whichdeclinedby22%comparedwiththe
previous-yearperiodto8.5billionSwissfrancs.Excludingexceptionalitems,netincomeattributableto
Rocheshareholdersincreasedby9%.
InviewofRoche’sstrongfull-yearoperatingresults,attheAnnualGeneralMeetingtheBoardofDirectors
willproposeanincreaseof20%inthedividendfor2009to6.00Swissfrancspershareandnon-voting
equitysecurity(2008:5.00Swissfrancs).Subjecttoyourapproval,thiswillbethe23rdconsecutive
annualdividendincrease.
03_L_Roche_AR09_ENG_Letter to Shareholdersindd 5 29012010 10:15:446
Roche Business Report 2009 Letter to Shareholders
TherapidspreadofthepandemicA(H1N1)influenzavirus(‘swineflu’),whichbeganinApril2009,pre-
sentedamajorchallengenotonlyforgovernmentsworldwide,butalsoforRocheduringthepastyear.We
havebeensupportingtheWorldHealthOrganization(WHO)andnationalgovernmentsinglobalefforts
tofightthenewvirus.InMayRocheannouncedthatanadditional5.65milliontreatmentcoursesofTamiflu
wouldbedonatedtoreplenishtheWHO’sregionalandrapid-responsestockpiles.Wehadpreviously
grantedsublicencestothreemanufacturerstoproducegenericoseltamivirforpandemicuseinChina,
Indiaandspecifieddevelopingcountries,toensurethatlocalpopulationsintheseareashaveaccessto
themedication.Inaddition,inJulyweinitiatedtheTamifluReservesProgramtofurtherimproveTamiflu
accessindevelopingcountries.InresponsetotheincreasedWHOpandemicthreatlevel,ournetworkof
manufacturingpartnersscaledupproductiontoapproximately33milliontreatmentcoursespermonth,
andwearenowabletosupplyupto400millionpacksannually,ifrequired.
TheRocheGroupreceivedsignificantrecognitionforachievementsinseveralareasduringthepastyear.
TheDowJonesSustainabilityIndexesnamedRochethenew‘SuperSectorLeader’inHealthcare,
rankingusasthemostsustainablehealthcarecompanyworldwide.RocheandGenentechwerealso
againvoted‘bestemployer’inanumberofcountries.
Wewouldliketotakethisopportunitytothankthemorethan80,000Groupemployeesworldwideforthe
outstandingdedicationandprofessionalismduringthiseventfulandchallengingtime.
Scientificexcellenceandinnovationinourcorepharmaanddiagnosticsbusinesseswillcontinuetobethe
foundationofoursuccess.Asidefromoncology,wearedevelopingnewtherapeuticsformetabolicand
autoimmunediseases,viralinfectionsanddisordersofthecentralnervoussystem.Astheworld’slargest
biotechcompanywehaveoneofthemostpromisingR&Dpipelinesintheworld.Fromatotalof59new
molecularentitiesinclinicaltesting,tenarealreadyinlatestagedevelopment—whichisremarkablebyany
standardsinourindustry.Inthelastyearalone,sixnewcompoundsenteredlatephasedevelopment,
includingpotentialnewtherapiesforbreastcancerandtype2diabetes.
Duringtheyearwepublishedexcitingearlyphaseclinicaltrialdataonatargetedtreatmentandcom-
paniondiagnosticinmalignantmelanomapatientswhosecancercellscarryaspecificgeneticmutation;
malignantmelanomaisthedeadliestformofskincancer.Thenewcompoundeffectivelyslowedtumor
progressionandincreasedpatients’qualityoflife.Thisisabeaconofhopeinthefightagainstacancer
thatuntilnowhasbeenregardedasvirtuallyuntreatable.
AmongthekeyachievementsinourDiagnosticsDivisionarethestartoftherolloutofthecobas8000
modularanalyserseriesforlargemedicallaboratoriesandthelaunchofnewproductsintheAccu-Chek
lineofblood-glucosemonitorsforpeoplewithdiabetes.
Attheendof2009WilliamM.Burns,CEOofthePharmaceuticalsDivision,JürgenSchwiezer,CEOofthe
DiagnosticsDivision,andJonathanK.C.Knowles,HeadofRocheGroupResearch,lefttheCorporate
ExecutiveCommitteeasplanned.EachofthemhasmadesignificantcontributionstoRoche’ssuccessand
helpedwriteanimportantchapterinthecompany’shistory.Everygenerationofmanagershasthetask
ofensuringRoche’shealthyfutureasanindependentcompany.BillBurns,JonathanKnowlesandJürgen
Schwiezerhavefulfilledthistaskinanexemplarymannerdrivenbyprofoundconviction.Theyhave
03_L_Roche_AR09_ENG_Letter to Shareholdersindd 6 29012010 10:15:447
Bringing Genentech fully into the Roche
Group is a major step on the road to
creating a stronger, even more innovative
organisation
significantlycontributedtoRoche’sstrongmarketpositionandsuccess.OnbehalfoftheentireBoardof
DirectorsandtheCorporateExecutiveCommittee,wewouldliketothankthemfortheirmanyyearsof
invaluableservice,loyaltytoRocheandforthegreatworkingrelationshipweenjoyed.
Inviewoftheiroutstandingindustryknowledge,theBoardofDirectorswillproposeappointingWilliam
M.BurnsandArthurD.Levinson,ChairmanofGenentechBoardofDirectors,totheBoardofDirectorsof
RocheHoldingLtdattheAnnualGeneralMeetingon2March2010.
Prof.HorstTeltschikandPeterBrabeckhavedecidednottostandforre-electionatthe2010Annual
GeneralMeeting.Weareverygratefulfortheirvaluablecontributionstothecompanyoveraperiodofmany
years.
Barringunforeseenevents,weexpectsalesin2010forthePharmaceuticalsDivisionandfortheGroup
toincreaseinthemid-single-digitrangeinlocalcurrencies1.IntheDiagnosticsDivision,weexpectfull-year
salestogrowconsiderablyaheadofthemarket.Furthermore,weareaimingtoachievedouble-digit
CoreEarningsperSharegrowthatconstantexchangeratesin2010.Weanticipatethatwewillalreadyhave
repaid25%ofthedebtraisedtofinancetheGenentechtransactionbytheendof2010.Basedonthe
Group’sstrongoperatingfreecashflow,Rocheexpectstoreturntoanetcashpositionbytheendof2015.
Wewillsimultaneouslymaintainourattractivedividendpolicy.
FranzB.Humer SeverinSchwan
ChairmanoftheBoard ChiefExecutiveOfficer
1 Excluding Tamiflu sales.
03_L_Roche_AR09_ENG_Letter to Shareholdersindd 7 29012010 10:15:4404_Bildstrecke_ENG_S08-09indd 1 28012010 23:35:27She’s working on a starvation diet
for aggressive brain tumours
Roche is tackling some of modern medicine’s greatest challenges in its search for medicines to combat
serious illnesses for which no effective treatment exists. It’s a quest that requires both sophisticated
technological capabilities and deep insights into molecular biology. To select optimal targets for drug
treatment, you first need to understand the complex biological mechanisms driving a disease. In the
case of Avastin, the targeted blockade of a blood-vessel growth factor — an approach first developed
by Genentech scientists — starves tumours of the nutrients and oxygen they need to grow and spread.
This has fundamentally changed the way we fight cancer. Avastin is currently approved to treat five types
of cancer and is being investigated as a possible treatment in over 30 different tumour types, giving
hope to thousands of patients.
Avastin is a monoclonal antibody used to treat advanced colorectal, breast,
non-small cell lung and kidney cancer. In 2009 it was also approved in the
US and eleven other countries for the treatment of relapsed glioblastoma
multiforme, the most aggressive type of brain tumour.
04_Bildstrecke_ENG_S08-09indd 2 28012010 23:35:32Roche Group | Very strong operating
performance in 2009. Group sales, ope­
rating profit (before exceptional items) and
Core Earnings per Share increased by
double digits. Roche anticipates another
double­digit rise in Core EPS in 2010.
The Group remains firmly focused on
prescription drugs and in vitro diagnostics.
Following the successful integration of
Genentech, Roche is better equipped than
ever to be a healthcare innovator.
05_L_Roche_AR09_ENG_Groupindd 10 29012010 10:17:1811
Roche Group TheGroup’soperatingfreecashflowincreased
strongly,rising34%inlocalcurrencies(27%inSwiss
Strong sales and trading results francs)to15.7billionSwissfrancs.TheGroup’s
Totalsalesgrewby10%inlocalcurrencies(8%in freecashflowremainedstrongin2009,increasingby
Swissfrancs;7%inUSdollars)to49.1billionSwiss 3.9billionSwissfrancsto8.9billionSwissfrancs.
francs,withthePharmaceuticalsDivisionaccounting
for80%ofGroupsalesandtheDiagnosticsDivision CoreEPS,whichexcludesexceptionalitems
contributing20%.Salesgrowthinbothdivisions andamortisationandimpairmentofintangibleassets,
exceededmarketgrowth. increased20%inlocalcurrencies(10%inSwiss
francs).
SalesbythePharmaceuticalsDivisionincreased
11%inlocalcurrencies(8%inSwissfrancs;8%in Significant impact of Genentech integration and
USdollars)to39.0billionSwissfrancsoralmost changes in Group organisation
doubletheglobalmarketgrowthrate.Demandfor Effective26March2009,theGroupobtainedfull
theGroup’scancermedicinesAvastin,Herceptin, ownershipofGenentech.Subsequently,theGroup
MabThera/Rituxan,TarcevaandXelodacontinuedto commencedarestructuringofitsUSPharmaceuticals
growstrongly.Additionalmajorgrowthdriversin businessaswellasanumberofglobalfunctions.
thePharmaceuticalsDivisionwereTamifluinvirology During2009restructuringandintegrationcostsof
andLucentisinophthalmology. 2.4billionSwissfrancswereincurred,mainlyin
connectionwiththediscontinuationofaconstruction
TheDiagnosticsDivisionachievedsalesgrowthof9% projectatthemanufacturingsiteatVacaville,California,
inlocalcurrencies(4%inSwissfrancs;4%inUSdol­ terminationcostsfortheclosureofmanufacturing
lars)to10.1billionSwissfrancs,therebystrengthening operationsatNutley,NewJersey,theclosureofthe
thedivisionsleadingmarketshareofaround20%. researchanddevelopmentsiteatPaloAlto,California,
andcostsassociatedwiththeconsolidationofthe
TheGroup’soperatingprofitbeforeexceptionalitems USadministrativefunctionsinSouthSanFrancisco.
increasedby14%inlocalcurrencies(8%inSwiss Approximately1.8billionSwissfrancsoftheseexcep­
francs)to15.0billionSwissfrancs.Operatingprofit tionaloperatingexpensesarenon­cash itemsrelated
inlocalcurrenciesgrew15%to14.2billionSwiss mainlytoimpairmentsofmanufacturingassets.
francsbeforeexceptionalitemsinthePharmaceuticals
Divisionand12%to1.2billionSwissfrancsinthe TheGroupfinancedtheGenentechtransactionby
DiagnosticsDivision. acombinationoftheGroup’sownfunds,bonds,notes
andcommercialpaper.TheGroupraisednetpro­
Atconstantexchangerates,theGroup’soperating ceedsof48.2billionSwissfrancsthroughaseries
profitmarginbeforeexceptionalitemsincreased ofbondandnoteofferings.Asaconsequence,interest
1.0percentagepoints,withthePharmaceuticalsDivi­ expensesincreasedsubstantiallyin2009,and
sionimproving1.2percentagepointsandtheDia­ financingcostsexceededfinancialincomeby1.7bil­
gnosticsDivision0.4percentagepoints.Duetoan lionSwissfrancs.Bytheendof2009,theGroup
unfavourablecombinationofexchangeratemove­ hadalreadyrepaiddebtof6.9billionSwissfrancs.
ments,however,theGroup’soperatingprofitmargin
beforeexceptionalitemsinSwissfrancsincreased Comparedto2008,netincomedecreasedby22%to
onlyslightly,by0.1percentagepointsto30.6%,with 8.5billionSwissfrancs,primarilyduetoexceptional
thePharmaceuticalsDivisionimproving0.2percent­ items.NetincomeattributabletoRocheshareholders
agepointsto36.3%andtheDiagnosticsDivision declined13%to7.8billionfrancs.Excludingexcep­
decreasing0.4percentagepointsto11.9%. tionalitems,netincomewasdown3%andnetincome
05_L_Roche_AR09_ENG_Groupindd 11 29012010 10:17:1812
Roche Business Report 2009 Roche Group
attributabletoRocheshareholderswas9%higher Weexpecttorepay25%ofthedebtraisedtofinance
comparedto2008. theGenentechtransactionbytheendof2010.
By2011theGroupaimstoachievepre­taxannual
ThenetdebtpositionoftheGroupis23.9billion synergiesofapproximately1billionSwissfrancs.
Swissfrancs,amovementof40.6billionSwissfrancs BasedontheGroup’sstrongoperatingfreecashflow,
fromanetcashpositionof16.7billionSwissfrancs weexpecttoreducedebtprogressivelyandto
on31December2008duetothe52.7billionSwiss returntoanetcashpositionby2015.Wewillsimulta­
francsusedintheGenentechtransaction. neouslymaintainourattractivedividendpolicy.
Outlook
Barringunforeseenevents,Rocheexpectssales
in2010forthePharmaceuticalsDivisionandfor
theGrouptoincreaseinthemid­single­digit range
inlocalcurrencies(excludingTamiflu).Inthe
DiagnosticsDivision,weexpectfull­year salesto
growsignificantlyaheadofthemarket.Despite
ananticipateddecreaseinTamiflusalesfrom3.2
to1.2billionSwissfrancs,weareaimingtoachieve
double­digit CoreEarningsperSharegrowthat
constantexchangerates.
Rocheexpectsresearchanddevelopmentexpendi­
turestodeclineslightlyin2010.However,theGroup’s
focusremainsfirmlyoninnovation,anditwill
continuetoinvesttosupportitsrichpharmaceuticals
developmentpipeline,whichcurrentlyincludes
tennewmolecularentitiesand30additionalindica­
tionsforexistingproductsinlate­stagedevelopment.
Overthenext12–18monthsthePharmaceuticals
Divisionexpectstofilemarketingapplicationsfor
severalmajorlineextensionsofourkeycancermedi­
cinesincludingAvastin,MabThera/Rituxanand
Xeloda,aswellasfortaspoglutidefortype2diabetes.
05_L_Roche_AR09_ENG_Groupindd 12 29012010 10:17:1813
Corporate Sustainability: key achievements in 2009
Responsible Named Healthcare Super Sector Leader in Dow Jones Sustainability Indexes (DJSI).
practices Reselected for the DJSI World and STOXX indices and the FTSE4Good index.
Produced five new position papers on: stem cells and cloning; nanotechnology; biobanks;
personalised healthcare; and the value of our products and services.
Launched Group-wide phone line and web-based system for reporting violations of our
Code of Conduct.
Developed new Supplier Code of Conduct to describe our requirements in ethics;
safety, health an environment; innovation; supplier diversity; economic sustainability and
social responsibility.
Patients and access OneWorld Health completed first screening of Roche’s chemical compound library
to healthcare to find new drugs to treat diarrhea.
Joined a public-private partnership with Novo Nordisk and the World Diabetes Foundation
to improve care for children with diabetes in Africa.
Donated 5.65 million additional Tamiflu courses to replenish WHO stockpiles.
Launched Tamiflu Reserves Program to increase access in developing countries.
Provided free treatment to 40,500 patients in the US through the Roche/Genentech Access
programmes.
Disclosed all financial and in-kind support for patient organisations on our website.
People Global employee Listening to You survey resulted in 91% of employees expressing job
satisfaction at Roche.
Genentech voted Science magazine’s top employer for the seventh time.
Rolled out globally aligned performance management and compensation principles and
began to align these between Genentech and Roche.
Expanded global leadership programme portfolio, providing key programmes at every stage
in the leadership development and talent pipeline.
Society Launched new Corporate policy on philanthropic donations and non-commercial sponsorship.
Launched cancer awareness campaign in rural South Africa, which trains nursing staff, offers
free screening for breast, cervical and prostate cancers, and raises awareness of the disease.
Safety, health and Produced manual on energy efficient design standards for our buildings.
environmental Launched e-learning programme on safety, security, health and environmental protection
protection for all employees.
Launched the Roche Environmental Awareness in Chemical Technology (REACT) programme
to reduce the environmental impact of our products.
To learn more about Roche’s achievements in these areas, see the Corporate Responsibility section of this report on pages 88–120.
05_L_Roche_AR09_ENG_Groupindd 13 29012010 10:17:1814
Roche Business Report 2009 Roche Group
Group Strategy
At Roche we focus on developing medicines and
diagnostics that will help patients live longer, better
lives. We strive to address unmet medical needs
through excellence in science. With Genentech now
fully integrated into the Roche Group, our research
and development teams can collaborate on projects
and share resources as never before. As part of
the integration, however, we have also ensured that
our future organisation will maintain the diversity
of approaches essential for successful innovation.
05_L_Roche_AR09_ENG_Groupindd 14 29012010 10:17:1815
The Roche Business Model:
Changing the practice of medicine
Our Focus Fitting treatments to patients
Our Distinctiveness Excellence in science
Our Delivery Value for all stakeholders
Roche Group Business Webelievethatmedicallydifferentiatedproducts
Whilethedemandfornewandimprovedtreatments aremorelikelytoobtainregulatoryapprovalandbe
keepsgrowing,sodoesthepressuretocontrol acceptedbypatients,physiciansandpayers.
healthcarecosts.Inthischangingandchallenging
environmentweseektodevelopmedicallydif­ Our Delivery
ferentiatedproducts—medicinesanddiagnostics Rocheaimstobenefitallstakeholders:
offeringsignificantclinicalandhealtheconomic • Wewanttoimprovethetreatmentoptions
benefitsoverexistingoptions.Toadvancethisgoal, availabletopatientsanddoctors,enablemedical
wehaverefinedourbusinessmodelalongthree laboratoriestoworkmoreefficientlyandhelp
dimensions:OurFocus,OurDistinctivenessandOur societiescontainhealthcarecosts.Weseekto
Delivery. ensurethatpeoplewhoneedourmedicines
anddiagnosticshaveaccesstothem(seepages
Our Focus 97–101).
Oursuccessasacompanyisbuiltonscientific • PeoplewhoworkatRochehaveachancetomake
discoveryandinnovation.Wefocusonprescription theirmarkandimprovelives.Weseektoprovide
pharmaceuticalsandin vitrodiagnosticsandhave everyRocheemployeewithopportunitiesto
nointentionofbranchingoutintootherhealthcare contribute,excel,learnandgrow.In2009Roche
sectorssuchasgenerics,over­the­counter medi­ andGenentechagainreceived‘bestemployer’
cinesormedicaldevices. awardsinanumberofcountries.
• WeaimtoprovideourinvestorswithaTotal
Innovationisessentialtoaddressingthemanymedi­ ShareholderReturninthetopquartileofour
calneedsthatarestillunmet.Despitesignificant industrypeerset.
progressinthefightagainstsomeofmankind’smost • Weconductourbusinessesresponsiblyandseek
seriousdiseases,therearestillsome5,000diseases tohaveasustainable,positiveimpactonsociety
forwhichnotreatmentexists.Andpatients’response andtheenvironment.In2009wewereratedasthe
ratestomanyavailabletreatmentsareunsatisfactory. newSuperSectorLeaderinHealthcareonthe
Today,breakthroughsinscienceandtechnology DowJonesSustainabilityIndexes,rankingusas
aretransformingourunderstandingofdiseasebiology theworld’sNo.1companyforsustainabilityinour
andpromisetotransformthepracticeofmedicine. sector.
AtRocheweareworkingtoharnessthesediscoveries
tomaketomorrow’streatmentssafer,moreeffective
andmorepersonalised—tobetterfitthemto
patients’geneticprofilesandothercharacteristics.
05_L_Roche_AR09_ENG_Groupindd 15 29012010 10:17:1816
Roche Business Report 2009 Roche Group
Excellence in Science:
Our Distinctiveness
Roche’s approach to innovation and excellence in science is distinctive in four ways:
Wepromotea diversity of approaches inourpursuitof
innovation.GenentechResearchandEarlyDevelopment
(gRED),PharmaResearchandEarlyDevelopment
(pRED),RocheDiagnosticsandChugaioperateinde­
pendentlywithintheGroup,formingthehubsofan
innovationnetworkthatincludesallianceswithover
150outsidecompanies.
Wetakea long­term perspective. Backedby
astablemajorityownershipdatingbackover100years,
wekeepoursightsonsustainablelong­term growth
ratherthanshort­term gains.Thisisreflectedinthecom­
pany’sincentivesystemandapproachtosuccession
management,andinfar­sighted businessmovessuch
asourearlyinvestmentsinbiotechnology.
Weseamlessly integrate our pharma and diag­
nosticscapabilitiesalongthewholevaluechain.
Fromdiscoverytocommercialisation,ourworld­class
pharmaceuticalsanddiagnosticsresearchorganisations
areworkingtogethertocreatebetter,morecost­
effectivetreatmentoptionstailoredtopatients’needs.
On c
T oec lh ono glo ygies I&
n
flM amet mh ao tid os
n N e u r o s c i e n c e M e
tB ai bo ol lo isg my
Virolo
DP gh
y
iaa gr nm oa
stics
u dO
t se
tinu rv
c
ep ir hs na nP io goh r n ta la hoslr el gm he nyaa le tv bc hede
a rs
u oie n et ui x d sc gp ua hine sls itr ntrta hy tin ei­s sl rd e e nfa iD ai edn lli i da
d
nmg
,
egn
w
vo io ehnls le it oct eci phc lu l mes tl c
h
eaD t
e
nr ui
y
v tabi acls i ni oo po dnrln oo ts aipg
n
ceh y
u
qra .
e
utv B y ie
t
soo a i­t nh d
tions.ThisexpertiseequipsRochetoplayapioneering
roleinadvancingpersonalisedhealthcare.
gnnaatns
aetunesVT
pRED
gRED
Chugai
60%
50%
40%
30%
20%
10%
4060
Pharmaceuticals
Research and early development Cinical development Commercialsaion
TSaelgecet io n LGeeande r aio Phase 0 Phase I Phase II Phase II Flng M Pha ar sk ee t IV
BTarogmeta idkeenrt idiecvaetloonpment C Peaoatmseinpbtai snietiyo e nac nd idoia n ugtnloisytic TDaxi oaeudn cphre/sPcorsbt­nga uanncdh m aosnsieosrsinmgent
Diagnostics
RNA A inrm ee rd fe a rI nn e t nbl cic o eo d s eci snS cu ecuebased duNa gn o dte ech sn io gog ny omuatonsseC meS Vra resstance Neurodegeneratio Sn ignalng pathways Ango Mge yn ee lsi os Ap d n o ncp e alo l ts i es b moo mg uy niy
Glycoengneeing -cell boogy
4D5N4A L Sifee Nq Su
Mm
iec cbnie oc
e
an rn rGcg
ae
ye
n
ss
cobas R, eL ai -g tih meC y Pc Cl Rer mmunoM assu acl soi bp al sex potein
anx acC lyoC sE
b
ie sL all sL ai ng ae ynscise
0791 2791 4791 6791 8791 0891 2891 4891 6891 8891 0991 2991 4991 6991 8991 0002 2002 4002 6002 8002
26
Page
32
Page
1 2 3 4 5 6 7 8 9 10
38
Page
54 Page
05_L_Roche_AR09_ENG_Groupindd 16 29012010 10:17:1917
The Roche Management Model:
Enabling an innovation-driven culture
Our People Integrity. Courage. Passion.
Our Decision Making Accountable and transparent
Our Structure Built for innovation
Roche Group Management Our Structure
Ourmanagementmodelisaimedatsustainingand Ourorganisationalstructureisdesignedforinnova­
strengtheningourcultureofinnovation.Likeour tion.Ourautonomousresearchanddevelopment
businessmodel,ithasthreeelements:OurPeople, centresandallianceswithexternalpartnersfoster
OurDecisionMakingandOurStructure. diversity.ThetrulyglobalscaleoftheGroup’sre­
search,development,manufacturingandmarketing
Our People operationsprovidesleverageaswellasaglobal
Oursuccessindrugresearchanddevelopment,our reachforinnovationandmarketsuccess.
abilitytodeployourcombinedexpertiseinpharma­
ceuticalsanddiagnosticstoadvancepersonalised
healthcareandourskillinbalancinglonger­term
investmentdecisionswithnear­termdeliverablesall
ultimatelydependononething:ourpeople(see
pages104–111).Roche’s80,000employeesrepresent
everycontinentandvirtuallyeverycountryonthe
globe,andtheybringtotheirworkadiversityof
perspectivesandexperiencesthatareakeyingredi­
entofcreativity.Respectfordiversity,asharedset
ofstandardsofintegrity,thecouragetoreachbeyond
boundariesandapassionaboutwhatwedoarethe
elementsthatbindustogetherasacompany.
Our Decision Making
Thesecondcomponentofourmanagementmodel
Dse et cs iso iu ot np sr nin ec ei dpl te os bfo er inef fofe rc mti ev de bd yec ais dio ian lom ga uk ein thg a.
tis
systematic,fact­based,openandtransparent.For
everydecisionthereshouldbeasingle,accountable
decisionmakerwhocollectsandcriticallyreviews
informationandcompetingviews.Empowermentis
crucial:sofaraspossibledecisionmakingshould
bedelegatedtothelowestqualifiedlevelinthe
organisation.
05_L_Roche_AR09_ENG_Groupindd 17 29012010 10:17:1906_Bildstrecke_ENG_S18-19indd 1 28012010 23:28:10He’s paving the way
for a new drug for
rheumatoid arthritis
Searching for a safe and effective new medicine is like looking for
a needle in a haystack: only one in many thousands of potential
candidates ever completes the journey from idea to pharmacy shelf.
Because we know that a diversity of approaches produces prom -
ising ideas faster, Roche has built a unique innovation network of
independent research and development (R & D) centres. In add i -
tion to Roche’s pharmaceutical and diagnostic R & D units, it
com prises Genentech Research and Early Development in the US
and Chugai R & D laboratories in Japan, as well as alliances with
around 150 partners worldwide. One of the most recent products
of successful collaboration of this kind is Actemra/RoActemra, a
biological medicine with a new target for use in patients with rheu-
matoid arthritis. Discovered by Chugai and codeveloped with
Roche, Actemra/RoActemra is now being made available to patients
all over the world thanks to the global reach of the Roche Group.
Actemra/RoActemra is a first-in-class monoclonal
antibody for the treatment of rheumatoid arthritis. It
binds to the interleukin-6 receptor and blocks
the effects of the signalling protein IL-6, a key driver
of inflammation in rheumatoid arthritis.
06_Bildstrecke_ENG_S18-19indd 2 28012010 23:28:15Pharmaceuticals | In 2009 demand
for key medicines and efficiency gains
resulted in double-digit increases in sales
and operating profit. Thirteen major
marketing approvals and positive results
from 16 phase III clinical trials confirmed
the division’s growth potential. The
Pharmaceuticals Division is focused on
translating excellence in science into
effective medicines for patients. It combines
cutting-edge research at Roche, Genentech
in the US, Chugai in Japan and over
150 partners worldwide with global scale
and reach in clinical development,
manufacturing and commercial operations.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 20 29012010 12:465821
Pharmaceuticals Division in brief
Key figures
% change % change in
In millions of CHF in CHF local currencies % of sales
Sales 38,996 8 11 100
— United States 14,805 6 5 38
— Western Europe 10,827 5 12 28
— Japan 4,765 43 29 12
— International (Asia—Pacific, CEMAI1, 8,599 4 13 22
Latin America, Canada, Others)
Operating profit before exceptional items 14,154 9 15 36.3
Operating free cash flow 14,923 24 30 38.3
Research and development 8,896 13 13 22.8
1 CEMAI: Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent.
Pharma Executive Committee | 31 December 2009
William M. Burns1 CEO Division Roche Pharmaceuticals
George B. Abercrombie1 North America
Jennifer M. Allerton Informatics
Silvia Ayyoubi Human Resources
Ian Clark2 Global Product Strategy
Jean-Jacques Garaud Development
Peter Hug Western Europe
Jonathan K.C. Knowles1, 3 Group Research
Dominic P. Moorhead1 Finance and Controlling
Christopher Murray3 Commercial Operations, Chugai
Pascal Soriot2 Commercial Operations, CEO Genentech
Klaus Strein4 Pharma Research
Jan van Koeveringe1 Global Technical Operations
Dan Zabrowski Pharma Partnering
1 To 31 December 2009 — see also Corporate Governance.
2 From 1 January 2010: CEO Genentech (I. Clark), Chief Operating Ofiicer Pharmaceuticals Division (P. Soriot).
3 Extended team.
4 Ad interim.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 21 29012010 12:465922
Roche Business Report 2009 Pharmaceuticals
Pharmaceuticals Division Sales by region
In operational terms, 2009wasatransformationalyearforthePharma­
2009 was another ceuticalsDivision.Afterobtainingfullownershipof United States 38% (+5%)
very good year for the GenentechinMarch,Rochemovedswiftlyto Asia—Pacific 5% (+20%)
Pharmaceuticals
combinethetwocompanies’clinicaldevelopment, Latin America 6% (+7%)
Division, with double-
manu­facturingandcommercialoperations.Genentech Other regions 3% (+12%)
digit increases
in both sales and ResearchandEarlyDevelopmentremainsaninde­ CEMAI 8% (+13%)
operating profit. pendentunitwithintheRocheGroup,preservingthe
The integration of diversityofscientificapproacheswebelievehelps
Genentech pro- todriveinnovation.TheintegrationofGenentechwas Western Europe 28% (+12%)
ceeded swiftly and
largelycompletebytheendoftheyear. Japan 12% (+29%)
was largely complete
by the end of the Italics = growth rates (local currencies).
Inoperationalterms,2009wasanotherverygood
year. CEMAI: Central and Eastern Europe, Middle East, Africa,
yearforthePharmaceuticalsDivision,withdouble­ Central Asia, Indian Subcontinent.
digitincreasesachievedinbothsalesandoperating
profit.Above­marketsalesgrowthwasdriven
primarilybystrongdemandforkeymedicinesfrom R&Dpipelineisnowoneoftherichestinthe
theGroup’svirologyandoncologyportfolios.The industry,witheightnewmolecularentitiescurrently
globalspreadofthepandemicA(H1N1)2009 inphaseIII/registration,16inphaseIIand35in
influenzavirusledtounprecedenteddemandfor phaseIclinicaldevelopment.
Tamiflufromthesecondquarteron.Rocheiscooper­
atingwiththeWorldHealthOrganizationandnational
governmentstoaddressthethreatposedbythe Results and main
newinfluenzastrainandhasincreasedproduction
business developments
capacitytoensureadequatesuppliesofTamiflu.
Inadditiontomarketingauthorisationforthetar­ SalesbythePharmaceuticalsDivisionrose11%in
getedbiologicActemra/RoActemra,forrheumatoid localcurrencies(8%inSwissfrancsandUSdollars)
arthritis,intheEuropeanUnionand,inJanuary2010, to39.0billionSwissfrancs,oralmostdoublethe
theUnitedStates,thedivisionalsogainedapprovals globalpharmaceuticalsmarketgrowthrate(6%)1.The
fornewindicationsformarketedproductssuch worldwidespreadofthepandemicA(H1N1)2009
asAvastin(cancer)andMabThera/Rituxan(cancer, influenzavirusledtoverystrongdemandforTamiflu
rheumatoidarthritis).Programmesaimedat fromthesecondquarteron.Overall,Tamiflucon­
expandingtheuseofkeyproductsorsupporting tributed2.6billionfrancs,or7percentagepoints,
plannedmarketingapplicationsfornewcompounds tofull­yearPharmaceuticalssalesgrowth.Excluding
resultedinpositivedatafrom16majorphaseIII Tamiflu,thedivision’ssalesincreased4%2,driven
clinicaltrials.Someoftheseresultshavealreadybeen bydemandforkeyproducts,includingAvastin,
usedtosupportregulatoryfilings.Goodprogress Herceptin,MabThera/Rituxan,Lucentis,Mircera,
wasmadeintheclinicaldevelopmentofpromising Tarceva,Activase/TNKaseandActemra/RoActemra.
newproductcandidatessuchasocrelizumab
(rheumatoidarthritis,multiplesclerosis),T­DM1
(breastcancer),RG7204(malignantmelanoma),
1 Pharmaceutical market growth according to IMS
taspoglutide(type2diabetes)andRG1678
(to end of September 2009).
(schizophrenia).ThecombinedRocheandGenentech 2 Unless otherwise stated, all growth rates are in local currencies.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 22 29012010 12:470023
The integration of Genentech and operational
restructuring made 2009 a transformational year
for the Pharmaceuticals Division
Year­on­yearsalesgrowthinthefourthquarter(8%) combinedRocheandGenentechportfolio(seebelow,
washeavilyimpactedbyplannedreductionsin p.37).Formoreinformationonthedivision’soperat­
wholesalerinventorylevelsinseveralmajormarkets. ingresults,seetheFinanceReport(Part2ofthis
Theseresultedinpartfromacomprehensivereview AnnualReport).
ofdistributionchannelexposureagainsttheback­
groundoftheglobalfinancialcrisis.Inaddition, Thedivisioncontinuedtogenerateastrongcashflow
theharmonisationofdistributionsystemsintheUS in2009.Operatingfreecashflowincreased30%in
followingthemergerofGenentechandRoche localcurrencies(24%inSwissfrancs)to14.9billion
Pharmaceuticalstriggeredareviewofwholesaler Swissfrancs,drivenbythestrongoperatingper­
inventorypolicyandsubsequentdestocking. formance.Continuouscostmanagementandcash­
flowgenerationarekeyprioritiesatRoche.This
Allregionscontributedtothedivision’sstrongsales isreflectedinongoingglobalinitiativestoincrease
growth.IntheUnitedStatesgrowthofkeyoncology operationalefficiencyandproductivityinareas
products,TamifluandLucentismorethancompen­ suchasinformationtechnology,manufacturingand
satedforlowersalesofCellCeptandBonivaandthe administration.Furtherstimulusisnowbeingprovided
voluntarywithdrawalofRaptiva.SalesinWestern bytheGenentechintegration,whichinvolveda
EuropeweredrivenbydemandforTamiflu,Avastin, majorreorganisationnotonlyofUSpharmaceutical
MabTheraandMircera,whichmorethanoffset operationsbutalsoofthedivision’sglobalfunctions.
decliningsalesofNeoRecormon.SalesbyChugaiin Synergiesarealreadybeinggeneratedasaresult
JapanincreasedstronglyduetodemandforTamiflu, oftheconsolidationinSouthSanFranciscoofadmin­
keycancermedicinesandActemra.Salesinthe istrativefunctionsforthecombinedUSorganisation,
Internationalregion(Asia—Pacific,CEMAI3,Latin theclosureofthePaloAltosite,andthereshapingof
America,Canada,Others)weredrivenbydemand globalmanufacturingoperations(seeManufacturing
forTamiflu,keycancermedicinesandPegasys. infrastructure, below).Weaimtoachievepre­tax
annualsynergiesofapproximately1billionSwiss
In2009thePharmaceuticalsDivision’soperating francsby2011.
profitbeforeexceptionalitemsadvancedsignificantly
fasterthansales,rising15%inlocalcurrencies(9%
inSwissfrancs)to14.2billionSwissfrancs.Thisstrong Manufacturing infrastructure
increasewasdrivenmainlybytheperformanceof
ourkeypharmaceuticalproductsandongoingmea­ Thecompanyiswellontrackwiththeintegrationand
surestoimproveefficiency.Theoperatingprofit optimisationofthecombinedRocheandGenentech
marginincreased1.2percentagepointsinlocalcur­ supplynetworkandisreshapingitsglobalmanu­
rencies(0.2percentagepointsinSwissfrancs)to facturingorganisationtoconcentrateactivities,align
36.3%despiteincreasedinvestmentsfornewproduct capacityrequirementsandimproveefficiency.Aspart
launchesandinresearchanddevelopment.The oftherealignment,asecondbulkdrugproduction
significantincreaseinR&Dcosts,up13%to8.9billion unitatGenentech’sVacaville(USA)facilitywillnotbe
Swissfrancs,reflectsinvestmentinthedivision’s commissionedandanewunitatRoche’sPenzberg
stronglate­stage pipeline,includingpromisingcom­ (Germany)plantwillnotbecompleted.
poundssuchasdalcetrapib,taspoglutide,pertuzumab
andT­DM1.TheriseinR&Dexpenseswasalso ThePharmaceuticalsDivisioncurrentlyoperates
drivenbyhigherimpairmentsofintangibleassets.At 24productionsitesworldwide.Althoughconsolidation
302million,thesewere203millionfrancshigherthan
in2008,dueprimarilytotheterminationofanumber
3 Central and Eastern Europe, Middle East, Africa, Central Asia,
ofprojectsfollowingacomprehensivereviewofthe Indian Subcontinent.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 23 29012010 12:470024
Roche Business Report 2009 Pharmaceuticals
Collaboration with istakingplaceinmanufacturing,Rochecontinuesto and51researchandtechnologycollaborations.In
external partners is an investinitssupplynetworktoensuredeliveryof addition,tenproductout­licensingagreementswere
integral part of marketedmedicinesandproductsinclinicaldevelop­ signed.Amongthemaintransactionswereasecond
Roche’s R & D strategy.
ment.InMayRocheopenedanadditionallarge­scale, licensingagreementwithPlexxikon,announced
In all, Roche and
multipurposechemicalproductionunitinFlorence, inJanuary,forPLX5568(RG7376),anovelkinase
Genentech signed
more than 100 new SouthCarolina(USA).Anewproductioncentre inhibitorforpolycystickidneydisease,andafurther
partnering agree- inKaiseraugst(Switzerland)forthemanufactureof agreementwithEvotec,announcedinMarch,for
ments in 2009, medicinesinsterileforms,includingliquidand phaseIIdevelopmentofEVT101fortreatment­
including product lyophilisedvialsandprefilledsyringes,wasinaugu­ resistantdepression.Rocheenteredintoaproduct
transactions and
ratedinJune.InAugustRocheexercisedanoption developmentagreementwithTekmiraPharmaceuticals
research and technol-
previouslyheldbyGenentechtopurchaseabiologic inMaytoadvanceRoche’sfirsttwoRNAinterfer­
ogy collaborations.
manufacturingfacilitybuiltbyLonzainSingapore. enceproductcandidatesintohumanclinicaltesting.
Thestate­of­the­artfacility,whichismechanically BothproductcandidateswillbebasedonTekmira’s
complete,hasbeenmergedwithanexistingbiologic stablenucleicacid­lipid particle(SNALP)technol­
manufacturingfacilitybuiltbyGenentech.Thecom­ ogy.
binedSingaporeoperations—Roche’sfirstsuch
facilitiesinAsia—willplayakeyroleintheGroup’s GenentechPartneringcompletedfourproducttrans­
globalmanufacturingnetwork.InNovemberthe actions,oneoutlicensingdealand46research
topping­out ceremonyforanewtechnicalresearch andtechnologycollaborationsduringtheyear.These
anddevelopmentbuildinginBasel(Switzerland) includeanagreementsignedinJunewithBayhill
tookplace.Thenewfacility,scheduledforcompletion TherapeuticsforanexclusivecollaborationforBayhill’s
in2011,willhouseacentreforthedevelopmentof promisingdrugcandidateBHT­3021,currentlyin
productionmethodsandthemanufactureofclinical phaseIdevelopmentfortype1diabetes.InOctober
trialssamples. GenentechsignedanagreementwithSurModics,
grantingGenentechanexclusivelicencetouse
Inresponsetotheworldwidespreadofthepandemic SurModics’proprietarybiodegradablemicroparticles
A(H1N1)influenzavirus,ourmanufacturingorgani­ drugdeliverysystemtodevelopandcommercialise
sationandsupplychainmanagementalsometthe asustaineddrugdeliveryformulationofLucentis.The
challengeofensuringadequateTamiflusuppliesto agreementalsoprovidesRocheandGenentech
patientsworldwide.Rocheanditsmanufacturing withopportunitiestodevelopadditionalcompounds
partnersrapidlyincreasedproductioncapacityfor forthetreatmentofophthalmicdiseases.
Tamiflutoapproximately33milliontreatmentcourses
permonthandarenowabletosupplyupto400mil­
lionpacksannually,ifrequired. Sales review —
selected key products
Pharma Partnering update
ThePharmaceuticalsDivision’ssalesgrowthis
Collaborationwithexternalpartnersisanintegralpart broadlybased.In2009elevenproductsfromsix
ofRoche’sR&Dstrategy.Accesstoexternalinno­ therapeuticareasgeneratedsalesofover1billion
vationthroughlicensingandtargetedacquisitionsis Swissfrancseach.Ofthesemedicines,thetop
asignificantmeansofstrengtheningtheR&Dportfolio threeachievedsalesofover5billionSwissfrancs
andexpandingtheGroup’stechnologycapabilities. each.CombinedsalesoftheGroup’stop20pharma­
In2009RochePharmaceuticalssignedatotalof55 ceuticalsamountedto34.3billionSwissfrancs,or
newagreements,includingfourproducttransactions 88%oftotaldivisionalsales.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 24 29012010 12:470025
Eleven products from six therapeutic areas
generated sales of over 1 billion francs each
Sales by therapeutic area
Oncology 53% (+8%)
Inflammatory and autoimmune diseases, transplantation 8% (–6%)
Central nervous system 2% (–5%)
Respiratory 3% (+8%)
Metabolic diseases, bone diseases 7% (–4%)
Infectious diseases 1% (–8%)
Cardiovascular diseases 3% (–2%)
Virology 15% (+79%)
Others 2% (–29%)
Renal anemia 3% (0%)
Ophthalmology 3% (+24%)
Italics = growth rates (local currencies).
Salesofthedivision’soncologyportfoliorose8% cancer.UptakeinJapan,whereAvastiniscurrently Sales of the division’s
to20.7billionSwissfrancsin2009,ledbythekey marketedforadvancedcolorectalcancer,remains oncology portfolio
productsAvastin,Herceptin,MabThera/Rituxan, particularlystrongandisexpectedtobeenhanced rose 8% to 20.7 billion
Swiss francs in 2009,
TarcevaandXeloda.Together,thesefivemedicines bytheproduct’srecentapprovalforadvancednon­
led by Avastin,
accountedforaroundhalfoftotalpharmaceutical smallcelllungcancer.SalesgrowthintheUnited
Herceptin, MabThera/
sales.Anincreaseof79%(+2.5billionSwissfrancs) Statesisbeingdrivenmainlybyuseinadvanced Rituxan, Tarceva
insalesofantiviralmedicines,forafull­yeartotalof breastcancerandthenewindicationsglioblastoma and Xeloda. Together,
5.9billionfrancs,wasdrivenprimarilybydemand andkidneycancer,whilehighpenetrationrates these five medicines
forTamiflu.Overallsalesoftherenalanemiaportfolio weremaintainedinestablishedindicationssuchas accounted for around
half of total pharma-
remainedstableat1.3billionSwissfrancsinan lungandcolorectalcancer.
ceutical sales.
increasinglycompetitive,cost­sensitivemarket.Sales
inthecombinedinflammation/autoimmune/transplan­ Overallsales(oncologyandrheumatoidarthritis)of
tationportfoliodeclinedto3.0billionfrancs,with MabThera/Rituxan(rituximab),fornon­Hodgkin’s
theexpectednegativeimpactoftheCellCeptpatent lymphoma(NHL),chroniclymphocyticleukemia
expiryintheUnitedStateslargelyoffsetbythe (CLL)andrheumatoidarthritis(RA),rose6%to
continuedsuccessofMabThera/Rituxaninrheuma­ 6.1billionSwissfrancs.Sustainedgrowthinthe
toidarthritis,aswellasstronguptakeofActemra/ oncologysegmentwasdrivenbyuptakeinCLL
RoActemrainJapananditsinitiallaunchmarketsin followingapprovalintheEUforfirst­line treatment4
WesternEuropeandelsewhere. andintherelapsed/refractorydiseasesettinginthe
firstandthirdquarters,respectively.Lowersales
Oncology growthintheUSreflectsthehighlevelsofadoption
SalesofAvastin(bevacizumab),foradvanced ofRituxaninitscancerindications.SalesintheRA
colorectal,breast,lungandkidneycancer,andfor segmentwereanestimated900millionSwissfrancs,
relapsedglioblastoma(atypeofbraintumour),rose or15%oftheproduct’stotalsales.Growthinthis
21%to6.2billionSwissfrancs.Soliddouble­digit segmentisbeingdrivenbyincreasingandearlieruse
growthwasrecordedinallregions,drivenprimarily
bycontinueduptakeincolorectal,breastandlung 4 First-line treatment is the initial treatment given after diagnosis.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 25 29012010 12:470026
Roche Business Report 2009 Pharmaceuticals
Excellence in science:
A unique diversity of approaches
150
Partners
Understanding the complex biology of disease is the biggest challenge we face in developing
new and better medicines and diagnostics. Scientific breakthroughs are most likely to occur
when scientists are free to tackle problems from different angles and in different ways.
Our scientists have this freedom. We believe that a diversity of views, cultures and approaches
promotes creativity, especially in research and early development. Our own autonomous
research and development hubs, augmented by over 150 alliances, provide a natural climate
for innovation.
pRED
gRED
Chugai
gRED pRED
GenentechResearchand RochePharmaResearchand
EarlyDevelopment EarlyDevelopment
NMEs in phase I and II
Oncology 17 FollowingtheintegrationofGenentech,pREDandgREDoperate
asautonomousinnovationcentresfocusingonnewdrug
targetsandnewmolecularentities(NMEs).Theyhavetheirown
Inflammation / Immunology 7
budgetsandexternalnetworksandtakedifferentapproaches
toturningexcellentscienceintoadvancesinmedicalcare.Thisnew
Central nervous system 11 organisationalstructurepreservesthevaluesandculturethat
enabledtheGenentechsuccessstorywhileatthesametime
strengtheningRochePharma’sabilitytodevelopnovelmedicines.
Ophthalmology 1
Italsomakesiteasierforourpharmaceuticalsanddiagnostics
researcherstoshareknowledgeandtechnologiesacrossdivisional
Virology 5 boundaries.
Metabolic/Cardiovascular 10
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 26 29012010 12:470127
ofMabThera/Rituxaninpatientswithaninadequate Virology Roche is cooperating
responsetooneormoretumournecrosisfactor Globalsalesoftheanti­influenza medicineTamiflu closely with the World
(TNF)inhibitors.MabTheraiswellestablishedasthe (oseltamivir)amountedto3.2billionSwissfrancsin Health Organization
and governments
medicineofchoicefollowinginadequateresponse 2009,anincreaseof435%,or2.6billionSwissfrancs,
worldwide to support
toTNFinhibitortreatmentandiscurrentlythemarket comparedwith2008.Thisveryhighgrowthwas
pandemic prepared-
leaderinthatsegmentintheEU. drivenbyunprecedenteddemandfromgovernments ness and supply
andintheretailpharmacysectorfollowingthepan­ Tamiflu to all patients
SalesofHerceptin(trastuzumab),forHER2­positive demicA(H1N1)2009influenzavirus(‘swineflu’) in need.
breastcancer,increased8%to5.3billionSwiss outbreak,whichbeganinAprilandspreadrapidly
francs.Solidgrowththroughouttheyearwasdriven worldwide.Salesforpandemicstockpilingamounted
bycontinuinguptakeforearlybreastcancer,espe­ to1.9billionfrancsforthefullyear.
ciallyinJapanandanumberofemergingmarkets,
aswellasincreasingmarketpenetrationinEastern Rocheisworkingwithnationalhealthauthoritiesto
Europe.ModeratesalesgrowthintheUSand expandapprovalforpandemicuseofTamifluto
WesternEuropereflectsthehighmarketpenetration includechildrenunderoneyearofage,aswellas
achievedinbothearlyandadvancedbreastcancer pregnantandlactatingwomen,andtogainregulatory
intheseregions. approvalforalternativemethodsofadministeringthe
medicinetoinfantsandyoungchildren.Thecompany
SalesofTarceva (erlotinib),foradvancedlungand alsocontinuestocooperatecloselywiththeWorld
pancreaticcancer,increased10%to1.3billionSwiss HealthOrganizationandgovernmentsworldwideto
francs.Demandisbeingdrivenbyincreaseduse supportpandemicpreparednessandsupplyTamifluto
ofthemedicineinsecond­line5non­small celllung allpatientsinneed.
cancer(NSCLC)outsidetheUSandinmetastatic
pancreaticcancer.Themainsalescontributionscame SalesofPegasys(peginterferonalfa­2a), forhepatitis
fromWesternEuropeandtheUnitedStates.Themore BandC,totalled1.7billionSwissfrancsin2009,
modestgrowthinUSsalesreflectsstablepenetration anincreaseof5%overthepreviousyear,drivenby
inNSCLCandpancreaticcancer,thecompetitive market­share gainsinmajormarkets.Growthis
environmentandreserveadjustmentstakenduring beinghelpedbynewstudydatademonstratingthe
theyear,primarilyforgovernmentprogrammes superiorityofPegasysoverothertreatmentoptions,
involvingdiscounts. increaseduseinthetreatmentofhepatitisB,and
increasingratesofhepatitisdiagnosisandtreatment
SalesofXeloda(capecitabine),forcolorectal, inemergingmarkets.
stomachandbreastcancer,increased7%to1.3billion
francs,drivenprimarilybystronggainsintheUnited Ophthalmology
States,JapanandChina.Growthisbeingdriven USsalesofLucentis(ranibizumab),forwetage­
byuseinmetastaticbreastcancer,adjuvant6colon relatedmaculardegeneration(AMD,themost
cancerandmetastaticcolorectalcancer.InChina commonformofage­related blindness)rose24%to
themajorityofgrowthiscomingfromuseinpatients 1.2billionSwissfrancs.Strongdouble­digit growth
withadvancedstomachcancer,whileinJapanChugai throughout2009wasdrivenprimarilybyanincrease
recordedsignificantadditionalgrowthinthefourth inthenumberofinjectionsadministeredtopatients
quarterfollowingapprovalofanexpandedmetastatic
colorectalcancerindication.
5 Second-line treatment is given if the initial, or first-line, treatment
does not work or if the cancer stops responding to it.
6 Adjuvant treatment is given after surgical removal of the tumour
to lower the risk of relapse.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 27 29012010 12:470128
Roche Business Report 2009 Pharmaceuticals
Top-selling pharmaceuticals — Roche Group | in millions of CHF
6,222 6,087 5,266 3,200 1,655
Avastin MabThera/Rituxan Herceptin Tamiflu Pegasys
+21% * +6% * +8% * +435% * +5% *
Active substance: Active substance: Active substance:: Active substance : Active substance :
bevacizumab rituximab trastuzumab oseltamivir peginterferon alfa-2a
Indications : Indications : Indications : Indications : Indication s:
colorectal cancer, breast non-Hodgkin’s lymphoma, HER2-positive breast treatment and prevention hepatitis B and C
cancer, non-small cell chronic lymphocytic cancer of influenza A and B
lung cancer, kidney leukemia, rheumatoid
cancer, glioblastoma arthritis
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 28 29012010 12:470429
Above-market sales growth was driven
primarily by strong demand for
key virology and oncology medicines
1,576 1,560 1,304 1,260 1,198
CellCept NeoRecormon, Epogin Tarceva Xeloda Lucentis **
–22% * –11% * +10% * +7% * +24% *
Active substance : Active substance : Active substance : Active substance : Active substance :
mycophenolate mofetil epoetin beta erlotinib capecitabine ranibizumab
Indications : Indication s: Indications : Indication s: Indications :
transplantation anemia advanced non-small cell colorectal cancer, breast wet age-related macular
lung cancer, advanced cancer, stomach cancer degeneration
pancreatic cancer
Images are not to scale.
* Year-on-year sales growth in local currencies.
** Jointly marketed by Genentech and Novartis.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 29 29012010 12:470630
Roche Business Report 2009 Pharmaceuticals
In May 2009 the FDA inthefirstandsecondyearoftreatment,growthinthe Transplantation
granted accelerated numberofpatientstreatedforwetAMD,andeasier SalesofCellCept(mycophenolatemofetil),forthe
approval for the reimbursement. preventionofsolidorgantransplantrejection,
use of Avastin for
decreased22%comparedwith2008to1.6billion
relapsed glioblas-
Anemia Swissfrancs.SalesintheUS,theproduct’slargest
toma, the most
aggressive form of Inahighlycompetitive,price­sensitive market,sales market,declinedsharplyfromMayonwardsfollowing
brain tumour. In oftherenalanemiamedicationMircera(methoxy expiryoftheUSpatent.Thecontinuingerosionof
January 2010 the polyethyleneglycol­epoetinbeta),whichisnow USsalesthroughgenericcompetitionisbeingoffset
agency approved availableinover80marketsworldwide,showed tosomeextentbysolidgrowthelsewhere,especially
Actemra for the treat-
consistentgrowththroughout2009,rising252%to inLatinAmericaandJapan.
ment of adult patients
179millionSwissfrancs.Salesarebeingdriven
with rheumatoid
primarilybythesuccessoftheproductinthepre­ Others
arthritis who have
not responded to TNF dialysissegment.CombinedsalesoftheGroup’s AtthebeginningofAprilRocheandGenentech
inhibitor therapy. establishedanemiamedicines,Roche’sNeoRecormon announcedaphasedvoluntarywithdrawalofthe
andChugai’sEpogin(epoetinbeta),declined11%to psoriasismedicineRaptiva(efalizumab)fromthe
1.6billionSwissfrancs.OutsideJapanthecombined USmarket.Thedecisionreflectsourcommitment
marketshareofRoche’sanemiafranchise(Mircera topatientsafetyandwasbasedontheassociation
andNeoRecormon)continuestoincreasedespite ofRaptivawithanincreasedriskofprogressive
competitionfromnewmarketentrants.Thedecline multi­focalleukoencephalopathy(PML),arareand
inNeoRecormonsalesof14%wasduemainlyto usuallyfataldiseaseofthecentralnervoussystem.
increasedpricepressureasnewbiosimilarsenterthe AspartofthemeasuresagreedbetweentheUS
market.Incontrast,theslightdeclineofEpoginin FoodandDrugAdministration(FDA)andGenentech,
Japan(–1%)reflectsstabilisationoftheproduct’s theRaptivamarketinglicencewasrevokedinJuly.
marketshareinthedialysissegmentandcontinued Genentechcontinuestomonitorpatientsafety.
expansioninthepredialysissetting.
Inflammation and autoimmune disorders Development highlights —
FollowingEUmarketingapprovalinJanuary2009,by
key marketed products
year­endthenovelrheumatoidarthritis(RA)medicine
RoActemra(tocilizumab,knownasActemraoutside
Europe)hadbeenlaunchedintenEUcountries, In2009thePharmaceuticalsDivisionfiled23major
includingGermany,France,SpainandtheUnited newmarketingapplicationsandgained13major
Kingdom.SalesuptakeintheinitialEuropeanlaunch regulatoryapprovals(seetable,p.31).Positiveresults
marketshasbeenstrong.Followinglaunchesin from16majorphaseIIIclinicaltrialsinvestigating
additionalmarkets,includingSwitzerland,Indiaand additionalindicationsforexistingkeyproductsorwith
Brazil,Actemra/RoActemraisnowavailableinover newproductssuchastaspoglutideandocrelizumab
25countriesworldwide.Theresponsefromphysicians werealsoreported(seetable,p.33).Thefollowing
isveryencouraging.Globalsalesrose289%to146 summariespresentapprovals,filingsandmajor
millionSwissfrancsin2009.InJapan,whereActemra clinicaltrialresultsforkeymarketedproducts,by
wasapprovedforRAinadultsandforrelatedpedi­ indication.
atricindicationsinApril2008,adoptionandmarket
penetrationareprogressingwell,withdoctorsalready Actemra/RoActemra
usingthemedicineasafirst­linebiologictreatmentin Approvals | InJanuary2010theUSFoodand
manypatients.SalesinJapanamountedto98million DrugAdministration(FDA)approvedActemrafor
Swissfrancs,anincreaseof146%. thetreatmentofadultpatientswithmoderatelyto
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 30 29012010 12:470631­
In 2009 the division filed 23 major
marketing applications and gained
13 major approvals
Major regulatory filings in 2009­1
Product Active substance Indication and/or dosage form Country
Avastin bevacizumab relapsed glioblastoma multiforme Switzerland
first-line metastatic breast cancer, combination EU, USA, Japan,
with standard chemotherapy Switzerland
ED-71 eldecalcitol osteoporosis Japan
Epogin epoetin beta chemotherapy-induced anemia Japan
Herceptin trastuzumab advanced HER2-positive gastric cancer EU, Switzerland
Lucentis ranibizumab macular edema following retinal vein occlusion USA
MabThera/ rituximab rheumatoid arthritis — patients with an inadequate EU, Switzerland
Rituxan response to a disease-modifying antirheumatic drug;
prevention of joint damage­2
first-line chronic lymphocytic leukemia USA
relapsed or refractory chronic lymphocytic leukemia EU, USA, Switzerland
RG744 methoxy renal anemia Japan
(Mircera) poly ethylene
glycol-epoetin beta
Tarceva erlotinib non-small cell lung cancer, first-line maintenance EU, USA, Switzerland
after chemotherapy
advanced pancreatic cancer Japan
Xeloda capecitabine adjuvant colon cancer, combination with oxaliplatin EU, Switzerland
Major regulatory approvals in 2009­1
Product Active substance Indication and/or dosage form Country
Avastin bevacizumab relapsed glioblastoma multiforme USA­3, Switzerland
metastatic breast cancer; combination with docetaxel EU, Switzerland
first-line metastatic renal cell carcinoma, combination USA
with interferon alfa-2a
unresectable advanced or recurrent non-squamous Japan
non-small cell lung cancer
MabThera/ rituximab relapsed or refractory chronic lymphocytic leukemia EU, Switzerland
Rituxan first-line chronic lymphocytic leukemia EU
rheumatoid arthritis, guidance on retreatment in patients USA
with an inadequate response to anti-TNF therapy
Actemra/ tocilizumab rheumatoid arthritis signs and symptoms EU, USA
RoActemra
Xeloda capecitabine advanced or refractory colorectal cancer, combination with Japan
oxaliplatin, with or without Avastin
1 Includes supplemental indications; updated to 8 January 2010.
2 A third indication, for use in patients not previously treated with methotrexate, is no longer being pursued (see p. 36).
3 Accelerated approval (FDA).
07_L_Roche_AR09_ENG_Pharmaceuticals.indd 31 04.02.2010 12:39:2070%
60%
50%
40%
30%
20%
10%
40
60
0791 2791 4791 6791 8791 0891 2891 4891 6891 8891 0991 2991 4991 6991 8991 0002 2002 4002 6002 8002
32
Roche Business Report 2009 Pharmaceuticals
Excellence in science:
Taking a long-term view
10
Biotech milestones
Sales of biotech medicines
Sales EstimatedSales
Biotechmedicines,orbiologics,
todayaccountfor65%of
Roche’spharmaceuticalsales—
apercentagethathasrisen
significantlyinrecentyears.
Biologicsnormallyhaveamore
targetedeffectandarebetter
toleratedthanconventional
chemicalmedicines.
1 2 3 4 5 6 7 8 9 10
1967 1970s 1978 1982 1986 1990 1997 1998 2004 2008
Rochefounds Researchon Rocheand Recombinant Roferon­A Rocheacquires MabThera/ NeoRecormon Avastin Actemra/
Institutefor monoclonal Genentech’s insulin 60%of Rituxan Herceptin RoActemra
Molecular antibody firstjoint Genentech
Biology production project
Discovering, developing and commercialising new medicines takes time and vision. To stay
at the leading edge of innovation, it is essential to invest early in promising new technologies.
We were one of the first pharmaceutical companies to embrace biotechnology, which led to
our acquiring a majority stake in Genentech in 1990. Today our biotech products are helping to
improve the lives of countless patients in a variety of disease areas, and we are the number-
one maker of biologics. We also invested in polymerase chain reaction (PCR) technology when
it was still in its infancy — a decision which has helped us to become the global market
leader in molecular diagnostics.
One of the technologies we are investing in today is RNA interference (RNAi), which offers
a way to target and ‘turn off’ specific genes. RNAi-based medicines could prove a ground-
breaking new approach to fighting disease and helping patients.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 32 29012010 12:470733
Avastin is being tested in more than 450
studies in some 30 different tumour types
Positive outcomes achieved in 16 major phase III trials
Disease area Product Indication Study
Oncology MabThera/Rituxan indolent non-Hodgkin’s lymphoma, PRIMA
first-line maintenance treatment
Avastin second-line metastatic breast cancer RIBBON-2
Xeloda adjuvant treatment of colon cancer NO16968 (XELOXA)
Herceptin HER2-positive stomach cancer ToGA
Tarceva non-small cell lung cancer, first-line maintenance treatment SATURN
(overall survival data)
Tarceva + Avastin non-small cell lung cancer, first-line maintenance treatment ATLAS
Inflammation Actemra rheumatoid arthritis, progression of joint damage LITHE, 2-year data
Actemra juvenile idiopathic arthritis, systemic onset TENDER
ocrelizumab rheumatoid arthritis, patients with inadequate response STAGE
to previous treatment with methotrexate
Ophthal- Lucentis macular edema following central retinal vein occlusion CRUISE
mology
Lucentis macular edema following branch retinal vein occlusion BRAVO
Metabolism taspoglutide type 2 diabetes T-emerge 1, 2, 4, 5, 7
severelyactiverheumatoidarthritis(RA)whohave regulatoryfilingsinthisindication.sJIA,adebilitating
hadaninadequateresponsetooneormoretumour anddifficult­to­treat diseasethataffectsthewhole
necrosisfactor(TNF)inhibitors.Actemra,thefirst body,representsanareaofhighunmetmedicalneed.
interleukin­6 receptor­inhibiting monoclonalanti­
bodyapprovedtotreatRA,maybeusedaloneorin Avastin
combinationwithmethotrexateorotherdisease TheglobaldevelopmentprogrammeforAvastinisone
modifyingantirheumaticdrugs. ofthemostcomprehensiveundertakingsincancer
researchsincechemotherapy.Morethan450clinical
Filings | InSeptemberRochefiledanapplication trialsworldwidewitharound40,000patientsare
withtheEU’sEuropeanMedicinesAgency(EMEA) currentlyinvestigatingtheuseofAvastininapproxi­
toexpandthemarketingauthorisationforRoActemra mately30differenttumourtypes(includingcolorectal,
toincludeinhibitionoftheprogressionofjointdamage breast,non­smallcelllung,brain,stomach,ovarian,
andimprovementofphysicalfunctioninpatients prostateandothers)andindifferentsettings
withRA.TheEUfilingissupportedbypositivetwo­ (advancedorearly­stagedisease).Resultsfrom
yeardatafromthephaseIIILITHEtrial. phaseIIItrialsinvestigatingthemedicine’spotential
inpatientswithmetastaticprostate,ovarianand
Clinical milestones | AninternationalphaseIII stomachcancerareexpectedin2010.
study(TENDER)metitsprimaryendpointinNovem­
ber,showingthatActemra/RoActemrasignificantly Approvals | InMaytheFDAapprovedtheuseof
improveddiseasesignsandsymptomsinchildren Avastininpatientswithpreviouslytreated(relapsed)
withsystemiconsetjuvenileidiopathicarthritis(sJIA) glioblastomamultiforme(GBM),themostaggressive
andconfirmingtheresultsofearlierJapanese formofbraintumour,undertheagency’saccelerated
studies.Rocheplanstousethedatatosupportglobal approvalprogramme.TheEU’sCommitteefor
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 33 29012010 12:470734
Roche Business Report 2009 Pharmaceuticals
Following an EU MedicinalProductsforHumanUse(CHMP)issueda suggestthatAvastinisactiveinpatientswithearly­
marketing application negativeopinioninSeptemberregardingRoche’s stagecoloncancer.FurthertrialsinvestigatingAvastin
by Roche in Sep- applicationforapprovalofthesameindication.The intheadjuvantsetting(early­stage disease,after
tember, the CHMP
USandEUfilingswerebasedonstrongclinical surgerytoremovethetumour)incolon,breastand
issued a positive
resultsfromthephaseIIBRAINstudy.Several lungcancerareongoing.Resultsareexpectedin
recommendation in
December for the investigator­led studiescontinuetoexploretherole 2010fromaseparate,Roche­sponsoredinternational
use of Herceptin in ofAvastininrelapsedGBM.Inaddition,alarge, phaseIIIstudy(AVANT)assessingAvastinincom­
advanced HER2- RochesponsoredphaseIIIstudy(AVAGLIO)inover binationwithchemotherapyforearly­stage colon
positive stomach 900patientswithnewlydiagnosedGBMiscurrently cancer.InOctoberpatientrecruitmentwascompleted
cancer. The filing
underwaywiththeaimofglobalfilings. forBEATRICE,aphaseIIItrialinvestigatingAvastin
was based on strong
inearlyHER2­negativeandhormonereceptor­
phase III data show-
RochereceivedEUapprovalinJulyforAvastinin negativebreastcancer.
ing that Herceptin
can extend survival combinationwithdocetaxel,acommonlyusedchemo­
in patients with therapy,inthefirst­line treatmentofmetastatic FullresultsofRIBBON­2,aphaseIIItrialofAvastin
in operable HER2- breastcancer.TheexpandedindicationfollowsEU assecond­line treatmentinwomenwithadvanced
positive stomach
approvalforcombinedAvastinandpaclitaxelin2007. HER2­negativebreastcancerwhohadpreviously
cancer.
Inaddition,inAugusttheFDAapprovedAvastinin receivedchemotherapy,werepresentedattheSan
combinationwithinterferonalfa­2a forthetreatment AntonioBreastCancerSymposiuminDecember.The
ofmetastaticrenalcellcarcinoma,themostcommon studymetitsprimaryendpoint,showingthatwomen
typeofkidneycancer.ThisfollowsEUapprovalof whoreceivedAvastinincombinationwithcommonly
thesameindicationin2008. usedchemotherapiesassecond­line treatmenthad
a28%improvementinprogression­free survival8
InNovemberChugaireceivedapprovalinJapanfor comparedwithchemotherapyalone.Genentechand
Avastinforthetreatmentofadvancednon­smallcell RocheplantofiletheRIBBON­2dataintheUS
lungcancer. andtheEUin2010.
Filings | Chugaifiledasupplementaryapplication Herceptin
inOctobertoexpandtheapprovedindicationsfor Filings | FollowinganEUmarketingapplicationby
AvastininJapantoincludemetastaticbreastcancer, RocheinSeptember,theCHMPissuedapositive
basedontheresultsoftheE2100,AVADO,and recommendationinDecemberfortheuseofHerceptin
RIBBON­1 trialsandJapanesestudies.InNovember inadvanced(metastatic)HER2­positivestomach
GenentechfiledtheAVADOandRIBBON­1 datawith cancer.Thisrecommendationwasissuedinrecord
theFDA,withtheaimofconvertingthecurrent time,reflectingthehighunmetmedicalneedandthe
acceleratedapprovalforHER2­negative breastcancer strengthofthedatafromToGA(seebelow).
(receivedin2008)tofullapprovalandallowing
Avastintobecombinedwithfurtherstandard Clinical milestones | Resultsfromtheinternational
chemotherapies.InNovemberRochealsofiledthe phaseIIIToGAtrialpresentedattheASCOmeetingin
RIBBON­1 datawiththeEUauthorities. June7showedthatcombiningHerceptinwithstandard
chemotherapy(Xelodaorintravenous5­fluorouracil
Clinical milestones | FullresultsofthefirstphaseIII pluscisplatin)extendsthelivesofpatientswith
trialofAvastininearly­stagecoloncancer(NSABP
C­08)werepresentedattheannualmeetingofthe
AmericanSocietyofClinicalOncology(ASCO)in
7 29 May to 2 June.
May7.Althoughthestudydidnotmeetitsprimary
8 Progression-free survival: the time patients live without
endpointofimprovingdisease­freesurvival,thedata their disease getting worse.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 34 29012010 12:470735
Five-year follow-up data confirmed the long-
term benefits of one year of adjuvant Herceptin
treatment for HER2-positive breast cancer
advancedinoperableHER2­positive stomachcancer MabThera/Rituxan (oncology)
onaveragebynearlythreemonthsto13.8months. Approvals | RochereceivedEUapprovalinFebruary
PatientswithtumoursexhibitinghighlevelsofHER2 forMabTheraincombinationwithchemotherapyfor
experiencedevengreaterbenefitfromtheaddition previouslyuntreatedchroniclymphocyticleukemia
ofHerceptin:theirliveswereextendedbymorethan (CLL)andinAugustforuseinpatientswithrelapsed
fourmonthsto16monthsonaverage. orrefractorydisease.CLListhemostcommonform
ofadultleukemia.InNovembertheUSFoodand
InOctoberRocheandHalozymeannouncedthe DrugAdministration(FDA)issuedaComplete
startofaphaseIIItrialinvestigatinginfusion­free, ResponsetotwosupplementalBiologicsLicense
subcutaneousadministrationofHerceptinfor ApplicationssubmittedbyGenentechandBiogen
womenwithHER2­positive breastcancer.Thenew Idec,forapprovalofRituxanplusstandardchemo­
subcutaneousformulationisbasedonHalozyme’s therapyinpreviouslyuntreatedortreatedCLL.The
Enhanzetechnology. FDAhasnotrequestedanynewdatatocomplete
itsreviewoftheseapplications.Thecompanieswill
Five­year followup­data fromtwolargestudies continuefinallabeldiscussionswiththeagencyand
evaluatingadjuvantHerceptininHER2­positive early­ remaincommittedtomakingRituxanincombination
stagebreastcancerwerepresentedattheSan withchemotherapyanFDA­approved optionforpeople
AntonioBreastCancerSymposiuminDecember,con­ withCLL.
firmingthelong­term benefitsofoneyearoftreatment
withHerceptin.N9831andBCIRG006,conducted Clinical milestones | InSeptemberRoche,Genentech
bytheNorthCentralCancerTreatmentGroupand andBiogenIdecannouncedpositiveresultsfroman
theBreastCancerInternationalResearchGroup, internationalphaseIIIstudy(PRIMA),showingthat
re­spectively, showedthatHerceptinreducedtherisk MabThera/Rituxanmaintenancetherapycansignifi­
ofthecancerreturningbyaboutonethird,compared cantlyincreasethetimeuntilthediseaseprogresses
withpatientsreceivingchemotherapyalone.Inboth innewlytreatedpatientswithadvancedfollicular
studies80%ormoreofwomenreceivingoneyear lymphoma,acommontypeofnon­Hodgkin’s lym­
ofHerceptinwerealiveandfreeofthediseaseatfive phoma.BecausePRIMAmetitsendpointduringa
years’follow­up. pre­planned interimanalysis,thestudywasstopped
early.RocheandGenentechplantofiledatafrom
Lucentis PRIMAwiththeEUandUShealthauthoritiesto
Filings | BasedontheresultsofBRAVOandCRUISE expandthecurrentmarketingapproval.
(seebelow),inDecemberGenentechfiledasupple­
mentaryapplicationwiththeFDAforapprovalofuse UpdatedresultsfromthephaseIIICLL8studywere
inpatientswithmacularedemafollowingretinalvein presentedattheannualmeetingoftheAmerican
occlusion. SocietyofHematologyinDecember.Theyshowed
thatpatientswithpreviouslyuntreatedCLLsurvived
Clinical milestones | ResultsofthephaseIIIBRAVO theirdiseaselongerwhentreatedwithMabThera/
andCRUISEstudiesannouncedinJulyshowedthat Rituxancomparedwithchemotherapyalone.CLL8is
Lucentisimprovedvisioninpatientswithswellingin thefirsttrialtodemonstrateimprovedoverallsurvival
theretina(macularedema)duetobranchretinalvein withaspecificfirst­line treatmentforCLL.
andcentralretinalveinocclusion(RVO),respectively.
RVOoccurswhenbloodflowthrougharetinalvein MabThera/Rituxan (rheumatoid arthritis)
becomesblocked,causingswelling(macularedema) Approvals | InOctobertheFDAapprovedupdated
andhemorrhagesintheretina,whichmayresultin Rituxanprescribinginformationthatincludesguidance
blurringorvisionlossinallorpartofoneeye. onretreatmentoflater­stage rheumatoidarthritis
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 35 29012010 12:470736
Roche Business Report 2009 Pharmaceuticals
(RA)patientswithaninadequateresponsetoanti­ theFDA’sOncologicDrugsAdvisoryCommittee
tumournecrosisfactortherapies.Clinicaltrialdataon recommendedagainstapprovingTarcevaforthisuse.
themedicine’sabilitytoimprovephysicalfunction Theagencyisnotboundbythisrecommendation.
andslowjointdamageforuptotwoyearswerealso InJanuary,followingthesubmissionbyOSIoffurther
added.Atthesametime,GenentechreceivedaCom­ data,theFDAextendedthereviewperiodforthe
pleteResponsefromtheFDAfortheuseofRituxan applicationandisnowexpectedtomakeadecision
plusmethotrexateinpatientswithmoderatelyto byApril2010.InSeptemberChugaifiledasupple­
severelyactiveRAwhonolongerrespondtotreat­ mentarymarketingapplicationinJapanforapproval
mentwithadiseasemodifyingantirheumaticdrug, ofTarcevainpancreaticcancer.
includingmethotrexate.Genentechisworkingwith
theFDAtodeterminenextstepsregardingthefiling Clinical milestones | ResultsfromaphaseIIIstudy
forthisindication. (ATLAS)releasedinFebruaryshowedthatTarceva
incombinationwithAvastinforfirst­linemaintenance
Filings | InJuneRochesubmittedacombined treatmentofpatientswithadvancedNSCLCsignifi­
filingtotheEUhealthauthoritiestoextendthemar­ cantlydelayedthetimetodiseaseprogression.InJuly
ketingapprovalforMabTheraasafirst­line biologic Roche,GenentechandOSIannouncedthatthe
therapyforrheumatoidarthritis(RA).Thenewindi­ SATURNtrialhadmetanimportantsecondaryend­
cationsbeingsoughtareforpatientswhohavehad pointofextendingoverallsurvivalinpatientswith
aninadequateresponsetomethotrexate,thecurrent advancedNSCLCwhoreceivedTarcevaimmediately
standardtreatmentoption,andfortheprevention afterinitialchemotherapy.Thisbuildsonearlier
ofjointdamageacrossallRApatientpopulations.The resultsfromSATURNshowingthatTarcevaimproved
combinedfilingfollowedpositiveresultsfromthe progression­free survival,thetrial’sprimaryendpoint.
IMAGE,SERENEandMIRRORtrials,whichshowed
thatMabTheraimprovesthesignsandsymptoms Xeloda
ofRAandcansignificantlyreducetheprogression Approvals | InSeptemberChugaireceivedapproval
ofjointdamage.Rocheisnolongerpursuingapproval inJapanforadditionalindicationsforXelodaand
forathirdindicationoriginallyincludedinthecom­ Avastin.Xelodacannowbeusedincombinationwith
binedfiling,foruseinpatientswhohavenothad oxaliplatinchemotherapy,withorwithoutAvastin,
previoustreatmentwithmethotrexate,basedona inthetreatmentofpatientswithmetastaticcolorectal
reassessmentoftherisk­benefit ratiointhispatient cancer.
population.
Filings | RochefiledanapplicationintheEUin
Tarceva DecemberforapprovalofXelodaincombinationwith
Approvals | InSeptembertheChinesehealthauthor­ oxaliplatinfortheadjuvant(post­surgical)treatment
itiesapprovedTarcevaforthesecond­line treatment ofpatientswithearlycoloncancer,basedon
ofpatientswithadvancednon­smallcelllungcancer datafromthephaseIIINO16968(XELOXA)trial.
(NSCLC).
Filings | InMarchRocheandOSIPharmaceuticals Research and development
submittedapplicationstotheEMEAandtheFDA,
respectively,forapprovalofTarcevaasmaintenance Toensureastrongflowofsuitablecandidatemolecules
therapyinpatientswithlocallyadvancedormetastatic intoitsdevelopmentpipeline,Rochehasbuilta
NSCLCwhosediseasehasnotprogressedfollowing uniqueinnovationnetworkofindependentresearch
first­line chemotherapy.Bothfilingswerebasedon anddevelopmentcentres.InadditiontoRocheand
datafromthephaseIIISATURNtrial.InDecember Genentech,itincludesChugaiinJapanandalliances
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 36 29012010 12:470837
Roche, Genentech, Chugai and over 150
partners worldwide form a unique innovation
network based on a diversity of approaches
withmorethan150partnerorganisationsworldwide. areabouttostartphaseIIIdevelopment.Atthe RG7204 is a targeted
Thispromotesadiversityofresearchapproaches, sametime,wearealsoexploringnewindicationsand inhibitor of abnormal
aswellasenablingaccesstonewtechnologiesand formulationsforexistingproducts,includingformu­ BRAF that exemplifies
the Roche Group’s
promisingdrugcandidates. lationsofHerceptin(seeabove,p.34)andother
personalised health-
biologicmedicinesthatcanbeadministeredbymore
care approach. It is
GenentechResearchandEarlyDevelopment(gRED) convenientsubcutaneousinjectioninsteadofintra­ currently in late-stage
continuestooperateasanindependentunit.Similarly, venousinfusion. clinical development
thenewlyformedPharmaResearchandEarlyDevel­ for malignant
opmentorganisation(pRED)enjoysfulloperational FollowingtheintegrationofGenentech’sR&D melanoma. Roche
is developing a
autonomy.gREDcontinuestobeinspiredbythe projectsintotheGroup’sglobalpharmaceuticals
dia g nostic test to
valuesandculturethatledtoGenentech’ssuccess, portfolio,RocheandGenentechconducteda
identify patients
whilepREDwillexpandRoche’scapabilitiesto comprehensivereviewoftheR&Dpipelineinthe
whose tumours
bringnovelmedicinestopatients.Atthesametime, fourthquarter.Thisresultedindecisionstoterminate carry the abnormal
subjecttoexistingthird­party obligations,bothunits anumberofearly­stage developmentprojects, BRAF gene.
arenowfreetoshareinformationandtechnologies omeofwhichhaverevertedtopartnercompanies.
thatcansupportandenhancetheiractivities. Theterminations,whichwereprimarilydrivenby
clinicaldata,arepartofanongoingefforttoprioritise
ClosecooperationbetweenthePharmaceuticals resourcestowardsahighlydifferentiateddevelopment
DivisionandRocheDiagnosticsisakeystrategic portfoliooffirst­in­class orbest­in­class medicines.
advantageforourcompany.Thetwodivisionscan
shareintellectualproperty,technologiesandresearch Atthebeginningof2010thedivision’sR&Dpipeline
findingsfreely.Amongotherthings,thisallowsRoche included111projectsinclinicaldevelopment(phaseI
tocombineandleveragebothdivisions’leadership toIII).Ofthese,59involvednewmolecularentities
inthekeyfieldofmolecularbiology.Inaddition,it (NMEs)and52involvedadditionalindications.Ten
enablesdiagnosticsexpertisetobeseamlesslyinte­ NMEsareinorabouttoenterlate­stage develop­
gratedintoallpartsofthepharmaceuticalsR&D ment(seetable,p.40).Thirtyprojectsinvestigating
process(seep.38).ThisiscentraltoRoche’sgoalof additionalindicationsforexistingproductsarein
advancingpersonalisedhealthcare,anapproach phaseIII.ThePharmaceuticalspipelineisshownin
thatseekstotailortreatmentstospecificpatientsub­ thefold­outinsidethefrontofcoverofthisreport.
populationsbasedonemergingscientificunder­ Furtherdetailsareavailableatwww.roche.com.
standingofbiologyanddiseaseatthemolecularlevel.
Oncology
Overthenextfewyearsthedivisionaimstoexpand Roche’sclinicaldevelopmentpipelineinoncology
itsproductportfoliowithanewgenerationof includes21newmolecularentities.ThePharma­
medicinesforpatientssufferingfromcancer,meta­ ceuticalsDivisionisfurtherstrengtheningitsoncology
bolicandautoimmunediseases,viralinfections portfoliothroughnewtargetedtherapeuticoptions
anddisordersofthecentralnervoussystem(CNS). andexpandingintonewindications.Fourcompounds
Late­stagedevelopmentofpromisinganticancer progressedintolate­stageclinicaltestingin2009.
compoundssuchaspertuzumabandT­DM1
(HER2­positivebreastcancer),RG7204(malignant RG7204(PLX4032,collaborationwithPlexxikon)isa
melanoma)andRG7159(leukemia,lymphoma)ison targetedinhibitorofabnormalBRAFthatexemplifies
track.Inaddition,twonovelcompoundsinthe theRocheGroup’spersonalisedhealthcareapproach
metabolicandCNSportfolios—aleglitazar(cardio­ usingbiomarkersanddiagnostictools.BRAFisa
vasculardiseaseinhigh­risk type2diabetespatients) proteinthatrelaysgrowthsignalsinsidecells.Incer­
andRG1678(negativesymptomsofschizophrenia)— taintypesofcancer,geneticchanges(mutations)
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 37 29012010 12:470838
Roche Business Report 2009 Pharmaceuticals
Excellence in science:
Seamless collaboration
1
Process
As a leading healthcare company with strengths in pharmaceuticals and diagnostics, we are
well equipped to advance personalised healthcare. The organisational realignment imple-
mented in our Pharmaceuticals and Diagnostics Divisions over the last several years enables
them to collaborate seamlessly along the whole value chain, from discovery to commerciali-
sation. This is particularly important since personalised healthcare starts early in the drug
development process. Our Diagnostics Division is there from the beginning, with technologies
and expertise to help identify potential drug targets, screen out less-promising candidate
compounds and select suitable patients for clinical trials. In some cases collaboration results
in a drug coupled with a companion diagnostic to guide treatment.
Pharmaceuticals
Research and early development Clinical development Commercialisation
Market
Target Lead
Phase 0 Phase I Phase II Phase III Filing
selection generation
Phase IV
Discovery Exploratory Proof Confirmatory
phase phase of concept phase
Companion diagnostic
Biomarker development Dx launch/post-launch assessment
feasibility and utility
Target identification Tailored prescribing and monitoring
Patient selection
Diagnostics
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 38 29012010 12:470839
Close cooperation between the Pharma-
ceuticals and Diagnostics Divisions
is a key strategic advantage for Roche
leadtoproductionofabnormalBRAFthatisalways (TDM4374g),presentedattheSanAntonioBreast
activeandcausesuncontrolledproliferationofcancer CancerSymposiuminDecember,showedanobjective
cells.MutatedBRAFisfoundinapproximately50% response(tumourshrinkage)in33%ofwomenwith
ofmalignantmelanomas,themostdeadlyformofskin advanced(metastatic)HER2­positivebreastcancer
cancer.FollowingpositivephaseIresults,aphaseII thathadworsenedfollowingprevioustreatment.
clinicaltrialwasinitiatedinSeptembertoinvestigate
RG7204inpreviouslytreatedpatientswithBRAF RG3616(GDC­0499;collaborationwithCuris)isa
mutation­positivemalignantmelanoma,andaphase novelcompoundtargetingthehedgehogsignalling
IIItrialinpreviouslyuntreatedpatientsbeganin pathway,whichisthoughttobeimplicatedinseveral
January2010.Adiagnostictestisbeingdevelopedin cancers.FollowingpositivephaseIresults,apivotal
collaborationwithRocheMolecularDiagnosticsto phaseIIstudyinvestigatingRG3616asapotential
identifypatientswhosetumourscarrytheabnormal treatmentforadvancedbasalcellcarcinomacom­
BRAFgeneandarethereforemostappropriatefor mencedinFebruary.RG3616isalsobeingevaluated
treatmentwithRG7204. inphaseIIstudiesasafirst­line therapyformeta­
staticcolorectalcancerandinthemaintenancetreat­
RG7159(GA101),thefirsttypeII,glycoengineered, mentofovariancancer.
fullyhumanisedanti­CD20monoclonalantibody,
iscurrentlybeinginvestigatedinlate­stageclinical Inflammation and autoimmune disorders
trialsasapotentialtreatmentforchroniclymphocytic Rochehaseightnewcompoundsindevelopmentfor
leukemia(CLL)andnon­Hodgkin’slymphoma chronicandprogressiveautoimmuneandinflammatory
(NHL).DatafromphaseIIstudieswerepresented diseasessuchasrheumatoidarthritis(RA)and
attheEuropeanHematologyAssociationmeeting asthma,fiveofwhichareinphaseIIorIIIclinicaltest­
inJune2009(CLL)andtheAmericanSociety ing.PhaseIIIprogrammesarecurrentlyinvestigating
ofHematologyinDecember2009(CLLandNHL). thenext­generation anti­CD20 antibodyocrelizumab
AphaseIIIstudyinpatientswithCLLwasinitiated inseveralRAsettings,includinginpatientswho
inDecember2009. respondinadequatelytothecurrentstandardofcare,
methotrexate,ortotumournecrosisfactor(TNF)
Pertuzumab(RG1273)isaHER2dimerisation inhibitors.Thefirstofthese,STAGE,inpatientswho
inhibitorthatisbeingstudiedincombinationwith didnotrespondtotreatmentwithmethotrexate,
HerceptinandstandardtherapyinHER2­positive wasreportedtohavemetitsprimaryendpointin
breastcancer.AphaseIIIstudy(CLEOPATRA) December.Whileoveralladverseeventsreportedin
evaluatingtheadditionofpertuzumabtoHerceptin thisstudywerecomparablebetweentheocrelizumab
andchemotherapyinthefirst­line treatmentof andplacebotreatmentgroups,ahigherpercentage
patientswithadvanced(metastatic)diseaseanda ofseriousinfectionswasobservedinthepooledocre­
phaseIItrial(NEOSPHERE)investigatingneoadjuvant lizumabgroupscomparedwiththeplacebogroup.An
(presurgical)treatmentwithpertuzumabareongoing. additionalmajorphaseIIIstudy(SCRIPT),inpatients
withinadequateresponsetoTNFinhibitors,isex­
Trastuzumab-DM1(T­DM1, RG3502),anovelanti­ pectedtoreportin2010.DosingintheFILMstudy,
body­drugconjugatethatcombinesananti­HER2 inpatientsnotpreviouslytreatedwithmethotrexate,
monoclonalantibodyandapowerfulcytotoxicagent, hasbeenstoppedfollowingreassessmentoftherisk­
isbeinginvestigatedinthesecond­andthird­line benefitprofileinthispatientpopulation.AphaseIII
treatmentofmetastaticHER2­positivebreastcancer. programmeinvestigatingocrelizumabinthetreatment
AphaseIIItrial(EMILIA),investigatingT­DM1 oflupusnephritis(BELONG)wasalsodiscontinued
inthesecond­line treatmentsetting,beganinthe followingreassessmentoftherisk­benefit profile.
firstquarter.PositiveresultsfromaphaseIIstudy
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 39 29012010 12:470840
Roche Business Report 2009 Pharmaceuticals
Ten new molecular entities in ongoing or planned late-stage studies
Compound Indication Status Market potential
ocrelizumab rheumatoid arthritis first phase III study (STAGE) met its primary endpoint best in class
in fourth quarter 2009, results from additional studies
expected in 2010
trastuzumab-DM1 HER2-positive metastatic phase III started in first quarter 2009 first in class
breast cancer (second-line treatment)
pertuzumab HER2-positive metastatic phase III started in 2008 first in class
breast cancer
RG7159 (GA101) non-Hodgkin’s lymphoma, phase III started in fourth quarter 2009 best in class
chronic lymphocytic (chronic lymphocytic leukemia)
leukemia
RG7204 (PLX4032) malignant melanoma registration studies started in 2009, January 2010 first in class
RG3616 advanced basal pivotal phase II started in first quarter 2009 first in class
(GDC-0499) cell carcinoma
RG1678 negative symptoms of positive phase II results in fourth quarter 2009, first in class
schizophrenia phase III planned to start in 2010
aleglitazar cardiovascular high risk phase III planned to start in first quarter 2010 first in class
in type 2 diabetes
taspoglutide type 2 diabetes first positive phase III results (T-emerge) in fourth best in class
quarter 2009, additional results expected in 2010
dalcetrapib dyslipidemia, phase III enrolment ongoing first in class
cardiovascular high risk
Metabolic and cardiovascular diseases patientswithtype2diabetes.Aleglitazar(RG1439)
Roche’smetabolicandcardiovascularportfolioof isaperoxisomeproliferator­activatedreceptor(PPAR)
12newmolecularentitiesatvariousstagesofclinical co­agonistwithdemonstratedeffectsonbloodfats,
developmentincludesthreepromisinglate­stage bloodpressureandbloodglucoseforthereductionof
compounds.Dalcetrapib(RG1658,JTT­705;licensed cardiovascularmorbidityandmortalityinpatientswith
fromJapanTobacco),isanovelcholesterolester type2diabetes.AphaseIIIprogramme(ALECAR­
transferprotein(CETP)inhibitorforthemanagement DIO)isexpectedtobeginrecruitmentearlyin2010.
ofcholesterollevelsintheblood.Recruitmentforthe
phaseIIIdal­HEART programmeisontrack.Anew Virology
imagingstudy,dal­PLAQUE2,wasannouncedinthe Rochecurrentlyhastwodirectantiviralagentsin
lastquarterof2009,andpatientrecruitmenthas developmentforthetreatmentofhepatitisC:
commenced.Taspoglutide(RG1583,BIM51077; thenucleosidepolymeraseinhibitorRG7128(colla­
licensedfromIpsen)isaonce­weekly humangluca­ borationwithPharmasset)andtheproteaseinhibitor
gon­likepeptide­1(GLP­1)hormoneanalogueforthe RG7227(ITMN­191; collaborationwithInterMune).
controlofbloodglucoselevels.Inlate2009initial BothoftheseoralagentsenteredphaseIIbstudies
resultsfromfivephaseIIItrialsintheT­emerge duringtheyear.RG7128andRG7227arebeinginves­
programmeshowedthattaspoglutideconsistently tigatedincombinationwithPegasysandCopegus
providespowerfulanddurableglycemiccontrolin (ribavirin),andincombinationwitheachotherin
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 40 29012010 12:470841
Cancer is not one disease but a group
of more than 100 distinct disorders,
each with its own medical challenges
aninterferon­free regimen.ResultsfromaphaseI Focus on unmet medical
study(INFORM­1) investigatingRG7227combined
needs
withRG7128inhepatitisCwerepresentedatthe
annualAmericanAssociationfortheStudyofLiver
DiseasescongressinNovember.Theyshowedforthe Cancer | AccordingtothelatestInternational The GlyT1 inhibitor
firsttimethatanalloral,interferon­freeregimen AgencyforResearchonCancer(IARC)estimate, RG1678 is being
canleadtosignificantviralsuppressioninpreviously in2008over12millionpeopleworldwidewere codeveloped with
Chugai for the treat-
untreatedpatientsandpatientsinwhomprevious diagnosedwithcancer,andsome7.6milliondiedof
ment of the negative
treatmenthasfailed. thedisease.TheIARCanticipatesthatcancerwill
symptoms of schizo-
surpassheartdiseaseastheleadingcauseofdeath phrenia, an area of
Central nervous system worldwidein2010andalsoforecaststhatby2030 high unmet medical
TheRocheportfoliohas12novelcompoundsin therewillbeover26millionnewcasesand17million need. RG1678 has
developmentfordisordersofthecentralnervoussys­ deathsperyearfromcancer.InEuropealone,one the potential to
enable patients to
tem,includingschizophrenia,multiplesclerosisand inthreepeoplecanexpecttodevelopcancerintheir
better establish social
otherseriousconditions.Oneofthesecompoundsis lifetime.Cancerisnotonediseasebutagroupof
relationships and
RG1678,aglycinetransportertype1(GlyT1)inhibitor morethan100distinctdisorders,eachwithitsown
parti cipate in every-
discoveredbyRoche.Itisbeingcodevelopedglobally medicalchallenges. day activities,
withChugaiforthetreatmentofthenegativesymp­ re ducing the burden
tomsofschizophrenia,anareaofhighunmetmedical Non-Hodgkin’s lymphoma | Agroupofover30 for patients and
caregivers alike.
need.RG1678hasthepotentialtoenablepatientsto cancersthataffectthelymphaticsystem.Thisclass
betterestablishsocialrelationshipsandparticipate ofcancercurrentlyaffectsover1.5millionpeople
ineverydayactivities,reducingtheburdenforpatients worldwide.Follicularlymphomaaccountsforabout
andcaregiversalike.InDecemberRocheannounced oneinfourofallcasesofnon­Hodgkin’slymphoma.
thataphaseIItrialwithRG1678hadmetitsprimary Itcanoccuratanytimeduringadulthood,though
andsecondaryendpoints,improvingboththenegative peoplearetypicallydiagnosedduringtheirsixties,
symptomsandthepersonalandsocialfunctioning anditaffectsasmanymenasitdoeswomen.
ofpatientswithschizophrenia.Thecompoundwas
welltoleratedatalldosestested.Rochehasnow Chronic lymphocytic leukemia |Themostcommon
decidedtoinitiatephaseIIIclinicaltesting,withthe typeofleukemiainadults,accountingforapproximately
firsttrialplannedtostartin2010. 25–30%ofallformsofleukemia.Theincidenceof
CLLinWesterncountriesisaround2–4per100,000,
AlsoinDecember,Rocheanditsdevelopmentpartner anditistwiceascommoninmenasinwomen.
BiogenIdecreportedpositiveresultsfromaphaseII
trialwiththehumanisedanti­CD20monoclonal Colorectal cancer | Cancerofthelargeintestine
antibody ocrelizumab (RG1594)inpatientswith orrectum,whichaccountsforover1millionnew
relapsing­remitting multiplesclerosis,oneofthelead­ cases(around10%ofallnewlydiagnosedcancers)
ingcausesofneurologicaldisabilityinyoungadults. worldwideeachyear.Itisthesecondmostcommon
Ocrelizumabshowedastrongeffectversusplacebo causeofcancerdeathsinEuropeandthethird
withahighlystatisticallysignificantreductioninsigns mostcommonworldwide.
ofdiseaseactivityasmeasuredbybrainlesions,the
primaryendpoint. Kidney cancer | Thistypeofcancerisnewlydiag­
nosedinaround200,000peopleandcauses100,000
deathsworldwideeveryyear,ratesthatareexpected
toincrease.Renalcellcarcinomaaccountsfor90%
ofallkidneycancers.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 41 29012010 12:470842
Roche Business Report 2009 Pharmaceuticals
Breast cancer | Themostcommoncanceramong Hepatitis B and C | ThehepatitisBandCviruses
womenworldwide.Over1millionwomenarenewly (HBV,HCV),whicharecommonlytransmittedthrough
diagnosedandover500,000diefromthedisease blood­to­blood contact,causeacuteandchronicliver
eachyear.Asthereareseveraldifferenttypesof disease,potentiallyleadingtoliverfailure,cirrhosis
breastcancer,knowledgeoftumourcharacteristics andlivercancer.Worldwide,350millionpeopleare
isimportantfortreatmentdecisions.Some20–30% thoughttobechronicallyinfectedwithHBV,ahighly
ofwomenwithbreastcancerhavetumourswith infectiousvirusthatisresponsibleforanestimated
abnormallyhighlevelsofaproteinknownasHER2. onemilliondeathsannually.Morethan170million
HER2­positive tumoursareparticularlyaggressive, peoplearoundtheworldareinfectedwithHCV,and
fast­growing andlikelytorelapse. 3to4millionnewcasesoccureachyear.HepatitisC
isthemainreasonforlivertransplantation.Arecent
Lung cancer | Themostcommonformofcancer studyontheHCV­related burdenofdiseasein22
worldwideandtheleadingcauseofcancerdeaths. Europeancountriesestimatedthatbetweenseven
Thereareanestimated1.4millionnewcasesannually. andninemillionpeople,orover1%ofthepopulation,
Non­small celllungcanceristhemostcommon areinfectedwithHCV.
form,accountingforapproximately80%ofallcases.
Influenza, or flu | Ahighlycontagious,debilitating
Pancreatic cancer | Aparticularlyaggressivedisease viralillnessthatoccursmainlyintheautumnand
thatisextremelydifficulttotreat.Itkillsahigher wintermonthsintemperateclimatesandyear­round
proportionofpatientsinthefirstyearafterdiagnosis intropicalareas.Itcanbeparticularlydangerous
thananyothercancer.Thefifthleadingcauseof foryoungchildren,theelderlyandpeoplewith
cancerdeathsinthedevelopedworld,pancreatic chronichealthproblemswhoareatgreaterriskof
cancerclaimsnearly80,000liveseveryyear. influenza­related complications.Pandemics,orglobal
epidemics,arecausedbynovelstrainsofinfluenza
Gastric (stomach) cancer |Accountsforover1million towhichpeoplehavenoimmunity.Pandemicsoccur
newcasesandsome800,000deathseachyear,making every10to40yearsandhavebeenassociatedwith
itthesecond­largest causeofcancerdeathsworld­ significantlevelsofillnessand,dependingontheviral
wide.ThevastmajorityofcasesoccurinAsia,where, strain,death.AccordingtotheWorldHealthOrgani­
withlungcancer,itistheleadingmalignancy.Advanced zation,thecurrentlycirculatingpandemicA(H1N1)
stomachcancerisassociatedwithapoorprognosis; 2009influenzavirusappearstobeascontagiousas
themediansurvivaltimeafterdiagnosisisapproxi­ seasonalinfluenzaandisspreadingfast,particularly
mately10–11monthswithcurrentlyavailabletherapies. amongpeopleaged10to45years.Thediseaseis
generallyclinicallymild,butsevereillnesscanoccur.
Anemia | Occurswhenthelevelofredbloodcells
and/orthehemoglobintheycontainfallsbelow Autoimmune disorders | Occurasaresultofa
normal,starvingorgansandtissuesofoxygen.Itis mistakenimmuneresponsetothebody’sowntissues.
seeninover80%ofpatientswithchronickidney Thecausesareunknown.Rheumatoidarthritis,
(renal)disease,whichaffectsmorethan500million multiplesclerosisandlupuserythematosusareamong
peopleworldwide.Inaddition,anemiaaffectsthree themostcommonautoimmunedisorders,whichaffect
outoffourcancerpatientsundergoingchemotherapy. millionsofpeopleworldwide.
Patientswithuntreatedanemiamayneedblood
transfusions.Thepotentiallong­term effectsofanemia Rheumatoid arthritis (RA) | Achronic,progressive
includecardiovasculardiseaseinrenalpatients, inflammatorydiseaseofthejointsandsurrounding
whileinpatientswithcanceritisassociatedwith tissuesthatisassociatedwithintensepain,irrevers­
diminishedqualityoflife. iblejointdestructionandsystemiccomplications.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 42 29012010 12:470943
Bcells(atypeofimmunecell)areknowntoplaya
keyroleintheinflammationassociatedwithRA.
Severalkeycytokines,orproteins,arealsoinvolved,
includingTNFalfa,interleukin­1 (IL­1) andinter­
leukin­6 (IL­6). IL­6 hasbeenidentifiedashaving
apivotalroleintheinflammationprocess.Around
21millionpeopleworldwidearethoughttobe
affectedbyRA.
Diabetes | Recognisedasaglobalepidemicbythe
WorldHealthOrganization.TheInternationalDiabetes
Federationestimatesthatsome360millionpeople
worldwidewillhavediabetesby2030.Accordingto
theWHO,type2(adultonset)diabetesaccountsfor
around90%ofallcases.Uncontrolledtype2diabetes
canleadtoseverecomplicationssuchascardio­
vasculardisease,stroke,blindness,amputations,
andkidneyfailure,resultinginsignificanthealthcare
burdenstosociety.
Schizophrenia | Aseverementaldisordercharacter­
isedbyprofounddisruptionsinthinkingthataffect
language,perceptionandthesenseofself.According
toWHOestimates,schizophreniaaffectsapproxi­
mately24millionpeopleworldwideandismostcom­
moninadultsagedbetween15and35years.The
symptomsofschizophreniaarebroadlycategorised
aspositive,negativeandcognitive.Positivesymptoms
arepsychoticbehaviourssuchashallucinationsand
delusions.Negativesymptomsareassociatedwith
disruptionofnormalbehaviourandemotions,suchas
inabilitytosustainplannedactivityoralackofmotiva­
tionandinterestinday­to­day living.Cognitive
symptomsincludetroublefocusingorpayingattention.
Persistentnegativesymptomsareamajorcauseof
chronicdisability.Thereiscurrentlynomarketed
productavailabletotreatthenegativesymptomsof
schizophrenia.
07_L_Roche_AR09_ENG_Pharmaceuticalsindd 43 29012010 12:4709Together they’re taking aim
with an innovative medicine
for skin cancer
Roche is not only the world leader in in vitro diagnostics. We also syste m ­
atically apply our diagnostic expertise to the research and development
of new medicines. This helps us to develop pharmaceuticals that target
the biological mechanisms that give rise to cancer. One example is
RG7204 (PLX4032), currently being tested in phase II clinical trials as
a possible treatment for malignant melanoma, a type of skin cancer.
RG7204 is a novel, highly selective BRAF kinase inhibitor that targets and
destroys cancer cells harbouring a specific cancer causing gene mutation
called BRAF V600E. To identify those patients whose tumours carry this
mutation — and are therefore considered most likely to respond to this
targeted medicine — Roche is developing a companion diagnostic test.
RG7204 is a promising compound in development
for the treatment of BRAF mutation­positive patients
with malignant melanomas, the deadliest form of
skin cancer. This oral medicine — a selective kinase
inhibitor — is being developed by Roche in
collaboration with Plexxikon.
08_Bildstrecke_ENG_S44-45indd 1 28012010 23:32:2708_Bildstrecke_ENG_S44-45indd 2 28012010 23:32:31Diagnostics | In 2009 sales again
grew well ahead of the market, with strong
uptake of new products contributing to
market share gains in key segments such
as immunoassays and tissue diagnostics.
All business areas launched major new
products that Roche believes will help drive
above-market growth in 2010. Efforts to
enhance operational efficiency are
ongoing throughout the division and
contributed to higher operating profit in
2009. The division will continue and
expand these efforts in order to improve
productivity and profitability further.
09_L_Roche_AR09_ENG_Diagnosticsindd 46 29012010 01:58:3947
Diagnostics Division in brief
Key figures
% change % change in
In millions of CHF in CHF local currencies % of sales
Sales 10,055 4 9 100
— Professional Diagnostics 4,553 4 9 45
— Diabetes Care 2,969 0 6 29
— Molecular Diagnostics 1,183 2 5 12
— Applied Science 870 12 15 9
— Tissue Diagnostics 480 28 29 5
Operating profit 1,198 1 12 11.9
Operating free cash flow 1,152 92 102 11.5
Research and development 978 4 5 9.7
Diagnostics Executive Committee | 31 December 2009
Jürgen Schwiezer 1 CEO Division Roche Diagnostics
Manfred Baier Applied Science
Roland Diggelmann Asia—Pacific
Dirk H. Ehlers Professional Diagnostics
Christian Hebich Finance and Services
Michael Heuer EMEA (Europe, Middle East, Africa) and Latin America
Alexander Keller Global Platforms and Support
Frank Lennartz Human Resources
Hany Massarany Tissue Diagnostics
Daniel O’Day 2 Molecular Diagnostics
Frank Pitzer 3 Regulatory Affairs and Quality Management
Claus-Joerg Ruetsch 3 Legal
Michael Tillmann North America
Robert Yates Business Development
1 To 31 December 2009 — see Corporate Governance.
2 Chief Operating Officer of Roche Diagnostics since 1 January 2010.
3 Associate member.
09_L_Roche_AR09_ENG_Diagnosticsindd 47 29012010 01:58:4048
Roche Business Report 2009 Diagnostics
Diagnostics Division Sales by region
Roche’s Diagnostics Roche’sDiagnosticsDivisionistheworld’sleading
Division is the global supplierofin vitro diagnostics(IVDs).IVDtests— Europe/Middle 53% (+9%)
leader in the 40 billion testsperformedinalaboratoryoratthepointofcare East/Africa
US dollar in vitro
onbloodandothersamplesfrompatients—area Japan 5% (+0%)
diagnostics market.
criticalsourceofobjectiveinformationabouthealth Asia—Pacific 10% (+25%)
The division strives to
develop systems that anddisease.Roche’sdiagnosticinstrumentsand
make testing more reagentshelpdoctorsdetectdiseases,selectappro- Latin America 6% (+15%)
efficient and provide priatetreatmentsandmonitorpatients’responsesto
results of high medi- care.Inaddition,scientistsusethedivision’sresearch North America 26% (+4%)
cal value.
productstogainabetterunderstandingofthe Other 0% (–14%)
causesofdiseaseanddiscovernewtreatments.
Italics = growth rates (in local currencies).
Inover150countriesthedivisionservescustomers
spanningtheentirehealthcarespectrum—from
hospitalsandcommercialmedicallabs,tophysicians, • Together,Roche’sPharmaceuticalsandDiagnostics
topatientswithconditionsrequiringthemtoself-test. Divisions are working to advance personalised
In2009Rochehada20%shareoftheglobalIVD healthcare. Activities are aligned to help increase
market,valuedatanestimated40billionUSdollars drug R&D productivity, discover more targeted
inannualsales.1 medicines and drive development of companion
diagnostics. This has the potential to ‘revalue’
diagnostics, which inform the majority of clinical
Strategic priorities decisions yet account for less than 3% of medical
spending.
Changingdemographics,newtechnologiesand • The Diagnostics Division is outperforming the
mountingpressureonbudgetsandpricingareamong market in the Emerging Seven (E7) countries 2,
thetrendsshapingthehealthcaremarket. most notably in China. To accelerate growth
TheDiagnosticsDivision’sstrategicprioritiesare further, it is expanding its local organisations and
designedtorespondtothesetrendsandcapitalise investing in programmes to bring products to
onthegrowthopportunitiestheypresent. market more quickly.
• Testing efficiency is one pillar of the division’s • The division intends to improve its profitability
business. Roche’s automated diagnostic systems further through a combination of strong sales
embody decades of engineering innovation. growth and efficiency initiatives targeting virtually
Future advances will include enhanced workflow every area of operations. This report contains
integration and IT capabilities supporting elec- information on progress made in 2009.
tronic patient record management.
• Testing efficiency alone is not enough. Products of
high medical value are critical for sustained
competitiveness and growth. Novel Roche tests
mark significant advances in oncology, cardiology
and other major therapy areas. Increased invest-
ment in biomarker research and in trials to 1 Figures on market growth, market share and market size are
demonstrate the clinical utility of new tests will estimates based on company and independent reports and
Roche analysis.
yield further innovations.
2 E7 markets = Brazil, Russia, India, China, South Korea, Mexico
and Turkey.
09_L_Roche_AR09_ENG_Diagnosticsindd 48 29012010 01:58:4149
Sales and instrument placements were up
strongly in 2009
Results and main business onscheduleintheEUandothermarketsinthe Divisional sales
secondhalfoftheyear.Rocheexpectsthismajor growth was broad
developments
additiontoitscobasfamilyofmodularSerum based, extending
across all five busi-
WorkAreasystemstoenhanceitscompetitiveness
ness areas and
In2009theDiagnosticsDivisionrecordedsales significantlyinbothclinicalchemistryandimmuno-
all major regional
of10.1billionSwissfrancs,anincreaseof9%inlocal assays.Altogether,thedivisionlaunchedover markets except Japan.
currencies(4%inSwissfrancs;4%inUSdollars) 20majorproductsin2009. All business areas
over2008.3Thiswasmorethantwicetheestimated again launched major
IVDmarketgrowthrate(3–4%). TheDiagnosticDivision’soperatingprofitrose12%in new products in 2009.
localcurrencies(1%inSwissfrancs)to1,198million
Allfivedivisionalbusinessareascontributedtosales Swissfrancs,andtheoperatingmarginatconstant
growth,ledbyProfessionalDiagnosticsandDiabetes exchangeratesadvanced0.4percentagepoints.
Care.Immunoassaysandsingle-stripbloodglucose Theseincreaseslargelyreflectsalesgrowth,tightcost
monitoringsystemsremainedthesebusinesses’ managementandthesignificantone-timeexpenses
primarygrowthdrivers.MolecularDiagnostics’core recordedin2008,includingthoserelatingtotheVen-
bloodscreeningandvirologysegmentsdelivereda tanaacquisition.InSwissfrancsthemargindecreased
solidsingle-digitriseinoverallsales.IntheApplied by0.4percentagepoints,to11.9%,duetoaparti-
Scienceunit,strongdemandfortheMagNAPureand cularlyunfavourablecombinationofexchangerate
LightCyclerproductlinesfuelledfurtherabove-market movements.Formoreinformationonthedivision’s
growth.TheTissueDiagnosticsbusiness,acquired operatingresults,seetheFinanceReport(Part2
in2008,continuedtogrowwellaheadofthemarket, ofthisAnnualReport).
drivenmainlybyitsadvancedtissuestainingportfolio.
Instrumentplacementswereagainupsignificantly Efficiency gains
forthedivisionasawholeandwereamajorgrowth Initiativestosimplifycoreprocesses,consolidate
driver. services,streamlineproductportfoliosandreduce
timetomarketareinplaceatanumberofmajorsites.
Geographically,theEMEA4andAsia—Pacificregions In2009suchinitiativescontributedtosignificant
contributedmosttogrowth,withallfivebusiness costsavingsandhelpedthedivisionlimitheadcount
areasrecordingsolidsalesgainsinthesemarkets. growthdespitetheacquisitionofSwisslaband
TissueDiagnosticsremainedtheprimarygrowth innovatisanddespiteasubstantialsalesforce
driverinNorthAmerica.InJapanProfessionalDiag- increaseinChina.Notablesuccessesincludedthe
nosticsandAppliedSciencegrewmoderatelyand consolidationofregionalcallcentres,thecreation
TissueDiagnosticsachievedhighdouble-digitgrowth, ofsharedservicecentresinNorthAmericaand
butdivisionalsalestherewereflatoverall,largely reductionsinmanufacturingcosts.Existingandnew
duetoreducedgovernmentIVDreimbursementand programmeswillbeintroducedatmoresitesto
lowerresearchfunding. improveproductivityfurtherandachieveadditional
costsavings.
SalesintheE7marketsgrew24%andaccountedfor
over10%oftotaldivisionalsalesrevenues.Increased
investmentinthesemarketsandstrongdemandfor
immunoassaysandotherleading-edgeRocheproducts
contributedtothisstrong,above-marketgrowth.
Thefirsttwomodulesofthecobas8000analyser
3 Unless otherwise stated, all growth rates are in local currencies.
seriesforhigh-throughputlaboratorieswerelaunched 4 EMEA = Europe, Middle East and Africa.
09_L_Roche_AR09_ENG_Diagnosticsindd 49 29012010 01:58:4150
Roche Business Report 2009 Diagnostics
Roche’s top-selling diagnostics | sales in millions of CHF
Accu-ChekMobile cobase601 cobasc501 CobasTaqMan48 cobasTaqScreen
MPXTest
2,969 1,627 1,275 566 314
Accu-Chek blood glucose cobas e modules cobas c modules Cobas AmpliPrep Cobas AmpliScreen
meters and insulin pump Modular Analytics Modular Analytics Cobas TaqMan cobas TaqScreen
systems Elecsys Cobas Integra
+6% * +19% * +4% * +4% * +8% *
Market segment : Market segment : Market segment : Market segment : Market segment :
Diabetes management Immunoassays Clinical chemistry Virology Blood screening
09_L_Roche_AR09_ENG_Diagnosticsindd 50 29012010 01:58:4251
An industry-leading portfolio of products for
clinical testing, blood screening and life science
research
CoaguChekxs VentanaIHCreagents MagNAPureLC2.0 SysmexXT-4000i GenomeSequencerFLX
293 281 255 141 139
CoaguChek meters Immunohistochemistry MagNa Pure Systems Sysmex analysers 454 Genome
reagents Light Cycler Systems Sequencers
+20% * +28% * +35% * +6% * +0% *
Market segment : Market segment : Market segment : Market segment : Market segment :
Coagulation Advanced Gene expression Hematology DNA sequencing
monitoring tissue staining research
Images are not to scale.
* Year-on-year sales growth in local currencies.
09_L_Roche_AR09_ENG_Diagnosticsindd 51 29012010 01:58:4352
Roche Business Report 2009 Diagnostics
Business area highlights Coagulationmonitoringsalesincreased20%,
reinforcingRoche’sleadershipinthissegment.
Immunoassay sales Professional Diagnostics — above-market growth Salesofthetop-sellingCoaguChekXSmonitor
were again a major and major new products forpatientusewereupstronglyagain,helped
growth driver, increas- RocheProfessionalDiagnosticsisaleadingsupplier bycontinuedrobustdemandinEuropeandexpanded
ing at roughly three
ofinstruments,tests,softwareandservicesfor Medicarereimbursementforhomecoagulation
times the market
laboratoriesandofdecentralisedtestingproductsto testingintheUS.Studiesindicatethatself-testing
growth rate. The new
cobas 8000 modular supportclinicaldecisionmakingatthepointofcare. helpspatientsonanticoagulantstokeeptheir
system will make In2009thebusinessareahada15%shareof medicationwithinthetherapeuticrangeandcan
Roche Professional aglobalmarketestimatedat28billionUSdollars. reducecomplications.
Diagnostics an even
stronger competitor
ProfessionalDiagnostics’full-yearsalesgrewnearly InAugustProfessionalDiagnosticsbeganrollingout
in both immunoassay
twiceasfastasthemarket,rising9%to4,553million thecobas8000modularanalyserseriesforhigh-
testing and clinical
Swissfrancs.Immunoassayandclinicalchemistry throughputlaboratoriesinEuropeandothermarkets
chemistry.
systemsforlaboratories,thetwolargestsegments thatrecogniseCEMarkcertification.Theresponse
bysales,remainedtheprimarygrowthdrivers. tothisnewflagshipcobasplatformhasbeen
Regionally,salesoutpacedmarketgrowtheverywhere overwhelminglypositive,withmorethan20orders
exceptNorthAmerica,wheretheindustryasawhole shippedbytheendof2009.Twoclinicalchemistry
experiencedflatornegativesalesgrowthinmost modules(c701andc502)werelaunchedin2009.
segmentsasaresultoftheeconomicdownturn. Bytheendof2010fourcobas8000clinicalchemistry
andimmunoassaymoduleswillbeavailableworld-
Theimmunoassaybusinessgainedfurthermarket widein38customisableconfigurations.Thenew
shareonsalesgrowthof19%;thiswasroughlythree platformisbasedonthesameproventechnologies
timesthemarketgrowthrate.Clinicalchemistrysales asthesmallercobas6000andcobas4000systems,
grewaheadofthemarket,advancing4%.Theplace- withexpandedsamplehandlingandworkflow
mentrateforcobasmodularanalysers,particularly capabilitiesandenhancedqualitymanagement
thecobas6000seriesformid-sizelaboratories, featurestomeettheneedsoflaboratoriesperforming
remainedhigh,fuellingsalesinboththesesegments. upto15milliontestsperyear.
ProfessionalDiagnostics’immunoassaybusiness InSeptemberRocheconcludedanexclusivelicense
hasconsistentlygrownatdouble-digitratesforthe agreementwithSt.Vincent’sHospital,Sydney
lastnineyearsthankstoalargeinstalledbaseand (Australia)forworldwidepatentrightsrelatingto
steadilyexpandingtestmenu.Newtestsintroduced theuseofgrowthdifferentiationfactor15(GDF-15)
in2009,liketheElecsysIL-6(interleukin-6)immuno- forthediagnosisofcardiacdysfunction.Elevated
assay(anaidinthemanagementofcriticallyill circulatinglevelsofGDF-15canhelpidentifyhigh-
patients)andthehighsensitivityElecsysTroponinT riskindividualswithavarietyofcardiovascular
assay(diagnosisofheartattackandcardiacrisk conditions,fromstablecoronaryarterydiseaseto
stratification),wereimportantgrowthdrivers.In2009 heartfailure.Togetherwithanagreementsignedwith
ProfessionalDiagnosticslaunchedsiximmunoassays HannoverMedicalSchool(Hannover,Germany)in
andfiveneworsecond-generationclinicalchemistry January2009,alsorelatingtoGDF-15,andRoche’s
testsforavarietyoftherapyareas,includingcardi- ownpatentsinthisfield,thislatestagreement
ology,women’shealthandcriticalcare.In2010 willfurtherstrengthenRoche’sleadingpositionin
thebusinessareawillexpanditstestmenufurther, thediagnosisofcardiovasculardiseases.
particularlyintheUS,whereitexpectstolaunch
eightimmunoassays.
09_L_Roche_AR09_ENG_Diagnosticsindd 52 29012010 01:58:4353
The new Accu-Chek portfolio delivered
solid sales growth in a difficult market
Diabetes Care — market leadership strengthened Combo,whichwaslaunchedinninemarketsduring Excellent uptake of
RocheDiabetesCaredevelopsandcommercialises 2009,andbycontinuedstrongdemandforAccu- the latest Accu-Chek
bloodglucose(BG)monitoringandinsulindelivery Chekinfusionsets. products helped drive
above-market sales
systemsthatenablepeoplewithdiabetestomanage
growth for Diabetes
theirconditionmoreeffectively.Itistheindustry InSeptemberDiabetesCareannouncedinterim
Care in 2009.
leaderwitha31%shareoftheglobalBGmonitoring datafromitsAccu-Chek360°ViewOutcomeStudy.
market,worthnearly7billionSwissfrancsinglobal Thedataindicatethatpeoplewithtype2diabetes
sales.Self-managementisacornerstoneofdiabetes whoarenotreceivinginsulincanimprovetheir
carebecausesomanydailyactivitiesaffectblood glycemiccontrolbytestingandanalysingtheirBG
glucoselevels.FrequentBGtestingcanlowertherisk levelsinastructuredwayandtranslatingtheresults
ofseriouslong-termdiabeticcomplicationslike intoappropriateaction.The12-monthstudyunder-
stroke,amputationandblindness,whilehelpingpeople scoresRoche’scommitmenttoenhancingthemedical
withdiabetestomaintainandimprovetheirquality valueofdiabetesself-management.Thefinalresults
oflife. willbeannouncedinJune2010.
In2009DiabetesCare’ssalesincreased6%to Molecular Diagnostics — new products lay the Molecular Diagnostics
2,969millionSwissfrancs.Thiswassignificantly foundation for future growth won several important
aheadofglobalmarketgrowth,whichwasflat RocheMolecularDiagnosticsdevelopsandcommer- new blood screening
accounts in 2009,
duetotheeconomicdownturn.Allregionsexcept cialisesadvanceddiagnosticandbloodscreening
contributing to signifi-
Japandeliveredsalesgrowth,withstrongsales platformsandtestsbasedonRoche’sproprietary
cant competitive gains
contributionsfromemergingmarkets.TheAccu-Chek real-timepolymerasechainreaction(PCR)technology. in some markets.
AvivaandAccu-ChekPerformaBGmonitoring Thefast-growing(+12%),highlycompetitivemolecu-
systemsremainedtheprimarygrowthdrivers.Accu- lardiagnosticsmarketisvaluedat4billionSwiss
ChekAviva,Roche’stop-sellingBGmonitoring francs;Rocheistheleaderwitha32%marketshare.
system,continuedtopoststrongdouble-digitsales
growth. MolecularDiagnostics’full-yearsalesadvanced5%
to1,183millionSwissfrancs.Growthwasledbysolid
IntroducedinFebruary2009,theAccu-ChekMobile, gainsintheEMEAregion,especiallyinthecore
thefirstandonlystrip-freeBGmonitoringsystem, bloodscreeningbusiness.Thefullyautomatedcobas
experiencedexcellentuptakeinitslaunchmarkets TaqScreenMPXTest,availableinEuropesince2006
andcontributedtomarketsharegainsinthehigh- andlaunchedlastyearintheUS,contributedstrongly
valuecustomersegment.Attheendof2009itwas to8%growthinthissegment,withsignificantcom-
availableinnineEuropeancountries.Accu-Chek petitivegainsinseveralmarkets.Thismultiplexblood
Mobile’senhancedeaseofuseisappreciated screeningtestdetectsfiveviraltargets.Invirology,
especiallybypeoplewithinsulin-dependentdiabetes thelargestsegmentbysales,MolecularDiagnostics
whoneedtotesttheirBGfrequently.Thelaunch retaineditsleadingmarketsharewith4%sales
ofthesleekAccu-ChekAvivaNanoandAccu-Chek growth.Strongvirologysalesandnewbloodscreening
PerformaNano,designedespeciallyforyounger accountsinPortugal,Spain,ThailandandtheUK
users,hasalsobeenasignificantsuccess;attheend resultedinabove-market,double-digitsalesgrowth
of2009thesenewsingle-stripmeterswereavailable intheAsia—PacificandEMEAregions.
inover20markets.
SinceitsEUlaunchinApril,Roche’sLightCycler
Salesofinsulindeliverysystemsshoweddouble-digit MRSAAdvancedTesthasexperiencedpositiveuptake
growthfortheyear,helpedbyexcellentuptakeof incountrieswherereportingmethicillin-resistant
thenew,interactiveinsulinpumpsystemAccu-Chek Staphylococcus aureus(MRSA)infectionsiscustomary
09_L_Roche_AR09_ENG_Diagnosticsindd 53 29012010 01:58:43Technolo Ggi lyRe cNs oA e& nA in grM m t ie ne e rt ed f ee h a r rI no n e
in
ts nd ii gbl cis c o e o d s i ec i se n St c r u e c t u re - b a se d d r uN a gn o dte ec h sn io g lo g n y fo rm ula tio n s s lle C m e tS Vir alresi sta nce N eur ode ge ner atio Sn i gn al li ng p at h w ay s A n gi o Mg e yn ee ls i o s A iB Ip d n oi ncpo t e alol Tl to s i e -sg b
c
i iy emol llo m bg uy ioni loty
gy Pharma
Oncology Inflammation Neuroscience Metabolism Virology
Diagnostics
anatneV
gniniats
eussiT
54
Roche Business Report 2009 Diagnostics
Excellence in science:
Expertise in molecular biology
5
Major disease areas
Over the years both Roche divisions have amassed tremendous expertise in molecular biology.
Today they are applying this knowledge and a wide range of technologies in the pursuit
of new tests and more targeted treatments in five major focus areas: oncology, inflammation,
neuroscience, metabolism and virology. At the same time they are working together to
gain further insights into molecular mechanisms that cause and drive disease. Every cancer
drug development programme at Roche, for example, involves biomarker research aimed
at validating treatment targets and identifying the patients most likely to respond to a new
drug. Almost 30 years of cancer research at the molecular level have helped us develop
new strategies that move us closer to the ultimate goal of one day curing cancer.
4 D5 N4
A
L Sif ee q uS ec ni ce in
ngces
xC CE eL llL ai ng ae lyn sc ise
Ni Mm icb rl oe arG re ayn s
cobas,
R
eL ai l-g
tiht
meC y Pc Cl Rer
I m m
u
n o
aM
ss
ayu
c
solt bi ap slex protein anac lo ysb isas
09_L_Roche_AR09_ENG_Diagnosticsindd 54 29012010 01:58:4355
Roche developed a test for the new pandemic
flu virus within weeks after the virus was first
reported
orrequired.Studiesindicatethatthetest’sspeed— ofdevelopingcervicalcancer),couldhelpincrease Tests for hospital-
itreliablyidentifiesMRSAcarriersinlessthantwo thesensitivityofscreeningforHPVinfectionsthatcan acquired infections
hours,versusonetothreedaysusingconventional leadtocervicalcancer.WhenHPVDNAtestingis like MRSA and for
human papillomavirus
methods—canhelpsignificantlyreducethespreadof performedinconjunctionwithaPapsmear,more
infection are two
thispotentiallydeadlymicrobeinhospitals.Screening womenwillbeidentifiedwithprecancerouscervical
of the fastest-growing
forMRSAisoneofthefastest-growingsegments diseaseduringthefirstroundofcancerscreening, segments in molecu-
intheNorthAmericanmoleculardiagnosticsmarket enablingappropriatemedicalintervention.Addition- lar diagnostics. In
andisexpandinginEMEAandsomeAsia—Pacific ally,becauseofthegreatersensitivityofHPVDNA 2009 Roche launched
markets.RocheexpectstolaunchtheLightCycler testing,womenwhoareHPVDNAnegativemay competitive new
products in both
MRSAAdvancedTestintheUSin2010. potentiallybedeferredtolongerscreeningintervals.
these segments in
Moreover,identificationofHPVgenotypes16and18
Europe.
InDecemberMolecularDiagnosticslaunchedits providesactionableinformationguidingtheclinician
newfullyautomatedcobas4800SysteminEurope toinvestigatefurtherthosewomenatthehighestrisk
andothermarketsthatacceptCEMarkcertification. forcancer.
Thesystemisdesignedtomeetthecurrentand
long-termmoleculardiagnostictestingneeds Applied Science — broad-based growth Demand for instru-
ofmid-tohigh-throughputlaboratories,andRoche RocheAppliedSciencesuppliesscientistsinacade- ments and reagents
expectsittobecomeasignificantgrowthdriver. miaandthebiotechandpharmaceuticalindustries for pandemic flu
testing were a major
Thetestmenucurrentlycomprisesdualtargettests withinstrumentsandhighlyspecificreagentsandtest
sales driver for Roche
forChlamydia trachomatis(CT)andNeisseria kitsforabroadrangeofresearchapplications.The
Applied Science
gonorrhoeae(NG)(thebacteriathatcausechlamydia globallifescienceresearchmarket,valuedat8billion
in 2009.
infectionsandgonorrhea)andascreeningand USdollars,grewapproximately8%in2009.
genotypingtestforhumanpapillomavirus(HPV),
themostcommonsexuallytransmittedinfection, AppliedScience’ssalesfor2009totalled870million
whichisresponsiblefornearlyallcervicalcancers Swissfrancs,anincreaseof15%overtheprevious
worldwide.InAustraliaandNewZealand,where year.TheMagNAPureandLightCyclerproductlines
thecobas4800Systemhasbeenavailablewiththe (nucleicacidsamplepreparation(NAP)andquanti-
CT/NGtestssinceSeptember,themarketresponse tativepolymerasechainreaction(qPCR)analysis)
hasbeenverystrong.Next-generationoncology wereagainthebiggestcontributorstogrowth,with
andmicrobiologyassaysforthesystemareindevel- salesup35%helpedbystrongdemandforinstruments
opment. andreagentsforpandemicinfluenzatestingand
surveillance.InMayAppliedSciencedevelopedand
InAugustMolecularDiagnosticscompletedenrolment launchedtheRealTimereadyInfluenzaA/H1N1
ofpatientsintoitspivotalATHENAclinicaltrial. DetectionSetforresearchuse,justweeksafterfirst
Thetrial,involvingapproximately47,000women, reportsofthenewpandemicfluvirusinMexico.
isdesignedtoassessthevalueofscreeningwomen Thesetenablesrapid,accuratedetectionofthevirus’s
forcervicalcancerusingRoche’scobas4800HPV RNA(geneticmaterial).TheFDAgrantedEmergency
assaytogetherwithastandardPapsmear.Initialtrial UseAuthorizationofthekitinNovember,makingit
datawillbeavailableinFebruary,andRocheexpects availableforclinicaluseinspeciallycertifiedlaborato-
tofilethefullATHENAdatasetwiththeFoodand riesintheUS.Othersignificantnewproducts
DrugAdministration(FDA)inthesecondquarterof includethefullyautomatedMagNAPure96System
2010.Ifapproved,theassay,whichprovidesan forhigh-throughputNAP.Uptakebyacademic
aggregateresultfor12high-riskHPVgenotypesand andindustrialcustomershasbeenrobustsincethe
individualresultsforHPVgenotypes16and18 system’sgloballaunchinSeptember.
(thegenotypesthatputwomenatthegreatestrisk
09_L_Roche_AR09_ENG_Diagnosticsindd 55 29012010 01:58:431
56
Roche Business Report 2009 Diagnostics
Significant product launches by business area
Total
(2010) (25)*
2009 23
2008 18
2007 11
0 4 8 12 16 20 24
Cellanalysissystemsshowedverystrongsalesgrowth throughput,benchtopversionoftheGenome
in2009,drivenmainlybythexCELLigenceproduct Sequencer(GS)FLXSystemin2010isexpectedto
t l | y
linebutalsopartlyattributabletotheacquisitionof spurfurthergrowth.TheGSJuniorSystemwillclose
innovatisAGinMarch.AppliedScience’slatestReal themarketgapbetweenlow-throughputtraditional
0
TimeCellAnalyser—thexCELLigenceRTCADP sequencingandtheultra-high-throughputofinstru-
6 (7)
(dualplate)instrument—hasbeenagrowthdriver mentsliketheGSFLXSystem,puttingnext-generation
( )
sinceitsworldwidelaunchinApril.Itsvalueasa sequencingtechnologywithinthereachofthousands
cancerresearchtoolwasenhancedfurtherbythe ofadditionalresearchersworldwide.
NovemberlaunchofthexCELLigenceSystem
D
CIM-Plate16,acultureplateenablingscientists Tissue Diagnostics — rapid penetration of new
l
tostudycellmigrationandinvasiondynamically, markets
1 0 e
inrealtime,overtheentiretimespanofanexperiment. RocheTissueDiagnostics(VentanaMedicalSystems
Thismayhelpresearchersidentifymoleculartargets inNorthAmerica)istheworld’sleadingsupplierof
fornewdrugsthatinhibitcancercells’abilityto tissue-basedcancerdiagnostics.Itsinstrumentsand
invadenearbytissuesandmigrate(metastasise) reagentsystemsareusedinhistology,cytologyand
todistantpartsofthebody. drugdiscoverylaboratoriesworldwide.In2009the
unithada20%shareofthetissuediagnosticsmarket,
Microarraysalesrose44%,nearlyfourtimesthe whichisvaluedatover2billionSwissfrancs.
globalarraymarketgrowthrate.Growthwasfuelled
bycontinuedstrongperformanceofNimbleGen’s TissueDiagnosticsrecordedsalesof480million
innovativeSequenceCapturetechnologies,which Swissfrancsin2009,a29%increaseovertheeleven
ideallycomplementthebusinessarea’snext-genera- months’salesconsolidatedayearearlierfollowingthe
tionsequencingsystems,andbytheintroduction VentanaacquisitioninFebruary2008.Onacompa-
ofthehigh-resolution,high-throughputMS200 rablebasis,salesrose21%,significantlyoutpacing
MicroarrayScanner. themarket,whichisestimatedtobegrowingat12%.
SalesofDNAsequencingreagentsshowedarobust Thebusinessarea’scoreadvancedtissuestaining
26%increase,butoverallsalesofDNAsequencing portfolioremainedtheprimarygrowthdriver,with
systemswereflatduetotheeconomicdownturnand immunohistochemistry(IHC)reagentsforcancer
theresultingdeclineinresearchfunding,particularly diagnosisandadvancedstaininginstrumentsfuelling
intheUS.TheUSadministration’s2009stimulus robust27%growthinthissegment.Placements
packageforbiomedicalresearchisexpectedtoalle- ofthefullyautomatedBenchMarkUltra,successfully
viatethesituationin2010.Thelaunchofamedium- launchedinNorthAmericaandEuropein2008,
09_L_Roche_AR09_ENG_Diagnosticsindd 56 29012010 01:58:4457
Roche has a biomarker programme for every
drug that it is developing
acceleratedsteadilyduringtheyear.Thisisthefirst Research and development
andonlysystemtoperformsimultaneousIHCand
in situhybridisation(ISH)testingonasinglecontinu- Roche’sDiagnosticsDivisioncontinuestoinvest The Diagnotics Divi-
ousandrandomaccessplatform,enablingsamples heavilyininnovation.In2009researchanddevelop- sion is focusing much
tobeaddedandremovedatanytimewithoutinter- ment(R&D)coststotalled978millionSwissfrancs, of its R & D spending
on high-growth areas
ruptingworkflow.Full-yearsalesoftheSymphony anincreaseof5%over2008.R&Dcostsasaper-
like molecular diag-
slidestaininginstrumentandhematoxylinandeosin centageofsalesremainedstableat9.7%.Projects
nostics, immuno-
reagentsforthehigh-volumeprimarystainingmarket accountingforasignificantshareofR&Dspending assays and tissue
grew39%. in2009,andwhichwillremainfundingprioritiesin diagnostics.
2010,includetheATHENAtrialofRocheMolecular
TissueDiagnosticswonmarketshareinallregions, Diagnostics’cobas4800HPVscreeningandgeno-
withespeciallystronggainsinAsia—PacificandLatin typingtestintheUS,developmentofthecobas Roche is working on
America.ItsuccessfullyleveragedtheexistingRoche 8000modularanalyserseriesanddevelopmentof potential companion
infrastructuretoexpeditethehiringofsalesperson- anext-generationmoleculardiagnosticplatform diagnostic tests in all
of the Group’s key
nelandtheintroductionofnewproductsinEMEA, formid-tohigh-throughputIVDtestingandblood
disease areas of inter-
Asia—PacificandLatinAmerica,contributingto screening.Thedivisionalsoinvestedindeveloping
est, particularly oncol-
above-marketgrowthintheseregions.Bythecloseof newproductsinitstissuediagnosticsbusiness. ogy.
2009thebusinessareahadestablisheditsownsales Expansionoftheimmunoassaymenuwillbeafurther
organisationsinsixoftheE7markets,andmostofits majorfocusofR&Dinvestmentin2010.
majorinstrumentsandIHCreagentswerealready
registeredandavailableinBrazil,India,Chinaand Thedivision’sR&Dproductivityhasimprovedin
Mexico.Rocheisaddressingtheincreasingdemand recentyears.Since2007thenumberofmajorproduct
forfullyautomatedproductsinemergingmarkets, launcheshasincreasedsignificantly,andthedivision
whichiscontributingtostrongmarketsharegains expects2010tobeanotherexcellentyearinterms
there. ofstrengtheningitsproductportfolio(seecharton
p.56andthetablesofMajor product launches on
In2009TissueDiagnosticslaunched17newIHC pp.60–61).
reagentstoaidindiagnosingvariouscancers,includ-
ingleukemia,lymphomaandcancersofthecolon Thediscoveryandvalidationofbiomarkersisessential
andprostate.WorkingcloselywithRoche’sPharma- torealisingthepromiseofpersonalisedhealthcare.
ceuticalsDivision,itcontinuedtodevelopexploratory InpharmaceuticalR&Dtheyhavemanyuses,from
teststhatmayonedayleadtocompaniondiagnostics identifyingnewtherapeutictargetsandscreeningout
forRochetherapies.Asadirectresultofthiscollabo- unpromisingdrugcandidatestoselectingappropriate
ration,TissueDiagnosticsexpectstwoHER2assays patientpopulationsforclinicaltrials.Intheclinic,
toreceiveCE-IVDMarkinginthefirsthalfof2010 biomarkertestsincreasinglyprovideinvaluableinfor-
foruseasaidsinassessingbothbreastandgastric mationforearlydiagnosisandaboutdiseasepre-
cancerpatientsforwhomHerceptintreatmentis disposition,prognosisandthelikelihoodoftreatment
beingconsidered. response(responseprediction),contributingtoear-
lier,moretargetedtherapeuticinterventions.Roche’s
IVDportfolioalreadyincludescompaniondiagnostics
contributingtomoreeffectivetreatmentinanumber
ofconditions,includingHER2-positivebreastcancer,
precancerouscervicalchangescausedbyhuman
papillomavirusinfection,hepatitisBandCinfection
andcytomegalovirusdisease.
09_L_Roche_AR09_ENG_Diagnosticsindd 57 29012010 01:58:4458
Roche Business Report 2009 Diagnostics
EverydrugbeingdevelopedatRochehasabiomarker morelikelythanseronegativepatientstoachieve
programmeassociatedwithit,andDiagnosticsex- asignificantimprovementintheirdiseasefollowing
pertiseandadvicearemadeavailableforeachof MabThera/Rituxantreatment.Thiscouldsignal
theseprogrammes.Attheendof2009Rochehad amajoradvanceoverthecurrenttrial-and-error
fivebiomarkertestsinlatestageandsixinearlystage approachtotreatingRA,inwhichpatientscycle
clinicalvalidationforuseaspotentialcompanion throughvarioustreatmentoptionsuntilanoptimum
diagnostictestsandover30exploratorystage responseisachieved.Rochealreadymarketsassays
diagnosticprogrammes,intheareasofoncology, forrheumatoidfactorandanti-CCP.
metabolism,virology,autoimmuneandinflammatory
diseaseandcentralnervoussystemdisorders.There
hastobeastrongcaseforabiomarker’sabilityto
detectdiseaseorpredictaclinicaloutcomebeforeit
movesintolate-stagevalidation,wheretheaimisto
establishclinicalvalidityconclusivelythroughfurther
testingonsamplescollectedinongoingdrugtrials.
GiventhePharmaceuticalsDivision’sstrongoncology
portfolio,identifyingandvalidatingbiomarkersto
supporttheuseofRoche’smarketedanddevelop-
mentalcancermedicinesisnaturallyamajorfocusof
research.EncouragingprojectsincludeaPCR-based
testforBRAFV600E,acancer-causinggenemutation
associatedwithpoorprognosisinseveralcancers,
includingmalignantmelanoma.DevelopedbyRoche
MolecularDiagnostics,thetestwasprovenessential
forselectingsuitablepatientsinaphaseItrial
withtheBRAFkinaseinhibitorRG7204inmetastatic
melanoma.RG7204,whichselectivelytargets
andinducescelldeathintumoursharbouringthe
BRAFV600Emutation,markedlyprolongedprogression-
freesurvivalinpatientsinthetrialwhotestedpositive
forthemutation.Thetesthasalsobeenused
successfullyinclinicaltrialstoidentifymutation-
positivecolorectalcancers.IfRG7204isapproved,
RocheexpectstolaunchtheBRAFV600Etestasthe
companiondiagnostic.
Twootherhighlypromisingbiomarkersthathave
alreadyreachedlate-stageclinicalvalidationarerheu-
matoidfactorandanti-cycliccitrullinatedpeptide
(anti-CCP)—antibodiesthatarefoundinthebloodof
manyrheumatoidarthritis(RA)patients.Ananalysis
ofpooleddatafromtwoclinicaltrialswithMabThera/
RituxaninRAshowthatpatientswhoareseropositive
foreitheroftheseantibodiesaretwotothreetimes
09_L_Roche_AR09_ENG_Diagnosticsindd 58 29012010 01:58:4459
Glossary Immunoassay | Alaboratorytestthatdetectsor
measuresatargetsubstanceinasampleusing
Biomarker | Acharacteristicthatcanbemeasured animmunochemicalreaction,inwhichanantibody
andevaluatedasanindicatorofanormalbiological bindstoaspecificantigen.Thetargetcanbeadrug,
process,adiseaseprocessoraresponsetoathera- aproteinoravirus,forexample.
peuticintervention.Elevatedlevelsoftheprotein
HER2incancer,forexample,areabiomarkerfora Immunohistochemistry (IHC) | Amethodofstaining
highprobabilityofresponsetoHerceptin. biologicaltissuesamplestodeterminethepresence,
levelandlocationofspecificproteinsincells;usedin
Cell analysis | Methodsofmeasuringtheproperties thediagnosisofcancerandotherdiseases.
ofcells,includingtheirsizeandshape,cellular
parameterssuchasthepresenceofspecificproteins, In situ hybridisation (ISH) | Amethodofstaining
andcellularprocessessuchasproliferationand biologicaltissuesamplestoidentifythepresenceand
growth.Cellanalysistechnologiesplayanimportant copynumberofspecificgenesorgeneticmutations
roleindrugdevelopmentandproduction. incells;usedinthediagnosisofcancerandother
diseases.
CE Mark certification | Certificationthatanin vitro
diagnostic(IVD)productcomplieswithallsafety, Polymerase chain reaction (PCR) | Alaboratory
healthandenvironmentalrequirementsforuseinthe methodwidelyusedinresearchandindustrytomake
EuropeanUnion.Certifieddiagnosticsarereferred millionsofcopiesofaDNAsequenceofinterest
toasCEIVDs. veryquickly.Real-timePCRsimultaneouslyamplifies
(copies)andquantifiesthetargetedDNAmolecule.
Clinical chemistry | Abranchofdiagnosticscom-
prisingteststhatdetectandmeasurechangesin Virology | Inmoleculardiagnostics,testingtodetect
thechemicalcompositionofbodyfluidsandtissues certainseriousandprevalentviralinfections(e.g.HIV
todiagnoseorpredictthecourseofadisease. andhepatitisC)ortomonitortheirtreatment.
DNA sequencing | Methodsofdeterminingthe
orderofnucleotides(molecularbuildingblocks)in
geneticmaterial.Knowinganindividual’sDNA
sequencecanprovideinsightsintogeneticchanges
whichcontributetohumandiseaseorinfluence
treatmentresponse.High-throughputtechnologies
readthousandsofsequencesatonce.
HER2 (human epidermal growth factor
receptor 2) | Aproteininvolvedinnormalcell
growthandfoundatincreasedlevelsinsome
cancers,includingsomebreastandgastriccancers.
Cancercellsmaybetestedinthelaboratoryfor
HER2levelstohelpchoosethemostappropriate
treatment.
09_L_Roche_AR09_ENG_Diagnosticsindd 59 29012010 01:58:4460
Roche Business Report 2009 Diagnostics
Product launches
in the Diagnostics Division
Major product launches in 2009
Business area Product Market and quarter
Professional Diagnostics Elecsys immunoassays for PlGF (placenta growth factor) and sFlt1 EU Q1
(soluble fms-like tyrosine kinase 1) for the diagnosis of preeclampsia
Elecsys IL-6 (interleukin-6) immunoassay to aid the management EU Q1
of critically ill patients
Elecsys Troponin I Assay: test for cardiac-specific troponin I levels EU Q1
to predict mortality risk in patients with acute coronary syndrome
High-sensitivity Elecsys Troponin T immunoassay for the diagnosis EU Q1
of heart attack and cardiac risk stratification US Q4
Sysmex XT-4000i: mid- to high-throughput hematology analyser Contractual territory in
with test capabilities for whole blood and other body fluids EMEA Q2
cobas c 701 clinical chemistry module for the cobas 8000 analyser series EU Q3
for high-throughput laboratories. Throughput: up to 2,000 tests/hour
cobas p 501 and cobas p 701 automated storage and retrieval modules EU Q3
for bar-coded primary and secondary sample tubes
cobas c 502 clinical chemistry module for the cobas 8000 analyser series. EU Q4
Throughput: up to 600 tests/hour
Diabetes Care Accu-Chek Mobile: integrated lancing and blood glucose monitoring EU Q1
device employing a unique ‘no strip’ technology that replaces test strips with
a continuous tape of 50 tests
Accu-Chek Aviva Nano and Accu-Chek Performa Nano: sleeker versions of EU Q1
the Accu-Chek Aviva and Accu-Chek Performa meters, offering an enhanced
feature set
Accu-Chek Combo: interactive insulin delivery system combining an insulin EU Q1
pump and a blood glucose meter with broad data management capabilities;
the meter also functions as a pump remote control
Accu-Chek Active: new version of an existing meter, featuring an extended EU Q1
memory and a number of fail-safe capabilities
Molecular Diagnostics LightCycler MRSA Advanced Test: automated real-time PCR-based test EU Q1
for methicillin-resistant Staphylococcus aureus. The test can identify MRSA
carriers in under two hours
cobas p 630 instrument and AmpliLink 3.3 software: the only pre-analytical EU Q4
instrument to unite primary tube handling with fully automated sample prepa-
ration, amplification and detection for molecular diagnostics
cobas 4800 platform for automated DNA extraction and real-time PCR EU Q4
amplification and detection; with tests for human papillomavirus, Chlamydia
trachomatis and Neisseria gonorrhoeae
Applied Science NimbleGen MS 200: fully automated high-resolution microarray scanner Worldwide Q2
for use with all NimbleGen DNA microarrays
xCELLigence RTCA DP (dual plate) system: highly flexible medium-throughput Worldwide Q2
system for real-time non-invasive cell analysis
LightCycler 1536 system for high-throughput quantitative PCR analysis Worldwide Q2
MagNA Pure 96 high-throughput system for preparing nucleic acid samples Worldwide Q4
for PCR analysis
Tissue Diagnostics INFORM EGFR DNA Probe: detects extra copies of the epidermal growth EMEA, APAC Q1
factor receptor (EGFR) gene, an abnormality associated with non-small cell
lung cancer
BenchMark XT advanced staining instrument LATAM, APAC Q1
BenchMark Ultra advanced staining system with continuous and random Additional European
processing and STAT capabilities markets, LATAM, Q1
Japan Q4
Intended use of CONFIRM anti-HER2/neu Primary Antibody and INFORM EMEA, APAC Q2
HER2 DNA Probe expanded to include analytical claims regarding perfor-
mance with gastric as well as breast tissue samples
EU = European Union; EMEA = Europe, Middle East and Africa; APAC = Asia—Pacific; LATAM = Latin America; US = United States.
09_L_Roche_AR09_ENG_Diagnosticsindd 60 29012010 01:58:4461
Major product launches planned for 2010 5
Business area Product Market and quarter
Professional Diagnostics cobas e 602 immunoassay module for the cobas 8000 modular analyser series EU Q1
for high-volume laboratories. Throughput: up to 170 tests/hour US Q3
Eight Elecsys immunoassays in the US; six in the EU Q1-Q4
cobas c 701 and cobas c 502 clinical chemistry modules for the cobas 8000 US Q2
modular analyser series. Throughput: up to 2,000 and 600 tests/hour, respec-
tively
cobas p 501 and cobas p 701 automated storage and retrieval modules for US Q2
bar-coded primary and secondary sample tubes
cobas c 702 advanced clinical chemistry module for the cobas 8000 modular EU Q4
analyser series. Features automated reagent loading, enabling consolidation of
a broader test menu. Throughput: up to 170 tests/hour
cobas b 123 benchtop multiparameter analyser (blood gas, electrolytes, EU Q4
CO-oximetry and metabolites) for use at the point of care
HIV combi 27 min: improved combination assay for HIV 1 antigen (p24) and EU Q4
HIV antibodies, enabling more reliable early detection of infection with the
human immunodeficiency virus
Diabetes Care Accu-Chek Mobile: integrated lancing and blood glucose monitoring device Additional EU
employing a unique ‘no strip’ technology that replaces test strips with a markets Q1-Q3
continuous tape of 50 tests APAC Q1
Accu-Chek Combo: interactive insulin delivery system combining an insulin Additional EU
pump and a blood glucose meter with broad data management capabilities; markets Q1
the meter also functions as a pump remote control APAC Q1, US Q3-Q4
Accu-Chek Aviva Nano: sleeker version of the Accu-Chek Performa meter, US Q3-Q4
offering an enhanced feature set
Molecular Diagnostics LightCycler MRSA Advanced Test: automated real-time PCR-based test for US Q2
methicillin-resistant Staphylococcus aureus
Cobas AmpliPrep/Cobas TaqMan CMV (CE IVD): a viral load monitoring test EU Q3
that will enable physicians to improve the management of cytomegalovirus
(CMV) disease in solid organ transplant patients
cobas TaqScreen DPX Test: multi-dye blood screening test designed EU Q3
to simultaneously provide a quantitative result for parvovirus B19 and
a qualitative result for hepatitis A virus
Cobas AmpliPrep/Cobas TaqMan HIV-1 v2: second-generation test with US Q4
a unique dual-target design enabling detection of two separate regions of
the HIV-1 genome
Cobas TaqMan 48 HIV v2 (CE IVD) High Pure virology test: offers a manual EU Q4
sample preparation option for customers with a low-volume workload
Applied Science GS Junior System: economical benchtop next-generation DNA sequencing Worldwide Q1
system for smaller laboratories
NimbleGen CGX-6 multiplex arrays: microarrays for high-resolution analysis of Worldwide Q1
chromosomal abnormalities; capable of analysing six samples simultaneously
xCELLigence RTCA HT instrument, for automated high-throughput cell analyses Worldwide Q1
and screening
SeqCap EZ Exome v.2: in-solution enrichment capture technology for targeted Worldwide Q2
next-generation sequencing
Next-generation ultra-high density NimbleGen microarrays Worldwide Q3–Q4
Tissue Diagnostics Dual colour/dual hapten in situ hybridisation (ISH) kit enabling target gene EU Q1
detection and control on a single slide. For use with all molecular markers;
specifically to support HER2 testing
Ventana anti-HER2 neu (4B5) primary antibody and Ventana HER2 DNA EU Q1–Q2
probe: CE IVDs for assessing the likelihood of response to Herceptin treatment
in both breast and gastric cancer patients
BenchMark GX: economical, low-volume advanced tissue staining platform EU, APAC Q2
that automates all slide processing steps from baking to staining
CE-IVD molecular probes targeting the enzyme TOP2A and the cell surface EU Q2-Q4
receptor IGF1R, for use as an aid in diagnosing and managing breast and lung
cancer
Discovery Ultra: platform for immunohistochemistry and in situ hybridisation US, EU Q2
research, offering significant improvements in ease of use, workflow and APAC, Japan,
flexibility LATAM Q4
5 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors.
EU = European Union; EMEA = Europe, Middle East and Africa; APAC = Asia—Pacific; LATAM = Latin America; US = United States.
09_L_Roche_AR09_ENG_Diagnosticsindd 61 29012010 01:58:44They’re reading genes
to help save lives one day
Precision and speed count in modern molecular diagnostics. We’re working to improve both. Our
genome sequencers can ‘read’ the building blocks of highly variable genes in a matter of days instead
of weeks, which is how long it takes to achieve the same precision with conventional sequencing
methods. This may one day help to extend and improve the lives of transplant patients. Currently
we are investigating the use of our sequencers for HLA (human leukocyte antigen) genotyping of blood
stem cells. Stem cell transplantation is performed to treat a number of diseases, including leukemia.
Donors’ and recipients’ cells need to be as HLA-compatible as possible for treatment to be successful.
Studies have shown that the Genome Sequencer FLX System * is a power-
ful research tool for high-resolution HLA genotyping, which is critical for people
needing transplants. The closer the match between the donor’s and recipient’s
HLA genes, the smaller the risk of transplant rejection.
* For life science research only. Not for use in diagnostic procedures.
10_Bildstrecke_ENG_S62-63indd 1 28012010 23:53:1810_Bildstrecke_ENG_S62-63indd 2 28012010 23:53:22Corporate Governance | Roche’s
commitment to all stakeholders is reflected
in its operating businesses’ focus on
value creation, in a management culture
that conforms to modern standards of
corporate governance and in the Group’s
policy of communicating transparently.
Remuneration Report | Roche’s
success depends on the abilities and
dedication of its people. Recognition of
this forms the basis of our remuneration
policy and system.
11_L_Roche_AR09_ENG_Corporate Governanceindd 64 29012010 00:50:1165
Corporate Governance
Rochecomplieswithallrelevantcorporategovernance AttheAGMon2March2010,theBoardofDirectors
requirements,inparticularwithallapplicablelaws, willnominateDeAnneJuliusandBeatriceWeder
theSwissStockExchange(SIXSwissExchange) diMauroforre­election totheBoardandArthurD.
directives(includingthecommentariesthereto)and Levinson and William M. Burns for election as new
theSwissCodeofBestPracticeforCorporateGover­ Members of the Board for a term of three years
nancepromulgatedbytheSwissbusinessfederation asprovidedbytheArticlesofIncorporation.Peter
‘economiesuisse’.Thecompany’sinternalgovernance Brabeck­LetmatheandHorstTeltschikhavedecided
framework,particularlyitsArticlesofIncorporation toretireasmembersoftheBoardofDirectorsafter
andBylaws,embodiesall theprinciplesneededto manyyearsofdistinguishedservice.TheBoardof
ensurethatthecompany’sbusinessesaremanaged Directorsthanksfortheirdedicationandtheirmany
andsupervisedinamannerconsistentwithgood contributionstoRoche.
corporategovernance,includingthenecessarychecks
andbalances.1
Corporate Executive
OurprintedAnnualReportcontainsselectedlinksto
Committee
theRochewebsite(www.roche.com).Readersare
thusprovidednotonlywitha‘snapshot’ofourcom­
panyatthereportingdatebutarealsodirectedto William M. Burns as CEO Division Roche Pharma­
sourceswhichtheycanconsultatanytimeforup­to­ ceuticals, Jürgen Schwiezer as CEO Division Roche
date informationabout corporate governance at DiagnosticsandJonathanKnowlesasHeadGroup
Roche.Whereaseachannualreportcoversasingle Researchretiredon31December2009andtherefore
financialyearending31December,ourwebsite steppeddownasmembersoftheCorporateExecutive
containsinformationofamorepermanentnatureas Committee.TheBoardofDirectorsthankstheleaving
wellasthelatestRochenews.Amendmentsto membersoftheCorporateExecutiveCommitteefor
ourcompany’sArticlesofIncorporationandBylaws theirdedicationandtheirmanycontributionstoRoche.
andchangesinthecurriculavitaeofthemembers
oftheBoardofDirectorsandtheCorporateExecutive TheBoardofDirectorsofRocheHoldingLtdwill
Committee are published in timely fashion on nominateWilliamM.BurnsforelectiontotheBoard
ourwebsite,wheretheycanbeaccessedbyanyone attheAGMon2March2010.
lookingforthisinformation.
AspartoftheGenentechtransaction,PascalSoriot
wasappointedasCEOofGenentech,Inc.andas
Board of Directors anewmemberoftheCorporateExecutiveCommittee
inApril2009.PascalSoriotrelinquishedhisrole
Atthe91th AnnualGeneralMeeting(AGM)of asCEOGenentech,Inc.asof31December2009and
RocheHoldingLtd,on10March2009,shareholders wasappointedasCOODivisionRochePharmaceu­
re­electedJohnI.Bell,AndréHoffmannandFranzB. ticalsstartingon1January2010.
HumerasmembersoftheBoardofDirectorsfor
atermofthreeyearsasprovidedbytheArticlesof
Incorporation.Atitsorganisingmeetingimmediately
followingthe2009AGM,theBoardofDirectorshas
approveditscommittees’structureanditscommittee
membershipsasshownonpage67. 1 http://www.roche.com/about_roche/corporate_governance.htm
11_L_Roche_AR09_ENG_Corporate Governanceindd 65 29012010 00:50:1166
Roche Business Report 2009 Corporate Governance
Board of Directors per 31 December 2009 (from left):
Dr Franz B. Humer, Prof. Bruno Gehrig, André Hoffmann,
Prof. Pius Baschera,
Prof. Sir John Irving Bell, Peter Brabeck-Letmathe, Lodewijk J.R. de Vink,
Dr Andreas Oeri, Dr DeAnne Julius, Walter Frey,
Prof. Beatrice Weder di Mauro, Prof. Horst Teltschik, Dr Wolfgang Ruttenstorfer
11_L_Roche_AR09_ENG_Corporate Governanceindd 66 29012010 00:50:1567
Board of Directors
Name (year of birth) Term ends First elected
Board of Directors Dr Franz B. Humer (1946) D*, E Chairman 2012 1995
Prof. Bruno Gehrig (1946) C*, D, E Vice-Chairman 2011 2004
André Hoffmann (1958) C, D, E Vice-Chairman 2012 1996
Prof. Pius Baschera (1950) A, E 2011 2007
Prof. Sir John Irving Bell (1952) C, E 2012 2001
Peter Brabeck-Letmathe (1944) E 2010 2000
Lodewijk J.R. de Vink (1945) C, E 2011 2004
Walter Frey (1943) A, B, E 2011 2001
Dr DeAnne Julius (1949) B*, E 2010 2002
Dr Andreas Oeri (1949) A*, E 2011 1996
Dr Wolfgang Ruttenstorfer (1950) B, E 2011 2007
Prof. Horst Teltschik (1940) A, B, E 2010 2002
Prof. Beatrice Weder di Mauro (1965) A, B, E 2010 2006
New proposed
members of the
Board of Directors,
nominated for
election at the
Annual General Meeting William M. Burns (1947)
on 2 March 2010 Dr Arthur D. Levinson (1950)
Secretary to the
Board of Directors Dr Gottlieb A. Keller (1954)
Honorary Chairman of
the Board of Directors Dr Fritz Gerber (1929)
A Corporate Governance and Sustainability Committee.
B Audit Committee.
C Remuneration Committee.
D Presidium/Nomination Committee.
E Non-executive director.
* Committee chairperson. 1 January 2010
11_L_Roche_AR09_ENG_Corporate Governanceindd 67 29012010 00:50:1568
Roche Business Report 2009 Corporate Governance
On this page
Corporate Executive Committee per 31 December 2009 (from left):
Dr Severin Schwan, William M. Burns, Dr Jürgen Schwiezer,
Dr Erich Hunziker, Silvia Ayyoubi, Prof. Jonathan Knowles,
Dr Gottlieb A. Keller, Pascal Soriot, Burkhard G. Piper,
Osamu Nagayama, Per-Olof Attinger, Richard Scheller,
René Kissling
Right page
New members as of 1 January 2010 (from left):
Daniel O'Day, Jean-Jacques Garaud, Dan Zabrowski
11_L_Roche_AR09_ENG_Corporate Governanceindd 68 29012010 00:50:2069
Corporate Executive Committee
Name (year of birth) Position
Corporate Executive Committee Dr Severin Schwan (1967) CEO of the Roche Group
Dr Erich Hunziker (1953) Chief Financial Officer and
Deputy Head of the Corporate Executive Committee
William M. Burns (1947)* CEO Division Roche Pharmaceuticals
Dr Jürgen Schwiezer (1944)* CEO Division Roche Diagnostics
Prof. Jonathan K.C. Knowles (1947)* Head Group Research
Dr Gottlieb A. Keller (1954) General Counsel
Silvia Ayyoubi (1953) Head Human Resources
Pascal Soriot (1959) CEO Genentech, Inc.;
as of 1.1.2010 COO Division Roche Pharmaceuticals
As of 1 January 2010 Daniel O’Day (1964) COO Division Roche Diagnostics
Enlarged Corporate Executive Burkhard G. Piper (1961)* Head Business Area Roche Diabetes Care
Committee Per-Olof Attinger (1960) Head Communications
Osamu Nagayama (1947) President and CEO Chugai
Richard Scheller (1953) Head Genentech Research and Early Development (gRED)
Head Roche Pharma
As of 1 January 2010 Jean-Jacques Garaud (1955) Research and Early Development (pRED)
Dan Zabrowski (1959) Head of Pharma Partnering
Secretary to the Corporate
Executive Committee René Kissling (1966)
KPMG Klynveld Peat Marwick Goerdeler SA (reporting years 2004–2008)
Statutory Auditors KPMG AG (since 2009)
of Roche Holding Ltd Auditor in charge: John A. Morris (since 2004)
Chief Compliance Officer Dr Urs Jaisli (1956)
* Member until 31 December 2009.
New members as of 1 January 2010 (from left):
Daniel O'Day, Jean-Jacques Garaud, Dan Zabrowski
11_L_Roche_AR09_ENG_Corporate Governanceindd 69 29012010 00:50:2170
Roche Business Report 2009 Corporate Governance
Asof1January2010DanielO’Daywasappointedas • MajorshareholdersarelistedintheFinanceReport,
COODivisionRocheDiagnosticsandasanew Notes 28and 33 to the Roche Group Consoli­
memberoftheCorporateExecutiveCommittee.As dated Financial Statements (‘Equity attributable
of31December2009,BurkhardPiperstepped to Roche shareholders’ and ‘Related parties’,
downasamemberoftheEnlargedCorporateExecu­ pages106and120)andinNote4totheFinancial
tiveCommitteeandisreportingtoDanielO’Day. Statements of Roche Holding Ltd (‘Significant
shareholders’,page141).
InApril2009,RichardSchellerwasappointedto • AndréHoffmann,Vice­ChairmanoftheBoardof
theEnlargedCorporateExecutiveCommittee. Directors,andAndreasOeri,MemberoftheBoard
HereportsdirectlytoGroupCEOSeverinSchwan. ofDirectorsandChairmanoftheBoard’sCorpo­
AstheformerHeadofGenentechResearch,he rateGovernanceandSustainabilityCommittee,
leadsGenentech’sResearchandEarlyDevelopment serveintheirrespectivecapacitiesontheBoardand
(gRED)whichwilloperateasanindependentcentre its Committees as representatives of the share­
withintheRocheGroup. holdersgroupwithpooledvotingrightsandreceive
theremunerationsetforthintheRemuneration
Jean­Jacques GaraudwasappointedasHeadof Reportonpage77andintheFinanceReport,
RochePharmaResearchandEarlyDevelopment Note33totheRocheGroupConsolidatedFinancial
(pRED)andasanewmemberoftheEnlarged Statements(‘Relatedparties’,page120)andNote6
CorporateExecutiveCommittee. totheFinancialStatementsofRocheHoldingLtd
(‘BoardandExecutiveremuneration’,page142).
DanZabrowskiasHeadofPharmaPartneringwas Nootherrelationshipsexistwiththeshareholders
appointedasanewmemberoftheEnlargedCorpo­ withpooledvotingrights.
rateExecutiveCommittee. • Therearenocross­shareholdings.
2 Capital structure
Information relating • InformationonRoche’scapitalstructureisprovided
intheFinanceReport,NotestotheFinancial
to Corporate Governance
Statements of Roche Holding Ltd (page 140 and
141). Additionaldetailsarecontainedinthe
1 Group structure and shareholders ArticlesofIncorporationofRocheHoldingLtd.2
• Roche’soperatingbusinessesareorganisedinto • ChangesinequityaredetailedintheFinance
twodivisions:PharmaceuticalsandDiagnostics.The Report, Notes to the Financial Statements of
PharmaceuticalsDivisioncomprisesthetwobusiness RocheHoldingLtd(page141).
segments Roche Pharmaceuticals and Chugai, • Thecompanyhasasharecapitalof160,000,000
whereasGenentechastheformerthirdsegmenthas Swissfrancs,dividedinto160,000,000fullypaid
beenintegratedintoRochePharmaceuticals.The bearershareswithanominalvalueof1Swissfranc
Diagnostics Division consists of the following five each.Therearenorestrictionsontheexercise
businessareas:AppliedScience,DiabetesCare, ofthevotingrightsoftheseshares.Upondeposit,
MolecularDiagnostics,ProfessionalDiagnosticsand sharescanbevotedwithoutanyrestrictions.
TissueDiagnostics.Businessactivitiesarecarriedout • Thereisnoauthorisedorconditionalcapital.
throughGroupsubsidiariesandassociatedcompa­ • Inaddition,702,562,700non­votingequity
nies.Significantsubsidiariesandassociatedcom­ securities(NES)havebeenissuedinbearerform.
paniesarelistedintheFinanceReport,Note34to
theRocheGroupConsolidatedFinancialStatements
2 http://www.roche.com/about_roche/corporate_governance/
(‘Subsidiariesandassociates’,pages122to124. article_of_incorporation.htm
11_L_Roche_AR09_ENG_Corporate Governanceindd 70 29012010 00:50:2171
Theydonotformpartofthesharecapitaland • WiththeexceptionofFranzB.Humer,noneofthe
confernovotingrights.EachNESconfersthesame membersoftheBoardofDirectorshasbeena
rights as one share to participate in available memberofRoche’sCorporateExecutiveCommittee
earningsandinanyliquidationproceedsfollowing orservedinanexecutivecapacityatanyGroup
repaymentofthesharecapital.Roche’sNES subsidiaryduringthethreefinancialyearspreceding
andtherightspertainingthereto(includingthe thecurrentreportingperiod.
provisionsprotectingtheinterestsofNESholders) • TheinternalorganisationoftheBoardofDirectors
aredescribedin§4oftheArticlesofIncorporation andthedivisionofauthorityandresponsibilities
ofRocheHoldingLtd. betweentheBoardandmanagement,theremitsof
• Information on debt instruments which have theBoardcommitteesandtheinformationand
beenissuedandonoutstandingbondsisprovided controlmechanismsavailabletotheBoardinits
in the Finance Report, Note 27 to the Roche dealingswithcorporatemanagementaregoverned
GroupConsolidatedFinancialStatements(‘Debt’, bytheBylaws.6
page 100). • The Board of Directors of Roche Holding Ltd is
• Additionalinformationonemployeestockoptions organised so as to ensure that the Group’s
isprovidedintheFinanceReport,Note11to businesses are conducted responsibly and with a
theRocheGroupConsolidatedFinancialStatements focusonlong­termvaluecreation.Tothisend,the
(‘Employeestockoptionsandotherequity Roche Board has delegated certain responsibilities
compensationbenefits’,page72). to several committees7. Their composition and
• Rochehasissuednooptionsapartfromemployee chairpersons as of 1 January 2010 are described
stockoptions,Stock­settledStockAppreciation on page 67. Each committees’ authorities and
Rights(S­SARs)andoptionsissuedinconnection responsibilities are defined in detail in the Bylaws
withdebtinstruments. of the Board of Directors.8
• Neithertheoptionsawardedtoemployeesnor • AllthecommitteesexceptthePresidiumarechaired
thedebtinstrumentswhichhavebeenissuedhave byindependentdirectors.
anyeffectonRoche’ssharecapital. • AccordingtotheBylawsoftheBoardofDirectors
attherequestofanyofitsmembersaBoard
3 Board of Directors and Corporate Executive meeting without the Chairman present may be
Committee convened. The Roche Board meets once a year to
• InformationoneachmemberoftheBoardof assesstheChairman’sperformance.Thismeeting,
Directors (including the years in which they were which is not attended by the Chairman, is chaired
electedandtheyearsinwhichtheirtermsend) byoneoftheVice­Chairmen.
and on each member of the Corporate Executive
Committeeislistedonpages65to70.Curricula
vitaeandotherinformation(includinginformation 3 http://www.roche.com/about_roche/management/
board_of_directors.htm and
on board memberships) are available on the
http://www.roche.com/about_roche/management/
Internet.3
executive_committee.htm
• TheAnnualGeneralMeetingelectsthemembers 4 http://www.roche.com/about_roche/corporate_governance/
oftheBoardofDirectorsinstaggeredelections article_of_incorporation.htm
5 http://www.roche.com/about_roche/corporate_governance/
inwhicheachnomineeisvotedonseparately(see
annual_general_meetings.htm
§18 of the Articles of Incorporation of Roche 6 http://www.roche.com/about_roche/corporate_governance/
Holding Ltd4and the Minutes of the 91thAnnual article_of_incorporation.htm
General Meeting of Roche Holding Ltd, held 7 http://www.roche.com/about_roche/corporate_governance/
committees.htm
10March20095).
8 http://www.roche.com/about_roche/corporate_governance/
article_of_incorporation.htm
11_L_Roche_AR09_ENG_Corporate Governanceindd 71 29012010 00:50:2172
Roche Business Report 2009 Corporate Governance
• TheBoardofDirectorshasestablishedasystemof — RemunerationCommittee:threemeetings9
controlswhichiscontinuouslymonitoredbythe (approx.2to3hourseach*).
AuditCommitteeandbytheCorporateGovernance • ThemembersoftheCorporateExecutiveCommittee
andSustainabilityCommitteeandconsistsofthe areinvitedtoattendfor,andreportinpersonon,
followingelements: those agenda items concerning them. When
— Reportsonfinancialandoperatingrisks(risk the situation warrants, members of the Enlarged
managementsystem) CorporateExecutiveCommitteemayalsobeinvited
— Systemofinternalcontrolsoverfinancialreport­ toattend.TheBoardcommitteesinvitetheChair­
ing(seepage125and128intheFinancereport) man of the Board and other Corporate Executive
— Internalaudits Committeememberstodeliverreportsatcommit­
— GroupComplianceOfficerandCompliance tee meetings and may elect to commission
officersinsubsidiaries independentexpertreportsandcallontheservices
— Safety,HealthandEnvironmentalProtection of consultants. The risk management system is
Department subject to continuous review, with findings being
— CorporateSustainabilityCommittee presented to the Audit Committee or the full
— ScientificandEthicsAdvisoryGroup(SEAG), Board.10 InternalAuditregularlybriefstheAudit
forissuesrelatingtogeneticsandgeneticengi­ Committeewithreferencetoongoingauditreports.
neering(establishedin1999). MembersofInternalAuditattendAuditCommittee
• Eachyearseveralblack­outperiodsareimposed meetings,asdoexternalauditors.Forinformation
duringwhichsenioremployeesareprohibitedfrom ontheexternalauditors,seepage73.
tradingincompanystock.Thefollowingblack­out • There are no management contracts which fall
periodsareineffectfor2010: within the scope of Subsection 4.3 of the
26Decemberto3February SIXDirectiveonInformationrelatingtoCorporate
1Aprilto15April Governance.
26Juneto22July
1Octoberto14October 4 Remuneration, shareholdings and loans
Black­outperiodscanbechangedbytheChairman Alldetailsregardingremuneration,shareholdings
oftheBoardofDirectorsifcircumstanceswarrant. andloansaresetforthintheseparateRemuner­
• In2009theBoardofDirectorsmetforfivemeet­ ationReportonpages75to85andintheFinance
ings,eachfrom3to6hoursinlength*;oncefora Report,Notes28and33totheRocheGroup
full­daymeeting*;andonceforathree­dayvisit ConsolidatedFinancialStatements(‘Equityattribut­
toamajorsubsidiary*whichincludedaBoardof abletoRocheshareholders’and‘Relatedparties’,
Directorsmeeting*.TheBoardcommitteesmet pages106and120)andarelistedintheNotes6
asfollowsin2009: and7totheFinancialStatementsofRocheHold­
— PresidiumoftheBoardofDirectors/Nomination ing Ltd (‘Board and Executive remuneration’ and
Committee:threemeetings(approx.2hours ‘BoardandExecutiveshareholdings’,pages142
each*) and144).
— AuditCommittee:fourmeetings(approx.3to
4hourseach*)
— CorporateGovernanceandSustainabilityCom­
mittee:threemeetings(approx.3hourseach*) 9 Remuneration Committee members are not permitted to con-
tribute to or attend Remuneration Committee meetings at which
matters concerning them are deliberated or decided.
* These figures indicate the actual length of meetings and do 10 Additional information is provided in the Finance Report, Note
not include the directors' extensive pre-meeting preparations 32 to the Roche Group Consolidated Financial Statements, ‘Risk
and post-meeting follow-up activities. management’, page 113).
11_L_Roche_AR09_ENG_Corporate Governanceindd 72 29012010 00:50:2173
5 Participatory rights of shareholders AuditCommittee,seeArticle8.1oftheBylaws12).
• Theparticipatoryrightsofshareholdersaredefined Thestatutoryauditorsparticipatedinall(four)
inRoche’sArticlesofIncorporation.11 AsRoche meetingsoftheAuditCommitteein2009.
sharesareissuedtobearer,therearenorestrictions
onadmissiontoAnnualGeneralMeetings,with ThereportsofstatutoryauditorsontheConsoli­
theexceptionthatsharesmustbedepositedwithin datedFinancialStatementsandontheFinancial
aspecifiedperiodbeforethedateofameeting Statementscanbefoundonpages126and149,
andanadmittancecardmustbeissuedintheshare­ respectively,ofthisyear’sFinanceReport.
holder’s name,asprovidedin§12oftheArticles
of Incorporation. Any shareholder can elect to KPMGreceivedthefollowingremunerationfor
berepresentedbyanothershareholderatanAnnual theirservicesasstatutoryauditorsofRocheHold­
General Meeting. The Articles of Incorporation ingLtdandotherRochecompanies:
contain no restrictions on the exercise of voting
rights, and the only quorum requirements are
2009 2008
those stipulated in §16, in conformity with the (millions of CHF)
Swiss CodeofObligations. Auditing services 21.9 19.7
• Under§10.2oftheArticlesofIncorporation, Audit-related services 3.7 4.6
shareholdersrepresentingshareswithanominal Tax consultancy services 1.3 1.8
valueofatleast1millionSwissfrancscanrequest Total 26.9 26.1
theplacementofitemsontheagendaofan
AnnualGeneralMeeting.Thismustbedoneno Thestatutoryauditorsareelectedeachyearbythe
laterthan60daysbeforethedateofthemeeting. AnnualGeneralMeeting.
6 Change of control and defensive measures Ernst&YoungLtdreceivedthefollowingremunera­
• TheArticlesofIncorporationcontainnoprovisions tionfortheirservicesastheauditorsofGenentech
onthemandatorybidrule.Swisslawapplies. andChugai:
• Therearenochange­of­controlclauses.Those
componentsofremunerationbasedonRocheNES
2009 2008
wouldbeterminatedintheeventofanacquisition, (millions of CHF)
andvestingperiodrestrictionsonpre­existing Chugai (2008 Genentech
awardswouldberemoved,sothatallsuchoptions and Chugai) audits 2.2 5.4
couldbeexercisedimmediately. Other consulting services
provided to Genentech
7 Relationship to statutory auditors and Chugai 2.2 1.7
AttheAnnualGeneralMeetingofRocheHolding Total 4.4 7.1
Ltdon10March2009,theshareholdersvoted
toappointKPMGAG(KPMG)asstatutoryauditors
(informationonhowlongtheauditorsandauditor
inchargehavebeenservinginthesecapacitiesis
providedonpage69).Thestatutoryauditors
participateinAuditCommitteemeetings.Theypre­ 11 http://www.roche.com/about_roche/corporate_governance/
parewrittenandoralreportsontheresultsoftheir article_of_incorporation.htm
audits.TheAuditCommitteeoverseesandassesses 12 http://www.roche.com/about_roche/corporate_governance/
article_of_incorporation.htm
theauditorsandmakesrecommendationstothe
13 http://www.roche.com/about_roche/corporate_governance/
Board(forinformationontheresponsibilitiesofthe article_of_incorporation.htm
11_L_Roche_AR09_ENG_Corporate Governanceindd 73 29012010 00:50:2274
Roche Business Report 2009 Corporate Governance
8 Information policy irregularitiesorcomplaintsintheircorresponding
• As provided by §33 of the Articles of Incorpora­ motherlanguageviaa‘speak­up hotline’.The
tion13, corporatenoticesarepublishedintheSwiss ChiefComplianceOfficerreportsregularlytothe
Official Gazette of Commerceandinotherdaily CorporateGovernanceandSustainabilityCommittee.
newspapersdesignatedbytheBoardofDirectors
(Basler Zeitung, Finanz und Wirtschaft, L’Agefi, 10 Non-applicability/negative disclosure
Le Temps, Neue Zürcher Zeitung). Itisexpresslynotedthatanyinformationnot
• Rochereportsitshalf­yearandfull­yearresultsin containedormentionedhereinisnon­applicable
businessreportspublishedinprintandonline oritsomissionistobeconstruedasanegative
formatsandatmediaevents.Inaddition,detailed declaration(asprovidedintheSIXSwissExchange
first­andthird­quartersalesfiguresarepublished CorporateGovernanceDirectiveandtheCom­
eachyearinAprilandOctober.Themostcurrent mentarythereto).
listofpublicationdatesisavailableinEnglishand
GermanontheInternet.14
• Allrelevantinformationanddocuments,including
allmediareleases,investorupdates15andpre­
sentationstoanalystandinvestorconferencesare
availableontheInternet.Furtherpublications
canbeorderedbye­mail, faxortelephone:basel.
webmaster@roche.com,tel.+41(0)616888339;
fax+41(0)616884343.
• ThecontactaddressforInvestorRelationsis:
F. Hoffmann­La Roche Ltd, Investor Relations,
CorporateFinance,4070Basel,Switzerland;
tel.+41(0)616888880,fax+41(0)616910014.
Additionalinformation,includingdetailsonspecific
contactpersons,isavailableontheInternet.16
9 Chief Compliance Officer
TheChiefComplianceOfficerwithhiscompliance
officersnetworkiscommittedtoensuringthat
Rochecorporateprinciplesareconsistentlycom­
pliedwiththroughouttheRocheGroupand
alsoservesasacontactpersonforshareholders,
employees,customers,suppliersandthegeneral
publiconissuesrelatingtotheimplementationof
andcompliancewiththeseprinciples.Employees
andotherpartieswhobecomeawareofviolations
ofRochecorporateprinciplescanbringthem
totheattentionoftheirmanagersorsupervisorsor
reportthemtotheChiefComplianceOfficer(Urs
Jaisli,directphonenumber:+41(0)616884018,
e­mail:urs.jaisli@roche.com).Suchdisclosures
14 http://www.roche.com/media.htm
willbetreatedconfidentially.Inaddition,asofthe
15 http://www.roche.com/investors.htm
endof2009,employeesmayanonymouslyreport 16 http://www.roche.com/investors/contacts.htm
11_L_Roche_AR09_ENG_Corporate Governanceindd 74 29012010 00:50:2275
Remuneration Report
Summary tionpolicyisdesignedtofostervaluecreationand
Roche’ssuccessdependsontheabilitiesand reinforceacultureofperformanceandinnovation,
dedicationofitspeople.Recognitionofthisforms anditappliestonon-managerialemployeesaswell
thebasisofourremunerationpolicyandsystem. astomanagers.Thekeyprinciplesunderpinningthis
policyare:
Oneoftheprimaryaimsofourremunerationpolicyis • Focusonvaluecreation
toencouragealong-termfocusandalignmanage- • Payforperformance
ment’sinterestswiththeinterestsofRoche’sshare- • Enablingemployeestoshareinthecompany’s
holdersandholdersofRoche’snon-votingequity success
securities(NES). • Fairnessandtransparencyinremuneration
decisions
• Thisremunerationreportwillbesubmitted • Abalancedmixoflong-andshort-term
separatelyforapprovalatthe2010AnnualGeneral remunerationcomponents
Meeting. • Market-competitiveness.
• TheremunerationofCorporateExecutive
Committee(CEC)membersandothersenior Basepay,bonuses,blockednon-votingequity
Rocheexecutivesiscomprisedof: securities(NES),awardsofStock-settledStock
— Basesalary AppreciationRights(S-SARs)andaPerformance
— Bonus SharePlansupporttheseprinciples.Theseremu-
— Specialstockawards(non-votingequity nerationcomponentsarelinkedtoourcompany’s
securitiessubjecttovestingperiod3–10years) financialperformanceandcommercialsuccessand
— Stock-settledStockAppreciationRights thusaligntheinterestsofRocheemployeeswith
(S-SARs)1 thoseoftheshareholders.Theamountoftheseparate
— PerformanceSharePlan(PSP)awards componentsofremunerationforeachindividual
• WiththeexceptionofSeverinSchwanandSilvia memberoftheCorporateExecutiveCommitteeis
Ayyoubi,noneoftheCECmembersreceivedan shownintheindividualdescriptionoftheremunera-
increaseinbasesalaryin2009.2 tionoftheCorporateExecutiveCommitteeinthis
• BasedonRoche’ssharepriceperformance,no report.
NESwillbeawardedforthe2007–2009PSPcycle.
• TheS-SARsgrantedin2006,2007and2008, Base pay
havestrikepricesabovethecurrentNESpriceand Basepaylevelsaredeterminedaccordingtomarket
havenovaluefortherecipients.Thiscanchange dataforspecificpositionsandindividualemployees’
ifRoche’sfutureNESpriceimproves. abilities,experienceandperformanceovertime.Pay
• Therehasbeennochangeinthebaseremunera- increasesarelinkedtoindividualperformanceand
tionoftheBoardofDirectorssince2001.
1 See ‘Stock options/Stock-settled Stock Appreciation Rights
Pleaseseetherestofthisreportforfulldetails3. (S-SARs)’, page 82.
2 On 1 April 2008, the base pay of the Corporate Executive
Remuneration policy Committee was generally increased for the last time. For
Gottlieb Keller resulted a difference between the base pay
Rochefundamentallyreneweditsremunerationpolicy
received for the calendar year 2008 and 2009 (see table on
in2004andreviseditwithminorchangesin2009. page 78) due to the increase of the base pay on April 2008.
Itispartofaframeworkofemployeepoliciesaimedat 3 See also in the Finance Report, Note 33 to the Roche Group
Consolidated Financial Statements (‘Related parties’, page 120)
motivatingandretainingcurrentemployees,attracting
and Notes 6 and 7 to the Financial Statements of Roche Holding
talentednewonesandhelpingallRocheemployees
Ltd (‘Board and Executive remuneration’ and ‘Board and Execu-
toperformatconsistentlyhighlevels.Ourremunera- tive shareholdings’, page 142 and 144).
12_L_Roche_AR09_ENG_Remuneration Reportindd 75 29012010 00:505876
Roche Business Report 2009 Remuneration Report
alsotakeintoaccountprevailingmarketconditions, isbasedonathree-yearcomparisonofthetotal
affordabilityandthecompany’soveralleconomic shareholderreturn(TSR)with17competingcompa-
situation. nies4.In2009therewerethreeoverlappingperfor-
mancecycles,PSP2007–2009,PSP2008–2010and
Bonuses PSP2009–2011ofwhichPSP2007–2009closed
Bonusesareawardedinrecognitionofindividualcon- on31December2009.
tributionstovaluecreationwhichgobeyondnormaljob
expectations,andtheyaremeanttobeanincentive DetailsforthePSP2007–2009calculationandaddi-
tocreateorstrengthennewbusinessopportunities tionalinformationaresetforthin‘Remuneration
andstriveforoutstandingresults.Bonusamountsare ofmembersoftheCorporateExecutiveCommittee,
linkedtoGroupordivisionalbusinessperformance D.PerformanceSharePlan(PSP)’,page80.
and to the achievement of individual and functional,
measurableandqualitativeperformanceobjectives. Remuneration of the Board of Directors and the
TheRemunerationCommitteeoftheBoardofDirectors Corporate Executive Committee
has defined the Corporate Executive Committee EachyeartheRemunerationCommittee,whichis
membersbonusesinDecember2009basedonresults entirelycomprisedofindependentexternalmembers
achievedfor2009. oftheBoardofDirectors,setsremunerationforthe
membersoftheBoardofDirectorsandtheCorporate
Special stock awards ExecutiveCommittee(cashpayments,bonuses,
In2009non-votingequitysecuritieshavebeen options,Stock-settledStockAppreciationRightsand
grantedtoaselectednumberofRocheemployees. policydecisionsaboutpensionbenefits).Theterms
Theawardsvestimmediatelybutareblockedfor ofthePerformanceSharePlanaredeterminedannu-
threeyears.Recipientshavetheoptiontoextendthe allybytheBoardofDirectors,actinguponrecommen-
blockingperiodtotenyears.Thegrantofthosenon- dationsfromtheRemunerationCommittee.The
votingequitysecuritieswasawardedaspartofthe RemunerationCommitteecontinuouslytrackssalary
bonuspaymentsfor2009withtheaimtobothimme- trendsinthemarketandreportstotheBoardof
diatelyrewardtheachievementofspecificobjectives Directors.Informationonthiscommittee’sremitand
andtofostertheinterestinalong-termpositive itsproceduresformakingremunerationdecisions
development. canbefoundintheBylawsoftheRocheBoardof
Directors5.
Stock-settled Stock Appreciation Rights (S-SARs)
Stock-settledStockAppreciationRightswereintro- Followingtherevisionoftheremunerationpolicy
ducedon1January2005,thusestablishingauniform includingmarketcomparisonswiththeworld’smajor
systemofremunerationthroughoutRoche.S-SARs pharmaceuticalcompanies,theRemunerationCom-
entitleholderstobenefitfinanciallyfromanyincrease mitteehasdeterminedthebonusesandremuneration
inthevalueofRoche’snon-votingequitysecurities oftheChairmanoftheBoardofDirectors,themem-
betweenthegrantdateandtheexercisedate.Detailed bersoftheCorporateExecutiveCommitteetakinginto
informationisavailableonpage79andpage82to85. considerationpersonnelchanges.Indoingso,the
­followingchangeswerenoted:
Performance Share Plan
ThemembersoftheCorporateExecutiveCommittee 4 Peer set for 2009: Abbott Laboratories, Amgen, Astellas, Astra-
andothermembersofseniormanagement(currently Zeneca, Bayer, Becton Dickinson, Biogen Idec, Bristol-Myers
some120individualsworldwide)participateinthe Squibb, Eli Lilly, Gilead, GlaxoSmithKline, Johnson & Johnson,
Merck & Co., Novartis, Pfizer, Sanofi-Aventis, Takeda.
PerformanceSharePlan(PSP).ThePSPwasestab-
5 http://www.roche.com/about_roche/corporate_governance/
lishedin2002forperiodsofthreeyearseachand article_of_incorporation.htm
12_L_Roche_AR09_ENG_Remuneration Reportindd 76 29012010 00:505877
• Afurtherimportantstepforthetransferofduties BoardofDirectorsandbyeachmemberoftheCorpo-
fromtheChairmantotheCEOhasbeencompleted rateExecutiveCommitteefor2009,incomparison
withthecompletionoftheintegrationofGenen- withfiguresforpreviousyears,andanoutlookonthe
tech.Accordingly,theBoardplanstoreducethe Chairman’sremunerationdevelopmentfor2010.
Chairman’sbasepayin2010(fordetailedinfor-
mationseepage82). 1 Remuneration
• On31December2009,WilliamM.Burns,Jonathan 1.1 Remuneration of members of the Board
K.C.KnowlesandJürgenSchwiezerretiredfrom of Directors | In2009themembersoftheBoard
the company and consequently stepped down as ofDirectors6receivedtheremunerationshown
membersoftheCorporateExecutiveCommittee. inthetable‘RemunerationofmembersoftheBoard
• Asof1January2010DanielO’Dayhastaken ofDirectors’belowfortheirBoardactivities.
overasChiefOperatingOfficer(COO)ofthe
DiagnosticsDivision. RemunerationofallmembersoftheBoardofDirectors
• Asof1January2010PascalSoriothastakenover willagainremainunchangedfor2010.Thenon-
hisnewfunctionasCOOofthePharmaceuticals executivemembersoftheBoardofDirectorswerenot
Division. awardedanyshares,non-votingequitysecurities,
Thefollowingpagesprovidedetailedinformationon
6 For a list of members, their positions and their committee mem-
theremunerationearnedbyeachmemberofthe berships and chairmanship, see page 67.
Remuneration of members of the Board of Directors
Additional compensation 2009
Remuneration 2009 for committee members/chairs 7
(in CHF) (in CHF) Additional special compensation 2009
F.B. Humer (see page 81 8) 50,000 (Remuneration as Chairman
of the Board of Directors
see page 81 8)
B. Gehrig 400,000 9 –
A. Hoffmann 400,000 9 –
P. Baschera 300,000 30,000
J.I. Bell 300,000 30,000
P. Brabeck-Letmathe 300,000 –
L.J.R. de Vink 300,000 30,000
W. Frey 300,000 60,000
D.A. Julius 300,000 60,000
A. Oeri 300,000 60,000
W. Ruttenstorfer 300,000 30,000
H. Teltschik 300,000 60,000 Compensation for serving
on the boards of Roche
subsidiaries, see page 78
B. Weder di Mauro 300,000 60,000 See page 78
7 With the exception of members of the Presidium and the Vice-Chairmen, Board members receive CHF 30,000/year for each committee
they serve on and CHF 60,000/year for each committee they chair.
8 See ‘G. Highest total remuneration to a member of the Board of Directors', page 81and 82.
9 Remuneration for serving as Vice-Chairman of the Board.
12_L_Roche_AR09_ENG_Remuneration Reportindd 77 29012010 00:505878
Roche Business Report 2009 Remuneration Report
Remuneration of members of the Corporate Executive Committee
A. Base pay | in CHF
Annual salary Annual salary Annual salary
2009 2008 2007
S. Schwan 2,875,002 2,283,340 1,100,000
S. Ayyoubi 725,004 481,670 *
W.M. Burns 2,000,000 2,000,000 2,000,000
E. Hunziker 2,000,000 2,000,000 2,000,000
G.A. Keller 1,500,000 1,350,000 900,000
J.K.C. Knowles 1,350,000 1,350,000 1,350,000
J. Schwiezer 1,200,000 1,200,000 *
P. Soriot 1,246,878 * *
Total 12,896,884
* Not a member of the Corporate Executive Committee.
Stock-settledStockAppreciationRights(S-SARs)10, dollars(5,450Swissfrancs)forherparticipation
stockoptionsorRestrictedStockUnits(RSUs)in atacourseon‘AuditCommitteesinanewEraof
2009.HorstTeltschikreceivedhonorariaamountingto Governance’atHarvardBusinessSchool.
19,635euros(29,648Swissfrancs)forservingon
theboardsofseveralRochesubsidiariesinGermany.
10 See ‘Stock options/Stock-settled Stock Appreciation Rights
BeatriceWederdiMaurowasreimbursed5,000US (S-SARs)’, page 82.
Bonus
Bonus Bonus Bonus
for 2009 for 2008 for 2007
Special stock awards
(Blocked non-voting equity securities)
Cash payment Blocking Value Total Cash payment Cash payment
(in CHF) Number period (years) (in CHF) (in CHF) (in CHF) (in CHF)
S. Schwan 3,000,000 20,450 10 1,675,178 ** 4,675,178 3,000,000 2,500,000
S. Ayyoubi 1,000,000 4,485 *** 3 637,909 **** 1,637,909 500,000 *
W.M. Burns 4,000,000 13,046 *** 3 1,606,905 ** 5,606,905 2,500,000 2,500,000
E. Hunziker 2,000,000 13,046 *** 3 1,606,905 ** 3,606,905 2,200,000 2,200,000
G.A. Keller 1,000,000 9,931 *** 10 813,506 ** 1,813,506 1,000,000 1,000,000
J.K.C. Knowles 1,000,000 – – 1,000,000 308,900 1,000,000
J. Schwiezer 2,000,000 – – 2,000,000 1,000,000 *
P. Soriot 2,000,000 – – 2,000,000 * *
Total 16,000,000 6,340,403 22,340,403
* Not a member of the Corporate Executive Committee.
** Day value at grant of non-voting equity securities: CHF 146.70/NES. Calculation of value in consideration of reduction of value due
to blocking period (reduced market value: for 3 years = 83.962%; for 10 years = 55.839%).
*** Excluding contribution to AHV/IV/ALV: Swiss social security programmes providing retirement, disability and unemployment benefits.
**** Day value at grant of non-voting equity securities: CHF 169.40/NES. Calculation of value in consideration of reduction of value due
to blocking period (reduced market value: for 3 years = 83.962%).
12_L_Roche_AR09_ENG_Remuneration Reportindd 78 29012010 00:505979
For2009themembersoftheBoardofDirectors B. Bonus
receivedremunerationtotalling18,608,650Swiss In2009thebonusforsomeofthemembersofthe
francs11. CorporateExecutiveCommitteeisdividedintwoparts:
• Forthreeortenyearsblockednon-votingequity
Noadditionalremunerationwaspaidtomembersof securities(grantedin2009)and
theBoardofDirectors. • Cashpaymentdueforpaymentattheendof
April2010.
1.2 Remuneration of members of the Corporate
Executive Committee |Thegeneralprovisions Withtheelementofblockednon-votingequity
assigningauthorityfordecisionsonCorporateExecu- securitiesthebonusreflectsanevenstrongerlink
tiveCommitteeremunerationtotheRemuneration tothelong-termperformanceofthecompany.
CommitteeandtotheBoardofDirectorsareoutlined
onpage76ofthisremunerationreport.For2009
themembersoftheCorporateExecutiveCommittee 11 See ‘Remuneration of members of the Board of Directors’,
page 77.
receivedremunerationtotalling54,858,227Swiss
12 See ‘Remuneration of members of the Corporate Executive
francs12. Committee’, (A.–F. and H.) excluding AHV/IV/ALV, page 78 to 83.
C. Stock-settled Stock Appreciation Rights (S-SARs)
S-SARs 13 S-SARs 13 S-SARs 13
2009 2008 2007
(value in CHF 14) (value in CHF 14) (value in CHF 14)
S. Schwan 3,559,849 2,225,542 1,068,062
S. Ayyoubi 889,993 445,146 *
W.M. Burns 2,224,920 2,225,542 1,780,140
E. Hunziker 1,957,935 1,958,480 1,780,140
G.A. Keller 1,334,989 1,335,313 890,125
J.K.C. Knowles 1,334,989 1,335,313 890,125
J. Schwiezer 889,993 890,229 *
P. Soriot 1,401,735 * *
Total 13,594,403
* Not a member of the Corporate Executive Committee.
13 See ‘Stock options/Stock-settled Stock Appreciation Rights (S-SARs)’, page 82.
14 Black-Scholes value as described in ‘Stock options/Stock-settled Stock Appreciation Rights (S-SARs)’, page 82 to 85.
Values for 2007 and 2008 according to Annual Report 2008, page 78.
AtthepresenttimetheStock-settledStockAppreci- FranciscofromMarchtoDecember2009,
ationRightsgrantedin2006,2007and2008,mostof receivedallowancesandtaxequalisationtotalling
whichcannowbeexercised,followingtheendof 635,246Swissfrancs.
thevestingperiodinFebruary2010,havenovaluefor
therecipients.15 MembersoftheCorporateExecutive
Committeeadditionallyreceiveannualexpenseallow-
ancesof30,000Swissfrancs,totalling210,000Swiss
15 See strike prices in table ‘Stock options and S-SARs’,
francs,whilePascalSoriot,whowasbasedinSan page 85.
12_L_Roche_AR09_ENG_Remuneration Reportindd 79 29012010 00:505980
Roche Business Report 2009 Remuneration Report
D. Performance Share Plan (PSP) thesecurities’marketpricesanddividendyields,
ThemembersoftheCorporateExecutiveCommittee i.e.onTotalShareholderReturn(TSR).Toreducethe
andothermembersofseniormanagement(currently effectofshort-termmarketfluctuations,security
some120individualsworldwide)participateinthe pricesareaveragedoverthethreemonths(Octoberto
PerformanceSharePlan(PSP). December)priortothestartofaperformancecycle
andoverthethreemonths(OctobertoDecember)
In2006thePSPmovedtooverlappingthree-year attheendofthecycle.IfRochesecuritiesperform
performancecycles,withanewcyclebeginningeach aswellasorbetterthanthoseof75%ofthepeer
year.In2009therewerethusthreecyclesinprogress setand,inaddition,Roche’sTSRincreasesatleast
(PSP2007–2009,PSP2008–2010andPSP2009–2011); 10%duringacycle,theBoardofDirectorscanelect
thePSP2007–2009endedon31December2009. toincreasethemaximumNESawardbyasmuch
astwo-fold.IntheeventthataninvestmentinRoche
Undertheprovisionsofthisplan,anumberofnon- securitiesunderperformstheaveragereturndelivered
votingequitysecurities(NES)havebeenreservedfor bythepeercompanies,fewerornoNESwillbe
theparticipantsineachcycle.Thenumberofsecu- awarded.
ritiesactuallyawardedwilldependonwhetherandto
whatextentaninvestmentinRochesecurities(shares In2009NESwerereservedundertheplanformembers
andNES)outperformstheaveragereturnonan oftheCorporateExecutiveCommitteeasshownin
investmentinsecuritiesissuedbyapeersetofcom-
paratorcompanies16.Comparisonsarebasedon 16 See footnote 4, page 76.
Performance Share Plan (PSP)
2009 17 2008 18 2007 18
Total estimated Total estimated Value of
value of value of PSP awards
PSP awards PSP awards (2005–2007,
(2007–2009 (2006–2008, 2006–2008
Target number Target number No NES and 2008–2010 2007–2009 and
of NES for PSP of NES for PSP awarded for PSP and 2009–2011) and 2008–2010) 2007–2009)
2009–2011 2008–2010 2007–2009 (value in CHF) (value in CHF) (value in CHF)
S. Schwan 5,011 1,965 – 408,793 217,804 557,264
S. Ayyoubi 1,002 638 – 96,104 84,392 *
W.M. Burns 4,009 3,276 – 426,901 447,200 1,612,918
E. Hunziker 4,009 3,276 – 426,901 454,188 1,904,622
G.A. Keller 3,006 1,474 – 262,528 202,908 738,912
J.K.C. Knowles – 2,211 – 129,564 318,392 1,364,636
J. Schwiezer 2,405 1,965 – 256,082 225,279 *
P. Soriot 2,104 1,638 – 219,281 * *
Total 21,546 16,443 – 2,226,154
* Not a member of the Corporate Executive Committee.
17 Total estimated value for 2009:
PSP 2007–2009: none of the originally targeted NES awarded.
PSP 2008–2010 and 2009–2011: Estimated value calculated using the year-end price as of 31 December 2009, CHF 175.80 per non-
voting equity security (NES), based on the number of NES originally targeted subject to changes in the number and value of NES
awardable under the plan on 31 December 2010 and 31 December 2011, respectively, and spread over the relevant period of time,
i.e. ¹⁄³ for the year 2009. The Board of Directors will vote on the actual allocation of NES originally targeted on 31 December 2010 and
31 December 2011, respectively, according to the TSR achieved.
18 Detailed calculation see Annual Report 2008, page 79.
12_L_Roche_AR09_ENG_Remuneration Reportindd 80 29012010 00:505981
thetableonpage80.TheBoardofDirectorswill non-votingequitysecurities(NES)uptoanamount
decideontheactuallevelofNESorcashequivalent equalto10%oftheirannualsalaryata20%discount.
awardsfor the cycles 2008–2010 and 2009–2011 NESpurchasedunderthisplanaresubjecttoa
after the close of the2010and2011financialyears, holdingperiod,whichisfouryearsinSwitzerland.
respectively.TheaimofthePSPistoprovidean
incentivetoparticipantstoachievesteadyvalue F. Other remuneration, emoluments and loans
growth. GottliebKellerreceivedanonrecurringspecial
payment of 50,000 Swiss francs for his 25 years’
AttheendofthePSP2007–2009cycle(basedona serviceforthecompany.In2009 pensionstotalling
three-monthmovingaverageatconstantexchange 2,083,820Swissfrancswerepaidtotwoformer
rates)withdistributeddividendstotalling11.211bil- CorporateExecutiveCommitteemembers.Four
lionSwissfrancs(2007:2.932billionSwissfrancs; membersoftheCorporateExecutiveCommittee
2008:3.967billionSwissfrancs;2009:4.312billion receivedatotalof93,750USdollars(102,187Swiss
Swissfrancs),theTSRoftheRochesecurities(NES francs)forservingontheChugaiBoard.
andshares)ranked#13,comparedwithitspeer
setofcompaniesoperatinginthesameindustry. G. Highest total remuneration to a member of
Therefore,accordingtothetermsoftheplan,the the Board of Directors
participantsreceivednoneoftheoriginallytargeted FranzB.Humerasthechairmanwasthemember
NES(seetableonpage80fordetails). oftheBoardwiththehighesttotalremunerationfor
2009(see‘RemunerationofmembersoftheBoard
E. Indirect benefits ofDirectors’,page77to79).TheChairman’sremu-
Employercontributionsmadein2009tosocialsecurity nerationconsistsofbasesalaryandbonusawards.
schemes,pensionplansandaGroup-wideemployee As Chairman of the Board after the handover of his
stockpurchaseplan(RocheConnect)inrespect executivefunctionasCEOattheAnnualGeneral
ofmembersoftheCorporateExecutiveCommitteeare Meeting on 4 March 2008, he did not receive any
showninthetable‘Indirectbenefitsin2009’below. additionalS-SARsorNESfromnewPSPcyclesand
RocheConnectisavoluntarystockpurchaseplan wasnolongerenrolledinanyRochestockoption
offeringemployeestheopportunitytobuyRoche planorS-SARs.
Indirect benefits in 2009
Payments for
Pension funds/MGB 19 AHV/IV/ALV 20 Roche Connect tax consulting services
(in CHF) (in CHF) (in CHF) (in CHF)
S. Schwan 456,941 386,096 69,790 5,488
S. Ayyoubi 449,635 117,920 2,375 1,937
W.M. Burns 37,120 405,969 30,000 33,378
E. Hunziker 650,892 311,819 49,992 5,985
G.A. Keller 530,330 177,106 37,500 –
J.K.C. Knowles 37,357 132,927 9,375 39,446
J. Schwiezer 77,695 128,335 9,600 5,563
P. Soriot 254,576 248,408 4,166 3,809
Total 2,494,546 1,908,580 212,798 95,606
19 MGB: Stiftung der F. Hoffmann-La Roche AG für Mitarbeiter-Gewinnbeteiligung (employee profit-sharing foundation supplementing
occupational pension benefits).
20 AHV/IV/ALV: Swiss social security programmes providing retirement, disability and unemployment benefits.
12_L_Roche_AR09_ENG_Remuneration Reportindd 81 29012010 00:505982
Roche Business Report 2009 Remuneration Report
TheBoardofDirectorsintendstoreducetheChair- familieswhoarecloselyassociatedwiththembelong
man’sbasesalaryin2010to4millionSwissfrancs toashareholdergroupwithpooledvotingrights.
(asof1April2010).Histotalremuneration,including Attheendof2009thisgroupheld80,020,000shares
bonuses,contributionstopensionfundsandaddi- (50.01%ofissuedshares).Detailedinformationabout
tionalcompensation(expenseallowance)will,depend- thisgroupcanbefoundintheFinanceReport,Note
ingontheachievementofobjectives,notexceedthe 33totheRocheGroupConsolidatedFinancialState-
maximumamountof11millionSwissfrancs. ments(‘Relatedparties’,page120)andintheNote4
totheFinancialStatementsofRocheHoldingLtd
H. Highest total remuneration to a member of the (‘Significantshareholders’,page141).Inaddition,as
Corporate Executive Committee of31December2009themembersoftheBoard
Severin Schwan as CEO was the member of the ofDirectorsandpersonscloselyassociatedwiththem
CorporateExecutiveCommitteewiththehighesttotal andthemembersoftheExecutiveCommitteeand
remunerationfor2009(see‘Remunerationofmem- personscloselyassociatedwiththemheldsharesand
bers of the Corporate Executive Committee’, A.–F., NESasshowninthetableonpage84.
page78topage81).Noadditionalremunerationwas
paid to current or former members of the Corporate 1.4 Stock options/Stock-settled Stock Appreciation
Executive Committee. Rights (S-SARs) | At31December2009FranzB.
Humer(beingtheonlymemberoftheBoardofDirec-
1.3 Security holdings | DirectorsAndréHoffmann torsholdingoptionsandasof1January2005S-SARs
andAndreasOeriandmembersofthefounders’ duetohisformerpositionasCEO)andthemembers
Highest total remuneration to a member of the Board of Directors
2009 2008 21
(in CHF) (in CHF)
Salary 6,030,000 6,030,000
Cash bonus 2,200,000 5,000,000
Special stock awards (for 10 years blocked non-voting 2,792,018 –
equity securities 22)
Total 11,022,018 11,030,000
Performance Share Plan 23
2007–2009 24
Total None awarded 918,613 25
Pension funds/MGB 26 2,995,109 2,955,697
Roche Connect 75,000 64,585
Total (value) 14,353,552 27 15,228,951
21 For detailed calculation of the remuneration as Chairman and CEO for 2008 see Annual Report 2008, page 81.
22 Bonus in form of for 10 years blocked non-voting equity securities; 34,084 non-voting equity securities (NES), day value at grant
of non-voting equity securities: CHF 146.70/NES. Calculation of value (including contribution to AHV/IV/ALV) in consideration of
reduction of value due to blocking period (reduced market value: for 10 years = 55.839%.
23 Franz B. Humer does not take part in the PSP 2008–2010 and 2009–2011.
24 PSP 2007–2009: None of the originally targeted NES awarded.
25 PSP award.
26 MGB: Stiftung der F. Hoffmann-La Roche AG für Mitarbeiter-Gewinnbeteiligung (employee profit-sharing foundation supplementing
occupational pension benefits).
27 Includes additional compensation for Committee members, payments for tax consulting services, remuneration for serving on the
Chugai Board, not including employer contribution to AHV/IV/ALV (CHF 762,644).
12_L_Roche_AR09_ENG_Remuneration Reportindd 82 29012010 00:505983­
Highest total remuneration to a member of the Corporate Executive Committee
2009 2008 28
(in CHF) (in CHF)
Salary 2,875,002 2,283,340
Cash bonus 3,000,000 3,000,000
Special stock awards (for 10 years blocked non-voting 1,675,178 –
equity securities 29 )
Total 7,550,180 5,283,340
S-SARs
(Black-Scholes value 30 at grant minus 11%) 3,559,849 2,225,542
Performance Share Plan 31
(2008–2010, 2009–2011)
Total 408,793 217,804
Pension funds/MGB 32 456,941 202,320
Roche Connect 69,790 48,956
Total (value) 12,101,478 33 8,018,883
28 For detailed information see Annual Report 2008, page 82.
29 Calculation see ‘Remuneration of members of the Corporate Executive Committee, B. Bonus’, page 78.
30 Black-Scholes value as described in ‘Stock options/Stock-settled Stock Appreciation Rights (S-SARs)’, page 82 to 85.
31 Basic rules and detailed calculation see ‘Remuneration of members of the Corporate Executive Committee, D. Performance Share Plan’,
page 80, footnote 17, respectively.
32 MGB: Stiftung der F. Hoffmann-La Roche AG für Mitarbeiter-Gewinnbeteiligung (employee profit-sharing foundation supplementing
occupational pension benefits).
33 Includes an annual expense allowance, payments for tax consulting services and remuneration for serving on the Chugai Board exclud-
ing employer contribution to AHV/IV/ALV payments.
of­the­Corporate­Executive­Committee­held­options­ (for­reasons­other­than­retirement),­while­vested­
and­Stock-settled­Stock­Appreciation­Rights­(S-SARs;­ options­must­be­exercised­within­a­limited­period­of­
first­introduced­on­1­January­2005)­as­shown­in­the­ time.­The­fair­value­of­the­options­is­calculated­at­­
table­‘Stock­options­and­S-SARs’­on­page­85. the­date­of­issue­using­the­Black-Scholes­formula­­
and­as­if­the­options­were­tradable,­with­an­11%­
All­of­the­options­shown­in­the­table­were­issued­by­ deduction­for­the­average­two-year­vesting­period.
Roche­as­employee­stock­options.­Each­option­entitles­
the­holder­to­purchase­one­Roche­non-voting­equity­ The­S-SARs­shown­in­the­table­on­page­85­were­
security­(NES). introduced­by­Roche­on­1­January­2005­in­place­­
of­stock­options.­S-SARs­entitle­holders­to­benefit­
Under­the­terms­of­this­multi-year­option­plan,­the­strike­ financially­from­any­increase­in­the­value­of­Roche’s­­
price­for­options­shown­was­the­closing­price­for­ NES­between­the­grant­date­and­the­exercise­date.­
Roche­NES­on­the­last­day­of­trading­prior­to­the­Roche­ The­strike­price­for­S-SARs­under­the­terms­of­this­
Annual­Media­Conference.­All­of­the­options­shown­ multi-year­plan­was­the­closing­price­for­Roche­NES­
are­non-tradable.­One-third­of­the­options­are­subject­ on­the­first­day­of­trading­after­the­Roche­Annual­
to­a­vesting­period­of­one­year,­one-third­have­a­­ Media­Conference.­All­S-SARs­vest­within­three­years­
vesting­period­of­two­years,­and­one-third­a­vesting­ of­the­grant­date:­i.e.­one-third­vest­at­the­end­of­­
period­of­three­years.­Unvested­options­lapse­without­ one­year,­one-third­at­the­end­of­two­years,­and­one-
compensation­if­employment­is­terminated­voluntarily­ third­at­the­end­of­three­years.­Vested­S-SARs­must­
12_L_Roche_AR09_ENG_Remuneration Report.indd 83 05.02.2010 09:37:4284
Roche Business Report 2009 Remuneration Report
Security holdings (at 31 December 2009)
Close
relatives’
Shares NES security holdings Others
(number) (number) (number/type) (number)
Board of Directors
F.B. Humer 3 196,528 – Stock options, S-SARs see 1.4
B. Gehrig 50 150 – –
A. Hoffmann –* 365,200** – 250,000 UBS Long/Short Certificates linked to
Roche Bearer Shares/Roche Non-Voting
Equity securities (Valor: 10 690 162,
ISIN: CH0106901629)
365,000 OTC Call options UBS AG on
Roche Non-Voting Equity securities,
21.08.2008–20.08.2010 (Valor: 4 103 145)**
P. Baschera 1 – – –
J.I. Bell 300 1,647 – –
P. Brabeck-Letmathe 800 2,195 – –
L.J.R. de Vink – – – 1,000 American Depository Receipts (ADR),
RHHBY, US ISIN: US7711951043
W. Frey 72,500 – – –
D.A. Julius 350 – 1,550 NES –
A. Oeri –* 351,793 250,000 UBS Long/Short Certificate linked to
Roche Bearer Shares/Roche Non-Voting
Equity securities (Valor: 10 690 162,
ISIN: CH0106901629)
W. Ruttenstorfer 1,000 – – –
H. Teltschik 385 – – –
B. Weder di Mauro 200 – – –
Total 75,589 917,513 1,550 NES
Corporate Executive Committee
S. Schwan 3 32,996 270 NES Stock options, S-SARs see 1.4
S. Ayyoubi 3 12,113 – Stock options, S-SARs see 1.4
W.M. Burns 3 78,167 – Stock options, S-SARs see 1.4
E. Hunziker 3 60,635 – Stock options, S-SARs see 1.4
G.A. Keller 1,063 27,937 140 NES Stock options, S-SARs see 1.4
J.K.C. Knowles 3 19,558 – Stock options, S-SARs see 1.4
J. Schwiezer 3 11,032 – Stock options, S-SARs see 1.4
P. Soriot 2 6,276 – Stock options, S-SARs see 1.4
Total 1,083 248,714 410 NES
* Shares held by the shareholders group with pooled voting rights not listed.
** Share-settled loan transaction as of 21 August 2008 reported to SIX Swiss Exchange.
12_L_Roche_AR09_ENG_Remuneration Reportindd 84 29012010 00:505985
Stock options and S-SARs
Number of stock options and S-SARs held by current and former members
of the Corporate Executive Committee on 31 December 2009 (S-SARs first issued in 2005)
2009 34 2008 34 2007 34 2006 34 2005 34 2004 35 2003 35 Total
Corporate Execu-
tive Committee
S. Schwan 175,362 105,576 29,190 15,696 4,983 35 1,864 1,635 334,306
S. Ayyoubi 43,842 21,117 3,243 2,517 3,957 2,360 – 77,036
W.M. Burns 109,602 105,576 48,651 26,160 34,074 14,874 – 338,937
E. Hunziker 96,450 92,907 48,651 26,160 34,074 20,915 – 319,157
G.A. Keller 65,763 63,345 24,327 15,696 3,150 4,000 – 176,281
J.K.C. Knowles 65,763 63,345 24,327 15,696 – – – 169,131
J. Schwiezer 43,842 42,231 9,819 5,565 8,871 5,610 – 115,938
P. Soriot 69,051 63,345 29,190 23,544 – – 206,766
+
21,636
Total 669,675 557,442 217,398 152,670 89,109 49,623 1,635 1,737,552
Former Corporate
Executive Commit-
tee members
F.B. Humer None 36 None 36 48,651 52,317 85,179 55,775 – 241,922
Strike price (CHF) 145.40 195.80 229.60 195.00 123.00 129.50 77.80
196.50
Market price per NES 175.80
on 31 December 2009
(CHF)
Expiry date 5.2.2016 31.1.2015 8.2.2014 2.2.2013 3.2.2012 3.2.2011 25.2.2010
2.1.2013
Grant value per 20.30 21.08 36.59 34.02 20.89 31.92 16.27
option 37.02
and (starting in 2005)
per S-SAR in CHF
(Black-Scholes value
minus 11%)
34 S-SARs.
35 Stock options.
36 As of 2008 Franz B. Humer does not receive any additional S-SARs.
beexercised(convertedintoNES)withinsevenyears The strike prices, expiry dates and grant values for
ofthegrantdate,andunexercisedS-SARslapse optionsandS-SARsareshowninthetableabove.
withoutcompensation.Thefairvalueoftheoptions ThenumbersofoptionsandS-SARsascalculated
iscalculatedatthedateofissueusingtheBlack- atthetimeofissuehavebeenenteredasvaluesin
Scholesformulaandasiftheoptionsweretradable, thetable‘RemunerationofmembersoftheCorporate
withan11%deductionfortheaveragetwo-year ExecutiveCommittee,C.Stock-settledStockAppre-
vestingperiod. ciationRights(S-SARs)’onpage79.
12_L_Roche_AR09_ENG_Remuneration Reportindd 85 29012010 00:5059He’s sharpening his weapons
for the fight against
advanced breast cancer
When biotechnology was in its infancy thirty years ago, nobody would
have guessed that it would one day give rise to a completely new
class of powerful, targeted medicines: monoclonal antibodies (MAbs).
Today, MAbs are being used successfully not only in the fight
against cancer but also to treat rheumatoid arthritis. It took courage,
skilful management and long-term commitment to enable Roche to
invest in this technology at such an early stage. The skill and dedication
of our people was vital in transforming MAbs into a medical and
business success story. Today, around two thirds of all Roche drugs are
based on biotechnology, and a new approach — joining MAbs with
chemotherapy — promises to make the treatment of cancer even more
targeted, with fewer side effects.
T-DM1 is a novel antibody-drug conjugate that combines
two anti-tumour strategies in one medicine: the directed
binding of a monoclonal antibody to a highly expressed
cancer protein, leading to the targeted delivery of a potent
chemotherapy agent. This selectively kills cancer cells and
minimises damage to healthy tissue.
13_Bildstrecke_ENG_S86-87indd 1 28012010 23:36:1913_Bildstrecke_ENG_S86-87indd 2 28012010 23:36:22Corporate Responsibility | As a
leading healthcare company, our goal is
to develop and make available products and
services that address unmet medical needs
and are of real value to society. We aim to
provide tangible improvements in patients’
health, quality and length of life – this is
our core contribution. We do this in a
responsible and sustainable manner that
respects the needs of the individual, the
society and the environment. To make this
possible, we are committed to finding and
retaining talented people and developing
their skills.
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 88 29012010 00:11:2489
In brief
Ourpursuitofscientificexcellenceenablesusto report,andonourwebsite.Oureffortswererewarded
addressunmetmedicalneeds,helpingpatientslead in2009whenRochewasnamedhealthcaresuper
longerandbetterlives.Wepioneerdifferentiated sectorleaderintheDowJonesSustainabilityIndexes
medicinesandtranslatethoseintobenefitsforpatients (DJSI)forthefirsttime.Rochehasbeenincludedin
throughoutreachprogrammes.Oureffortstounder- theDJSIWorldIndexesforsixconsecutiveyearsand
standdiseasebiologyandtodevelopmedicines isincludedintheFTSE4GoodIndex.
anddiagnosticsthatprevent,detect,correctlydiag-
noseandeffectivelytreatdiseasehelpusachieve Managing corporate responsibility
ourgoalofpersonalisedhealthcare(PHC)throughout Corporateresponsibilityisanintegralpartofourdaily
ourvaluechain. workratherthanthedutyofasingledepartment.
OurCorporateSustainabilityCommittee(CSC)co-
Asweseeit,ourgreatestresponsibilityistokeepup ordinatesourapproach.Withrepresentativesfromall
thiswork.Ourmedicinestakebetweeneightand corefunctionsandbusinessesacrosstheGroup,the
twelveyearstobringtomarket,soafocusonlong- CSCreportstotheCorporateExecutiveCommittee
termsuccessiscritical.Werunourbusinessina andtheBoard’sCorporateGovernanceandSustain-
sustainablemannerthatrespectsindividuals,society abilityCommittee.TheCSCworkstoidentifyand
andtheenvironment,andwefind,retainanddevelop assesssignificantsocial,ethicalandenvironmental
talentedpeopletomakethispossible.Ourvaluesof risksaswellasrelatedopportunities.Italsodevelops
integrity,courageandpassionguidethedailybe- andrevisescorporatepositionsandguidelineson
haviouranddecisionsofallemployees,andweseek topicsofkeyinteresttoourstakeholders.InOctober
evidenceofthesevaluesfromleadersinparticular. 2009theCSChelditsfifthannualworkshop,
Thesevaluesencapsulatetheworkingenvironment attendedbyaround60employeesacrosstheGroup.
andattitudesrequiredtocreateinnovativethinking. Maintopicsdiscussedwereaccesstohealthcare
andthevalueofourproductsandservices.During
Our approach theyear,theCSCdevelopedfivenewpositionpapers
Wetrytobalanceeconomicprosperity,socialcommit- ontopicsrelatedtocorporateresponsibility.
mentandenvironmentalprotectionineveryaspect
ofourbusiness.Webelievethiscreatesvalueforall 2010 objectives
ourstakeholdersandhelpsearntheirtrustand • Remainoneofthetophealthcarecompanies
commitment.Engagingwithrelevantgroupsensures intheDJSI
ourapproachiseffective.Wehaveidentifiedsix • IntegratebestpracticesfromGenentech’s
materialcorporateresponsibilityareas: sustainabilityactivities
• Innovationcapacities • Improveenergyefficiency(gigajoulesper
• ValueofRocheproductsandservices employee)by10%by2014from2009.
• Pricingandreimbursementconditions
• AccesstoRocheproductsandservices More on the web
• Relationshipwithstakeholders • Sustainability principles, strategy and management:
• Beinganattractiveandresponsibleemployer. www.roche.com/principles
• Stakeholder engagement:
www.roche.com/stakeholder_dialogue
Wemonitortheeffectivenessofourapproachandour • Corporate Sustainability Committee Charter:
progressintheseareasusingasetofkeyperfor- www.roche.com/csr_committees
manceindicators(KPIs),forwhichwenowhavetwo • Key performance indicators:
www.roche.com/sus-kpi.pdf
fullyearsofdata.WhiletheseKPIsareforinternal
• Safety, health and environment performance:
managementonly,weincludearangeofperformance www.roche.com/she_figures_and_facts
measuresthroughoutthissectionofourannual • Employee topline figures: www.roche.com/employees
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 89 29012010 00:11:2490
Roche Business Report 2009 Corporate Responsibility
Responsible practices
Howwedothingsisasimportantaswhatwedo. providinginstantreportsandinformationbasedon
Thetrustofthemanydiversegroupsweencounterin historicalinformation,customerfeedbackandmarket
thecourseofourworkdependsonuscarryingout analysis,toaidourplanning.
eachandeveryaspectofourbusinessresponsibly.
Asaninnovationdrivencompanywefocusonunder- Customersatisfactionisparticularlyimportantin
standingthemechanismsunderlyingthedisease consumerbusinesses.Patientswithdiseasessuchas
andtranslatingthisintodevelopingproductsthat diabetes,whouseourproductsdaily,tendtogive
improvepatients’health.Thisoftenmeansexploring regularfeedback,whichispivotaltofutureproduct
emergingtechnologiesastheycouldprovideim- development.Wealsousedetailedmarketresearch
portantmedicalbreakthroughsandformthebasisof andfocusgroupstodevelopproductsandservices
ourproductpipelineinthelongterm.Atthesame thatsimplifydailydiabetesmanagement.
time,wemustassessanyrisksorethicaldilemmas
thatcutting-edgetechnologiesposewithgreat HalfourDiagnosticsemployeesworkincustomer
scrutinybeforeandwhileusingthem. serviceandsupport.Wealsoencourageemployees
withlittleornocontactwithcustomerstospend
Customer relationships timelearningabouttheirneeds.Forexample,Roche
Ourcustomersrangefrompatients,healthcarepro- DiagnosticsinRotkreuz,Switzerland,hasacustomer
fessionals,hospitalsandreferencelaboratoriesto orientationprogrammeduringwhichtechnical
publicandprivatehealthcarepayers.Understanding specialistsspendninemonthsattendingworkshops,
andrespondingtotheirdifferentneedsandexpec- visitinglaboratoriesandhospitals,andevaluating
tationshelpstoimproveourcommercialeffectiveness. whattheyhavelearnedbeforepresentingtheir
Variouscustomergroupsprovideinputinto: findingstomanagement.Theyworkedonprojects
• Productprofiles,forexampletheeaseofuseof includinganonlinesurveytohelpimprovetheway
medication,instrumentspecifications healthcareproviderscopewithmethicillin-resistant
• Clinicaldevelopmentplans,forexampleby Staphylococcus aureus—amajorprobleminhospitals.
designingandparticipatingintrials
• Publicationoftrialresults Pandemic preparedness
• Regulatoryfiling In2009theWorldHealthOrganization(WHO)
• Developmentofhealthoutcomestudies declaredaglobalpandemicofH1N1influenza.Infor-
• Diseaseawarenessplansandproductinformation mationfromtheWHOandtheUSCenterforDis-
• Educationandawarenessprogrammes easeControlandPrevention(CDC)indicatedthat
• Treatmentguidelines. Tamifluwasoneofonlytwoapprovedantiviralswith
activityagainstthenovelstrain.Theseeventstrig-
Wealsoobtainfeedbackfromcustomergroups geredRochetoimplementitspandemicplan,which
throughourmedicalliaisonsandclinicalresearch hadbeenindevelopmentsince2004,withafocus
associates,advisoryboards,andeducationand onincreasingTamifluproductionanddistributionto
awarenessprogrammesweareinvolvedin. meetincreaseddemand,andensurelow-income
countrieshadaccesstothedrug.Ourpoliciesforthe
Wecarryoutcomprehensivemarketresearchand prioritisationofdrugsupplywereinaccordancewith
analysis,oftenatadivisionalorlocallevel,tohelpus Preparing for the Next Influenza Pandemic — Roles
meetspecificmarketneeds.Eachcountryorgani- and Responsibilities of Roche and Other Stakeholders,
sationisresponsibleformanagingitsrelationship publishedinMay2008.
withitscustomersandsharingrelevantinformation
withintheGroup.Wehavearangeofinitiativesto Tamiflu stockpiles | WehaveworkedwiththeWHO
enablethissuchasUNITEacompany-widedatabase andgovernmentstobuildstockpilesofTamifluand
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 90 29012010 00:11:2491
helpprepareforaflupandemic.In2005wedo- A/H1N1test.Itallowsrapidandaccurateidentification
natedthreemilliontreatmentcoursesfortheWHO’s ofpatientsinfectedwiththevirussoappropriate
RapidResponsestockpile.Westoredthestockpile patientmanagementcanstartasearlyaspossible.
until2009,whentheWHOdistributeditto72of
theworld’sneediestcountries.In2006wedonated Emergingdataunderscoretheimportantrolethedrug
andshippedanadditionaltwomilliontreatment playedinreducingtheimpactofthismostrecent
coursesfortheWHO’sRegionalstockpile,whichhas flupandemic.Forexample,arecentstudybyJainetal
alsobeendistributedtocountriesinneed. fromtheUSCentreforDiseaseControl,published
intheNewEnglandJournalofMedicine,reportedon
InMay2009weagreedtodonateafurtherfivemil- theclinicaloutcomeofpatientshospitalisedwith
lioncoursestoreplenishbothstockpiles.Wealso H1N1influenzain2009.Thestudyshowedthatanti-
agreedtoestablishastockpileof650,000treatment viraldrugsweretheonlytreatmentthatmadeastatis-
coursesofpediatriccapsules,whichweprovide ticallysignificantdifferenceinhelpingpatientsto
alongwithinstructionsformixingthecontentswith recover,andthatoseltamivirwastheantiviraltaken
food,forchildrenunabletoswallowthemwhole. inaround90%ofcases.
Thisbringsthetotalnumberoftreatmentcourses
donatedtoaround11million. Public policy
Theprivatesectorhasacrucialandlegitimaterole
Since2005wehavebeenprovidinggovernments toplayindevelopingpublicpolicy.Weshareour
Tamifluatsubstantiallyreducedpricestoassisttheir expertisewithpolicymakerstohelpdevelopeffective
pandemicpreparedness.However,werecognised laws,regulationsandpoliciesrelatingtopublic
thatmanydevelopingcountrieswereunabletocreate health,aswellasmoregeneralareasaffectingour
anadequatestockpileevenatreducedprices.InJuly business,suchastaxpolicy.Ourgoodpractice
2009welaunchedtheTamifluReservesProgramme guidelinesforworkingwithgovernmentofficialsguide
toincreaseaccessinthesecountries.Weproduce ouremployeesondoingsoinanappropriateand
andstoreTamifluforspecifieddevelopingcountriesat professionalmanner.
asignificantlyreducedprice,andspreadthecost
overanumberofyears.Wewillshipthestockpileif Muchofourpublicpolicyworktakesplacethrough
theWHOannouncesaflupandemic,orwhenagov- ourmembershipofindustrybodiessuchasthe
ernmentrequestsittodealwithanationaloutbreak. EuropeanFederationofPharmaceuticalIndustriesand
Associations(EFPIA),theEuropeanDiagnostics
Tofurtherincreaseavailability,wehavelicensed ManufacturersAssociation(EDMA)andtheInterna-
companiesinChinaandIndiatomanufacturegeneric tionalFederationofPharmaceuticalManufacturers
oseltamivir.Wehavealsosupportedtheeffortsofa andAssociations(IFPMA),aswellastheirnational
SouthAfricanmanufacturerbygivingthemaccess members.Wealsomeetdirectlywithpolicymakers
totheknowledgeandskillsneededtoproduce suchasgovernments,publichealthorganisations,
oseltamivir.Theycannowproducethedrugfreelyas thinktanksandacademics.
wedonotenforcepatentsinsub-SaharanAfrica.
Ourmajorpublicpolicyworkin2009included:
RocheDiagnosticsproducedapolymerasechain • WorkingwiththeWorldBusinessCouncilfor
reaction(PCR)basedtestfortheH1N1strainofthe SustainableDevelopment,EuropeanRoundtable
fluvirususingourLightCyclerSystem,withinweeks ofIndustrialistsandPrinceofWalesCorporate
ofthevirusbeingidentified.InNovember2009the LeadersGrouponClimateChangeonpolicy
USFoodandDrugAdministrationgrantedEmergency statementsaheadoftheCopenhagenClimate
UseAuthorisationofthisRealTimeReadyInfluenza ConferenceinDecember
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 91 29012010 00:11:2592
Roche Business Report 2009 Corporate Responsibility
• ShowingMembersoftheEuropeanParliament andareobtainedfromlivingsystemsusingadvanced
aroundouranimalfacilityinBaselduringthe processesthatareverydifficulttoreproduce.More
developmentoftheanimalresearchdirective,to testingisneededtodemonstratethesimilarity,safety
demonstrateourwelfarestandardsandthe andefficacyoffollow-onproductscomparedwiththe
importanceofanimalresearchinhealthcare original.
• Co-organisingadinnerdebateonanimal
researchintheEuropeanParliamentwiththe Webelievebiosimilarsshouldbesubjecttowell-
EuropeanPlatformforPatientOrganisations, definedandtransparentregulationsthatcoverdevel-
ScienceandIndustry(EPPOSI) opment,approvalandpost-authorisationprocedures,
• Explainingourpositiononproposedlegislation basedonthosefortheoriginalproducts.
coveringpharmacovigilance,informationto
patientsandcounterfeitmedicinestoMembers In2009weworkedwithregulatoryauthoritiesand
oftheEuropeanParliament. industrybodies,particularlytheInternationalFedera-
tionofPharmaceuticalManufacturersandAssocia-
Combating counterfeits | Counterfeitpharmaceuti- tions,toensurepolicymakersfullyunderstandbiosim-
calanddiagnosticproductsareillegalandaserious ilarscience.Thisworkwillsupportthecreationof
globalpublichealthproblem.Theyendangerpatients, appropriatepoliciesregardingfuturebiosimilarmono-
undermineconfidenceinhealthcaresystemsand clonalantibodiesandthenamingofbiopharmaceuti-
companies,infringeintellectualpropertyrightsand cals.Rochehasalsomadescientificandmedical
wastevaluablehealthcarebudgets. presentationsonbiosimilarstoregulators,scientists
andotherkeyaudiences,andcontributedtoscientific
Wecontinuouslymonitorandimproveproductsecu- journals.
rityandusetechnologytoquicklyidentifycounterfeits.
Wetakepartinnationalandinternationalindustry Political contributions | Rochedoesnotfinancially
andgovernmentaleffortstostrengthenthelaw,im- supportindividualpoliticiansanywhere.USemploy-
proveenforcement,trainlocalofficialsandeducate eescanmakepersonalcontributionsthroughthe
thepublic. Hoffmann-LaRocheGoodGovernmentCommittee
(GGC),avoluntarypoliticalactioncommittee,orpar-
In2009weupdatedourpositiononcounterfeiting, ticipateintheRocheActionProgramme.
whichisavailableonourwebsite.Wearetakingpart
inanEFPIApilotprojectinSwedenofatracking Integrity and compliance
systemwhichtracesdrugsbacktotheirsource, TheRocheGroupCodeofConductguidesour
improvingpatientsafety.Weapplyauniquebarcode employees’businessbehaviour.
toeachpackofmedicineproduced,whichpharma-
cistsscanwhendispensingthemedicinetocheckit InDecember2009welaunchedtheRocheGroup
isauthentic.Wecontinuetoprovideinput,through SpeakUptelephonelineandwebservicefor
EFPIA,intotheproposedEUlegislationoncounter- employeestoraiseconcernsaboutcompliancewith
feiting. theCodeofConduct,anonymouslyifpreferred.
Athird-partyorganisationoperatesSpeakUpand
Generic and biosimilar products | Thepatentperi- PricewaterhouseCoopershasprovidedassurancethat
odsforsomeinnovativebiologicalproductssuchas thesystemprotectsemployees’identities.
proteinsandantibodiesareexpiring,andproducts
claimingtobesimilarareappearingonthemarket. In2009,141businessethicsincidentswerereported
Whileitisrelativelyeasytocopychemicaldrugs,bio- totheChiefComplianceOfficer.Weinvestigatedthem
logicalproductshavecomplexmolecularstructures allandtookcorrectiveactionswherenecessarywith
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 92 29012010 00:11:2593
73employmentcontractsbeingterminatedasaresult In2009weintroducedasustainabilityriskmanage-
ofunethicalbehaviour. mentprocessandtargetsforourmarketingagencies.
Wealsointroducedanewstandardoperatingpro-
Welaunchedseveralinitiativestostimulatetheshar- cedureandrelatedtrainingtostrengthencompliance
ingofbestpracticesamongRoche’s110local withmarketingcodesinourpharmaceuticaland
complianceofficers,includingaComplianceOfficers’ diagnosticsbusinesses.
Network,aseriesofregionalcompliancemeetings
andadedicatedintranetsite.Thecomplianceofficers Wedonotsellover-the-countermedicinesandso
helplinemanagerstocontrolriskslocallyandmeet donotadvertisedirectlytoconsumersinthemajority
therequirementsofourGroupCodeofConduct. ofourmarkets.IntheUS,whereitislegaltoadver-
tiseprescriptionmedicines,wehavedetailedpolicies
Wealsoupdatedourperformancemanagement inplacetoensurethisisdonelegallyandethically.
systemtoensureweassessemployeesnotjuston Wesendalltelevisionadvertisingcampaignstothe
whethertheyachievetheirobjectives,butalsoon FoodandDrugAdministrationforapprovalbefore
howtheyachievethem. broadcast.
Finally,wesetupanExportComplianceCouncilto WedecidedtoendourmembershipofthePharma-
ensureourmanufacturinganddistributionsitesmeet ceuticalResearchandManufacturersAssociation
thecomplexlegalrequirementsforsellingand (PhRMA)intheUnitedStatesandinsteadjointhe
exportingourproducts. BiotechnologyIndustryOrganization(BIO),ofwhich
Genentechwasalreadyamember.
Risk and crisis management
OurRiskManagementCharterdefinesourrisk Sustainable supply chain
managementapproachandresponsibilities,andis Rochespentaround18billionSwissfrancsonprod-
availableonourwebsitealongwithafulllistof uctsandservicesin2009.Theserangefromraw
riskstoourbusiness.Weincludesignificantsocial, materialsandactivepharmaceuticalingredientsto
environmentalandethicalrisksidentifiedinthe equipment,laboratoryandofficesupplies,andser-
Groupriskmanagementprocess. viceslikeconsultancy,travelandmarketing.Wemust
ensurethesesuppliersmeetthenecessarysocialand
Responsible marketing environmentalstandardstosecurereliablesupplies
Therearestrictregulationsandindustryguidelines andenablethesustainablegrowthofourcompany.
onthesaleandmarketingofmedicinesanddiagnos-
tics,tomakesuretheyareprescribed,administered Ourapproachisto:
andusedcorrectly,andthatpatientsunderstand • Raiseawarenesswithoursupplyofficers
thebenefitsandrisksoftakingthem. • Raiseawarenesswithsuppliers
• Helpsuppliersimprovetheirstandards
Healthcareprofessionalsneedtobeabletoselect • Developjointinitiativestoincreasetheirperfor-
thebesttreatmentoptionfortheirpatients.We mance.
providescientificandclinicallyrelevantinformation
thatenablesthemtoprescribeoruseourproductsin WeendorsethePharmaceuticalIndustryPrinciples
circumstanceswhichdeliverthegreatestmedical (PSCIPrinciples)whichrequiresupplierstoimple-
benefittothepatient.Alistoftheexternalguidelines mentResponsibleSupplyChainManagementinthe
andcodesofpracticewefollowwhenmarketing areasofethics,safety,healthandenvironment(SHE),
ourproductsisavailableonourwebsite. socialresponsibility,managementsystems,innovation
andeconomicsustainability,andarecommittedto
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 93 29012010 00:11:2594
Roche Business Report 2009 Corporate Responsibility
integratingthesePrinciplesintoourbusiness.In2009 clinicalresearch,suchaswhatthedifferenttrial
wedevelopedanewSupplierCodeofConduct,which phasesareandwhattheendofatrialmeansforthe
includesthePSCIPrinciples,andnowrequireallour patientstakingpart.
supplierstosignourCodeofConduct.
Aspartofourclinicaltrialsprogramme,westore
OurPharmaceuticalsandDiagnosticsDivisionsaudit biologicalmaterialsuchastissue,organs,bloodand
business-criticalsuppliersandassessnewsuppliers otherbodilyfluidsinhumanspecimenrepositories,
toidentifyandcorrectproblems,usingexternaland orbiobanks.Theseareinvaluableforlearningmore
internalauditors.Weshareourexpertiseandprovide aboutdiseaseandexploringpossibletreatments.
trainingtohelpsuppliersimplementanyrequired Theyalsocontainsensitiveinformationaboutthe
improvements.Internalauditorscarryoutfollow-up personwhoprovidedthesample.Wearededicatedto
inspectionstoensuresuppliershavemadethe protectingdonors’privacyandensuringtheyarefully
necessarychanges.In2009weauditedsocialand informedabouthowtheirsampleanddatawillbe
safety,healthandenvironmentalstandardsat40 usedbeforetheyagreetotakepart.
existingsuppliersandcarriedoutfollow-upaudits
atfive.Werejectedorceasedtradingwithonesup- Wehaveaclearprocedureforresolvingethical
plierthatwecouldnothelptoimprove.Themain dilemmasemployeesencounterintheirwork.Ifthey
areaforimprovementourauditsflaggedupwas cannotresolvetheissuewithintheirteam,employees
industrialhygiene. cancontactourGlobalEthicsLiaisonOffice,which
willconsultpeersandinternalexpertstofinda
Weareintheprocessofextendingoursustainable solution.Aninternalcommitteehandlesanyremaining
procurementactivitiestosuppliersofnon-production concerns,andourindependentClinicalResearch
materialsandservices. EthicsAdvisoryGroup(CREAG)providescounselon
thetoughestchallenges.Wealsoprovideregular
Wehaveestablishedafinancialriskmanagement onlineethicstrainingforemployees.In2009theGlobal
processinprocurementtoidentifysuppliersatriskof EthicsLiaisonOfficereceived21queries.Allwere
bankruptcyandtomitigatethoserisks.Wecontinued resolvedwithoutescalation.
toapplyoursupplychainriskmanagementprocess
toallsuppliersofkeyrawmaterials,drugsubstances TheCREAGmeetsannuallytoreviewconcernsraised
anddrugproducts.Wealsoworkedwithsuppliers withtheGlobalEthicsLiaisonOfficeanddiscuss
ofmaterialsforkeyRochedrugproductstoensure otherrelevanttopics.In2009weupdatedtheCREAG
theyhavebusinesscontinuityplansforpandemicrisk. onrecentquerieshandledbytheGlobalEthicsLiai-
sonOffice,aswellasonthestatusoftheemployee
Research practices ethicseducationprogrammes.TheCREAGalso
Ethicalconcernssometimesariseaswepushscientific reviewedthelatestrevisionstotheDeclarationof
boundariesandexplorenewtechnologiestodevelop Helsinki,astatementofethicalprinciplesformedical
innovativenewtherapiesanddiagnostics.Wemust researchinvolvinghumansubjectsreleasedbythe
exploreandcarefullymanagetheseconcernsto WorldMedicalAssociation.
ensuretheopportunitiespresentedarenotlost.
Anotherindependentpanel,theScienceandEthics
Ethics in R & D | Ourglobalpositiononclinical AdvisoryGroup(SEAG),advisesandguidesus
researchcommitsustohighethicalstandardsand ongenetics,genomicsandproteomics.In2009the
clarifiesourpositiononspecificareasofconcern. SEAGadvisedonissuesincludingtheuseand
Weupdatedthispositionin2009toincludestraight- storageofhumanbiologicalmaterialsinspecific
forwardanswerstofrequentlyaskedquestionsabout researchprojects.WeexpandedtheSEAG’sadvisory
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 94 29012010 00:11:2595
Breakdown of animals used in research | in 2009 Inthescientificcategory,firstplacewenttoateam
whichfoundanewinvitrotestfordetectingtoxic
compoundsbeforetestingnewdrugsonanimals.Our
Mice 86.6% diagnosticsbusinessdevelopedthetest,whichisnow
Rats 11.4% availableforpharmaceuticalpreclinicalresearch.The
winningprojectinthelabcareandanimalmanage-
Guinea pigs 0.33% mentcategorygraduallyrehabilitatedmonkeysthat
Hamsters 0.17% hadbeenhousedindividuallybackintolargergroups,
Gerbils 0.41% increasingtheirsocialinteractionandimprovingtheir
Fish 0.18% wellbeing.Wewillimplementtheseandotherprojects
Frogs 0.02% intoouroperationswhereverpossible,andrunthe
Dogs 0.14% 3RsAwardagainin2011.
Rabbits 0.53%
Primates 0.15% In2009wecreatedanewjointscienceandtechnol-
Other 0.09% ogylaboratoryinBaselbetweenthePharmaceuticals
andDiagnosticsDivisionsaimedatinvestigating
organtoxicitiesofdrugs.Usinganinnovativecellana-
functions,withtheiragreement,tocoverallinnovative lysersystem,xCELLigence,researcherscantest
technologiessuchasnanotechnologyandstem-cell whetherpharmacologicallyactivesubstancesare
research. likelytoprovetoxictoorganssuchastheheartand
liver,bycontinuous,real-timeviewingofthecells
Animal welfare | Werecogniseandtakeseriously reactiontothemolecule.Thiscanbeperformedin
publicconcernaboutanimalresearch.However,we theearlypreclinicalstageofresearch,makingmany
couldnotdeveloplife-savingmedicinessuchascan- animalstudiesredundant.
cerdrugswithoutit.Whileweworkhardtofindand
usealternativemethods,thelimitationsofthose WealsoestablishedaninternalAnimalWelfareEthics
methodsmeanwestillneedtotestnewdrugsand Committeetoexamineallstudiesinnon-human
technologiesonanimalsforsafetyandlegalreasons. primatesbeforeregulatoryapproval,andtoadvise
employeesworkingwithanimals.Thiscommittee
In2009weusedatotalof478,252animalsinour willbecomefullyoperationalin2010.
research,ofwhicharound98%weremiceandrats.
Innovation and new technologies | Evolvingtech-
Wearecommittedtothe3Rsconceptofreplacing nologiessuchasnanotechnology,stem-cellresearch
animaltestswherepossible,reducingthenumberof andsystemsbiologyhavemanypotentialbenefitsin
animalsweuse,andrefiningexistingscientificprac- pharmaceuticalsanddiagnostics.Theseadvantages
tices,animalwelfareandhusbandry.Allemployees mustbecarefullybalancedwiththeethicaldilemmas
andcontractorswhoperformanimaltestingforus andpotentialrisksposed,andweassessthesewith
mustcomplywithapplicablelawsandmeetorexceed greatscrutinybeforeenteringnewfields.
industrystandards.
Nanotechnologyisthemanipulationofmaterialson
Wecontinuedour3RsAwardforInnovationand ascale80,000timessmallerthanthediameterofa
ContinualImprovementinAnimalWelfarewithin humanhair.Ithaspotentialinmanyareas,particularly
Rochein2009.Fifteenteamsofscientistsandanimal drugdelivery,regenerativemedicineandsmall-scale,
carespecialistsfromourresearchsitesenteredfor portablediagnostics.However,manyquestions
awardsintwocategories. remainabouttheeffectsnanotechnologymayhaveon
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 95 29012010 00:11:2596
Roche Business Report 2009 Corporate Responsibility
peopleandtheenvironment.Therisksandbenefits • LobbythroughEFPIAontheproposedEU
havetobecarefullyevaluatedbeforenanotechnology legislationoncounterfeitmedicinalproducts
isusedinmedicalproducts.Webelievethatexisting • Establisha3Rsdatabaseforsharingbestpractices
safetytestsandregulationsprovideanappropriate inanimaltestingwithinRoche
frameworkfordoingso. • LaunchRoche’sEthicsCommitteeonanimal
welfare
Stemcellsandtheirapplicationsofferanenormous • Commenceauditofsuppliersinindirectspend.
potentialforthetreatmentandreliefofchronic
painandevenforthecureofdiseases,extendingand More on the web
enhancingthequalityoflife.However,theresearch • Responsible marketing, risk management and compliance:
alsoraisesethicalquestions,becausesomepeople www.roche.com/business_integrity_and_responsible_marketing_
www.roche.com/risk_management_and_compliance
believeembryonicstemcellsarehumanswitha
• Pandemic influenza and Tamiflu information:
righttolifeandshouldnotbeusedinresearchor
www.roche.com/roche-influenza
treatments. www.pandemictoolkit.com
• The Pharmaceutical Industry Principles for Responsible Supply
Chain Management:
Rocheiskeenlyawareofthetremendouspotentialof
http://pharmaceuticalsupplychain.org
thisresourceforbasicscienceandfuturehealth- • Patents, counterfeiting and biosimilars:
careapplications.Wehave,therefore,enteredinto www.roche.com/medical_value_patents_and_pricing
www.roche.com/patents
researchcollaborations.Forexample,weworkwith
• Innovation, new products and technologies:
StemCells4SaferMedicines(SC4SM)intheUK
www.roche.com/csr_research_and_development
andwithCellularDynamicsInternationalIncinthe www.roche.com/innovation_and_technologies
US.Rochebeganstem-cellresearchanditsrelated • All position papers:
www.roche.com/policies_guidelines_and_positions
applicationasadiscoverytoolandweplantobegin
researchtousestemcellsasapotentialtherapeutic
modality.Rochealsoplanstodevelopexpertise
tobecometechnicallyenabledinthisresearcharea
andtoconductresearchonhumanembryonicstem
cellsandtheiruseindrugdiscovery.
In2009weheldastem-cellresearchworkshopin
partnershipwithCambridgeUniversityintheUK.
Attendeesincluded70Rochespecialistsand17
academicexperts.Theydiscussedstemcellscience
andpossibleapplications,aswellasstepsforindus-
trytotaketomaximisethemedicalandbusiness
opportunitiespresented.
2010 objectives
• ImplementtheRocheGroupSpeakUpLine
• LaunchtherevisedRocheGroupCodeofConduct
andupdatetheBehaviourinBusinesse-learning
programme
• Rolloutnewsuppliercodeofconductandinclude
compliancewiththisinourexistingsupplieraudit
programme
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 96 29012010 00:11:2697
Patients
Patientsinallaspectsofhealthcarebenefitfromour Themajorityofhealthcarepayersrecognisethemedical
productsandservices.Ourdifferentiatedmedicines andeconomicvalueofourproducts.Forexample,
anddiagnosticscomefromdiverseapproachesto whilecancerdrugssuchasHerceptinandXeloda
researchanddevelopment.Weconstantlypursue mayseemcostly,notonlydotheyextendthelivesof
scientificexcellence,whichhelpsustailorourprod- patientswithterminalillnessandpreventdisease
uctsandservicesinawaythatensuresPersonalised recurrenceinpatientswithearlierstagecancer,
Healthcare.Thismeanspatientscanleadlonger theycanalsoeasepressureonhealthcarebudgets
andbetterlivesbecausetheyreceivetreatmentsthat byreducingorpreventinghospitalvisits,surgeryand
moreeffectivelypreventandcuredisease,alleviate theneedforpalliativecare.Inmanycases,theyhelp
symptomsandhastenrecovery. patientsreturntoworkmorequickly.
Wecanamplifythiscontributiontosocietyby: In2009wepublishedanewpositiononassessing
• Helpingtoimproveaccesstoourproducts thevalueofourproductsandservices,whichcontains
• Ensuringtheyprovidevalueformoney aseriesofguidingprinciplesforcarryingoutsuch
• Providingfactualinformationonourproducts assessments.Weemployexperiencedhealthecono-
• Listeningandrespondingtocustomers’views. mistswhoworkwithhealthauthoritiestounderstand
andproviderobustevidenceregardingtheeconomic
The value of medicines and diagnostics andhealthbenefitsofourproductsandservices
Differentpeopleexperiencediseaseandrespond withintherelevantregionalandlocalhealthcare
totreatmentindifferentways.Ourapproachof systems.
personalisedhealthcare(PHC)takesthisintoaccount
andfitstreatmenttodifferentgroupsofpatients. Wealsoengagewithhealthcarepayersthroughout
Weuseourdiagnosticexpertisetodeepenourunder- aproduct’slifecycle.Weprovideguidanceonassess-
standingofdisease,howtreatmentsworkandhow ingthevalueofourproductsandservices(Health
differentpatientsrespond.Thishelpsusdevelop TechnologyAssessment—HTA)priortothemdecid-
better,saferdrugsandidentifythepatientswhowill ingreimbursementandfundingconditions.
benefitmost,improvingclinicaloutcomesand
increasingcosteffectiveness.In2009wepublished Global access to healthcare
anewpositiononpersonalisedhealthcareto Patientscanaccessourproductsthroughdoctors,
describeourapproachinmoredetail. hospitals,laboratoriesandpharmaciesinroughly
180countries.Whilewesellthemajorityofourprod-
Healthcarepayershavetomakedifficultdecisions uctsindevelopedcountrieswithadvancedhealth-
aboutgrantingaccessto,orprovidingreimbursement caresystems,aroundathirdoftheworld’spopulation
for,healthcareproductsandservices,basedon lacksadequateaccesstohealthcare.TheWorld
costeffectivenessandbudgetconstraintsaswellas HealthOrganization(WHO)listsmanyofourproducts
medicalneedandclinicalimpact.Thesedecisions asessentialmedicines.
haveaprofoundeffectonpatientsandtheirfamilies,
andcaninfluencewhereresearch-basedcompanies Ourindustryhasanimportantroletoplayinparts
likeRochefocustheirfutureinvestment.Objective, oftheworldwherehealthcarestandardsandaware-
consistentandopenprocessesareessential nessofthecauses,preventionandtreatmentof
forassessingthetotalvalueofmedicalproducts, diseasearelower.Buttherearemanyothersystemic
toindividualpatientsandtosocietyasawhole, problemscontributingtohealthinequalities,and
throughouttheirlifecycle,sothatthedecisionsmade wecannottacklethesealone.Weworkwithgovern-
arefair. ments,non-governmentalorganisations(NGOs),
patientgroupsandhealthcareproviderstotackle
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 97 29012010 00:11:2698
Roche Business Report 2009 Corporate Responsibility
healthinequalitiesandincreaseaccesstoour servicetospeedupthedeliveryofHIVtestresultsin
products.Wetailorourapproachindifferentregions remoteareas.
tocaterfortheirspecificneeds.
Cancerkillsmorepeopleindevelopingcountrieseach
Access for those most in need | Theworld’sleast yearthanAIDS,malariaandtuberculosiscombined.
developedcountries(LDCs)arehardesthitbydis- Morethanhalfofallcancercasesareinthedevelop-
easeandhavethepooresthealthcaresystemstodeal ingworld,butonlyabout5%ofglobalcancer
withthisburden.Therearetoofewhospitals,labora- resourcesarespentthere.Internationalhealthcare
toriesandhealthcareprofessionalstomeetdemand. programmesfocusoninfectiousdiseasesandthere
Weaimtoincreaseaccesstohealthcareinpoor isverylittleoncologyinvestment,infrastructureor
countriesinsustainablewaysthatinclude: expertise.Asaleadingproviderofcancertherapies,
• Fairpatentandpricingpolicies wehaveanimportantroletoplayintacklingthis
• R&Dintodiseaseswithunmetmedicalneeds badlyneglectedproblem.
• Partnershipswithgovernments,NGOsandothers
• Education,trainingandknowledge-transfer. In2009weevaluatednewpartnershipstoimprove
trainingincancercareforhealthcareworkersinsub-
Ourapproachistojointlydevelopaccessprogrammes SaharanAfrica.Wewillfocusonsharingourexpertise
thatraiseawareness,educateandtrain,andassist ratherthansimplycashordrugdonations,aswe
indevelopinghealthcareinfrastructure.Thiscollabo- believethatbuildinglocalcapabilitieswillmakeabig-
rativeapproachensuresneedsaremet,whilefuture gerdifferenceinthelongterm.Trainingwilltake
businessopportunitiesforbothsidesareenhanced placelocallytoencouragehealthcareprofessionals
throughtheincreasedcapabilityofinstitutionsand tostayintheirhomecountryratherthanleavingfor
organisationsindevelopingcountries. opportunitiesabroad.
Theillustrationshowsthecircumstancesunderwhich WealsojoinedtheChangingDiabetesinChildren
wedonotfileorenforceanypatents.Italsoillustrates programmein2009.Thisisapublic/privatepartner-
ourno-profitpricingpolicyinaction. shipbetweenNovoNordisk,theWorldDiabetes
FoundationandgovernmentsinAfricancountries.
In2009wecompletedourtechnologytransferini- Theprojectaimstomakelifebetterforthegrowing
tiative(TTI),throughwhichwesharedtheknowledge numberofdiabetespatientsinAfrica,wherethe
requiredtoproduceourHIVtreatmentsaquinavir standardofcareisoftenpoor.Theobjectiveistopro-
withlocalmanufacturers,freeofcharge.Weworked ducecareguidelines,educatehealthcareworkersand
withall41interestedmanufacturersandreached ensureallchildrenenteringtheprogrammeareregis-
agreementwith13companiesintheLDCs,whichare teredandmonitoredsotheirconditioncanbecon-
nowfreetoproducesaquinavirorusethisknow- trolled.ThefirstphasewilltargetCameroon,the
ledgetoproduceotherproducts.Wealsoheldthree DemocraticRepublicofCongo,Guinea-Conakry,
AfricanGoodManufacturingPractice(GMP)train- TanzaniaandUganda.
ingseminarstoimprovelocallyproducedessential
medicines. In2008wegavetheInstituteforOneWorldHealth
accesstoourchemicalcompoundlibrarysoitcould
WealsocontinuedourpartnershipwiththeClinton searchfornewmedicinestotreatchildhooddiarrhea.
Foundation’sHIV/AIDSinitiative(CHAI).Togetherwe OneWorldHealthcompletedthefirstscreeningin
haveestablishedandtrainedsevenlabsforHIVtest- 2009,andidentified40compoundstoinvestigateas
ing,developedanovelsolutionfordiagnosingand possiblenewtreatments.
monitoringHIVininfants,anddevisedatextmessage
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 98 29012010 00:11:2699
68% of people living with HIV covered by
our no profit prices for antiretroviral
medicines
Global access to healthcare
Pricing and patents – Nopatentsfiledorenforcedonanymedicines
in least-developed countries – TwoantiretroviralHIVmedicinessoldatnoprofit,covering68%ofHIVpatients
– ValcytesoldatreducedpricestoNGOstreatingAIDS-relatedcytomegalovirus
Pricing and patents in other – NopatentsfiledorenforcedonantiretroviralHIVmedicines
sub-Saharan African countries – TwoantiretroviralHIVmedicinessoldatnoprofit
– ValcytesoldatreducedpricestoNGOstreatingAIDS-relatedcytomegalovirus
Pricing for low and lower- to – TwoantiretroviralHIVmedicinessoldatreducedprofit
middle-income economies
Planning for pandemic influenza – TamifludonatedtoWorldHealthOrganizationstockpilesforcountriesmostinneed
– Tamiflusoldatreducedpricestodevelopingcountries
– TamifluReservesProgrammecreatesstockpilesfordevelopingcountries
– Tamiflusub-licensingagreementsinChinaandIndiaandtechnologytransfer
agreementinSouthAfrica
Access programmes in – RochePatientAssistanceProgramandGenentechAccessSolutionsprovideadvice
wealthy nations andfinancialsupportforuninsuredorunderinsuredpatients
– Over40,000patientsbenefittedfromthesepatientassistanceprogrammesin2009
Tackling HIV/AIDS in the – AIDStechnologytransferagreementsinBangladesh,Ethiopia,Kenya,SouthAfrica,
developing world TanzaniaandZimbabwe
– EmployeesecondmentsinEthiopia,Niger,SwazilandandTogo
– UNICEF&EuropeanCoalitionofPositivePeopleAIDSOrphanProgrammesinMalawi
– AmplicaresuppliesHIVviralloadtestsinsub-SaharanAfrica,SouthAmericaand
theleast-developedcountries
– ClintonFoundationHIV/AIDSinitiative(CHAI)insub-SaharanAfrica
Broader healthcare partnerships – PhelophepaHealthcareTraininruralSouthAfrica
in the developing world – Newoncologysustainabilityinitiativeinsub-SaharanAfricain2010
– ChangingDiabetesinChildrenwithNovoNordiskandtheWorldDiabetesFoundation
inCameroon,theDemocraticRepublicofCongo,Guinea-Conakry,TanzaniaandUganda
– InstituteforOneWorldHealthoninfectiousdiseases
– Google.orgoninfectiousdiseasesinKenya
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 99 29012010 00:11:27100
Roche Business Report 2009 Corporate Responsibility
InJuly2009weteamedupwithGoogle.orgonanini- Access in the developed world | Weworkclosely
tiativetohelppredictandpreventemerginginfectious withpayersinallcountriestodemonstratethemedi-
diseasesinEastAfrica.Rochedonatedagenome calandeconomicvalueofourproductsandwe
sequencingsystemtobeinstalledintheInternational establishpricesthatenableaccess.However,many
LivestockResearchInstitutelaboratoryinNairobi, peopleindevelopedcountriescannotaffordtreat-
Kenya.TheinitiativewillbeginbyinvestigatingRift mentortheinsurancetopayforit.IntheUS,where
ValleyFever,adiseasespreadbymosquitoeswhich asyetthereisnouniversalhealthcaresystem,we
ispotentiallylethaltopeopleandlivestock. providefreedrugstothoseinneedthroughboththe
RochePatientAssistanceProgram(PAP)andthe
WeproducedourfirstAccesstoMedicinesandDiag- GenentechAccesstoCareFoundation(GATCF).In
nosticsreportin2009.Thiscontainsmoredetailsof 2009,22,200patientsbenefitedfromthePAPand
allourpoliciesandprogrammestoincreaseaccessto 18,500patientsreceivedfreetreatmentthrough
ourproductsandisavailableonourwebsite. GATCF.Wealsosupportindustryeffortstoraise
awarenessofassistanceprogramsviathePartnership
Access in emerging markets | Healthcareinmiddle- forPrescriptionAssistance.
incomecountriesisimprovingandpresentsasub-
stantialopportunityforRoche.However,eachcoun- In2010,followingthemergerofRocheandGenen-
try’shealthcaresystemisatadifferentstageof tech,GATCFwillassumeresponsibilityfortheRoche
developmentandhasitsownspecificneeds.We PAPpatientstocreateoneofthefivelargestcharita-
workinpartnershipwithgovernmentsinthesecoun- blefoundationsintheUS.
triestohelpestablishprocessesandclinicaltrialpro-
grammesandimproveeducation. GATCFispartofGenentech’sbroaderprogramme
tohelppatientsgainaccesstoprescribedtherapies.
OurdedicatedMedicalAffairsGroupdevelops TheGenentechAccessSolutionsdepartmentcom-
specificprogrammesforindividualemergingmarkets, prisesnearly400employeeswhohelppatientsnavi-
wheremanypatientscannotaffordthelong-term gatethecomplexUSreimbursementlandscape.
treatmentnecessaryfordiseasessuchascancer,
hepatitisCandrheumatoidarthritis.InChina,for Forinsuredpatients,GenentechAccessSolutions
example,weoffercost-sharingprogrammesforour clarifiesbenefitscoverageandreimbursementre-
oncologydrugstoensureaccesstothepatientswho quirements,helpingfindwaystoassistincovering
willbenefitmost.InSouthKorea,ourreducedprices patientexpenseswherepossible.Uninsuredpatients
forcancerdrugscovertheentirepopulation,whilein orpatientswhoqualifyforassistancecanobtainfree
Egypt,whichhasoneofthehighestratesofhepatitis medicinefromGATCF.
Cinfectionintheworld,weprovidePegasysata
speciallowpriceforpublicsectorpatients. In2009theserviceadvised82,000peopleaboutcov-
erageandreimbursementissuesandGATCFprovided
Wealsosupplyourproductstoprivatepayersin 18,500patientswithfreetreatmentworthatotalof
emergingmarkets,andworkwithinsuranceand 295millionUSdollars.
re-insurancecompaniesinChinaandRussiato
expandprivateinsurancecoverageandincrease InJapan,ChugaiestablishedtheAcademyforAd-
accesstoourmedicines.Wecontinuetosupply vancedOncology(CHAAO)in2009,tohelpbring
twoHIVmedicinesatreducedpricesinthelow standardsofcancerresearchandtreatmentuptothe
andlower-middleincomecountriesdefinedbythe samestandardsasthoseinEuropeandNorthAmerica.
WorldBank.
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 100 29012010 00:11:27101
Impact of our access programmes Patients and facilities benefiting from clinical
trials (excludes Genentech)
2009 2008
% of HIV-infected patients 2009 2008
living in countries eligible Number of clinical trials 1,493 1,535
for no-profit medicines 68% 68% Number of healthcare centres
% of HIV-infected patients involved 27,457 26,652
living in countries eligible Number of patients in phase
for reduced-price medicines 83% 83% I–IV clinical trials 269,895 235,420
Patients benefiting from USA
patient assistance programmes 40,000+ 38,000+ presentbothresearchandclinicalfindingsatmedical
andscientificmeetingsandengagewithkeyleaders
Clinical trials ineachfield.
Clinicaltrialsareessentialtodemonstratethesafety
andefficacyofnewdrugs.Theyalsoprovideeduca- Wecollecttheinformationgainedthroughclinical
tional,financialandmedicalsupportforparticipating trialsandpost-marketingsurveillanceandusethisfor
hospitalsandaccesstothelatesttreatmentsfor acontinuousassessmentofthebenefitsandrisks
cancer,arthritisandotherdiseases.Patientstaking ofaproductindevelopmentoranestablishedmedi-
partintrialsreceivefreeaccesstothemostadvanced cine.Wealsouseittobetterplannewclinicaldevel-
therapiesduringthetrialandwhentherearenovalid opmentprogrammes.Weprovidethisinformationto
therapeuticalternativesthiscontinuesuntilthedrug regulatoryauthoritiesasrequired.
isavailableforsaleoronprescription.Wedonot
performclinicaltrialsincountrieswherewedonot Weapplystrictdataprotectionprinciplestoall
plantomarketthedrug. personalmedicaldatacollectedduringclinicaltrials,
inlinewithourdirectiveontheprotectionofpersonal
Peopleseekingnewclinicaltrialstotakepartinor data.Theseprinciplesapplyequallytodataabout
wishingtolearnfromtheresultsofcompletedtrials ourcustomers,suppliersandemployees.
canaccessthisinformationatwww.roche-trials.com.
Patient safety
Asof31December2009thesitecontaineddetails Allmedicinesmaycauseadverseeffects(sideeffects)
of649pharmaceuticalprotocols,28diagnosticproto- insomepatients.Ourpriorityistomakesuretheben-
colsand283trialresults.Thesestudiescovermore efitsoftakingourproductsinclinicaldevelopment
than95conditionsincludingAlzheimer’sdisease, andourmedicinesoutweighanyidentifiedorexpec-
asthma,around33cancers,cardiovasculardisease, tedsafetyrisk.Wehaverobustprocessesoperating
depression,diabetes,hepatitis,HIV/AIDS,influenza worldwidetounderstandourmedicinesandtheir
andobesity.Thewebsitehadmorethan430,000 adverseeventsandtominimisetheirlikelihood.Medi-
pagevisitsin2009representingmorethan65,000 cinesareregularlyanalysedagainstvariousreference
visitors.Detailsofourclinicaltrialsarealsoavailable databasestohelpusdetectpotentialsafetysignals.
throughtheInternationalFederationofPharmaceu- Allourproductsinclinicaldevelopmenthavean
ticalManufacturersandAssociations(IFPMA)clinical individualsafetymanagementplanandallourmedi-
trialsportalatwww.ifpma.org/clinicaltrials,and cineshaveariskmanagementplanreviewedand
theUSNationalInstitutesofHealth’sglobalregistry approvedbymajorhealthauthorities.
atwww.clinicaltrials.gov.Wepublishourclinical
trialdatatoensurethatalllessonsfromthesetrials Continuousmonitoringandworkingwiththehealth
aremadeaccessibletothewidercommunity.Wealso authoritiesenableregularupdatestoprescription
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 101 29012010 00:11:27102
Roche Business Report 2009 Corporate Responsibility
instructions(labellingandproductinformation), wesupport.Wepubliclylistpatientgroupswegive
includingemergingsafetyinformation,contraindica- non-financialsupporttoifthesupportissignificantor
tionandspecialprecautionsofuse.Whennecessary, meaningful,asguidedbyEuropeanFederationof
lettersaresenttophysiciansandhealthcareprovid- PharmaceuticalEFPIAIndustriesandAssociations.
ersallowingthemtoadjusttheirmedicalpractice.
Examplesofpatientadvocacywesupportedin2009
Diagnosticsproductsmaygiveerroneousresults, includetheWorldHepatitisAlliance’sworktoraise
causedbyaproductperformanceoruserhandling awarenessofviralhepatitisandpromoteactionto
issue.Thiscouldeventuallyleadtoanincorrectther- improvepatientcare.Wecontinuedtosupportthe
apyforapatient.Duringthedevelopmentofdiagnos- EuropeanPatients’RightsDayorganisedbyActive
ticproducts,extensivetestingisperformedusing Citizenshipeachyear.In2009,34patientgroupsin
patientsamplesundervariousrealisticconditionsto 24EuropeancountriescelebratedthethirdPatients’
ensureoptimalperformanceofthefinalproduct. RightsDay.
Weinvestigateallreportedadverseeventstoascer- Education and awareness
tainiftheyarerelatedtoourproducts.Ifthereisa Ouraffiliatesoftengetinvolvedininitiativestoraise
link,were-evaluatewhetherthebenefitsofthemedi- awarenessofdisease.Forexample,RocheTurkey
cineordiagnosticproductstilloutweightherisks. heldaone-daycyclingeventatashoppingmallin
Wealsohaverobustproceduresinplacetopromptly Istanbul,inpartnershipwiththeTurkishBicycle
informpatients,physicians,healthcareproviders FederationandtheMinistryofHealth’scancercontrol
andregulatorsofanynewproductsafetyinformation. department.Rochemadeadonationtothepatient
organisation,Hand-in-HandAgainstCancer,onbe-
Wehavearobustprocesstoensurethatproducts halfofeachpersontakingpart.Demonstrations
canberecalledrapidlyandwithdrawnfromcirculation onprostheticbreastshelpedtrainwomeninself-
ifunanticipatedissueswiththeirqualityarise.In2009 examination.
therewerenorecallsinvolvingthepublic.
InBrazil,12millionpeoplehavediabetesbut44%
Patient advocacy donotrealiseit.RocheDiabetesCarechallenged
Wesharewithpatientgroupsaninterestinhelping fashionstudentstodesignapracticalandfashionable
patientsunderstandandmanagetheirdisease accessoryforcarryingAccu-Chekbloodsugartests
andgainaccesstotheinformationandtreatment andotherdiabetescareitems,toraiseawareness
theyneed. ofthediseaseamongteenagersandyoungadults.
Whiletheiraimsvary,eachpatientgroupinteracts 2010 goals
withmanypatientsandcarers,understandstheir • InitiateRocheoncologysustainabilityinitiativein
needsandprioritiesandknowshowtoprovideemo- sub-SaharanAfrica
tionalsupportandpracticaladvice.Wedescribe • ExpandpartnershipwithAlbertEinsteinCollegeof
ourapproachtoworkingwithpatientgroupsinour MedicineinEthiopiatoincludeoncologytraining
positionstatementandguidelinesforworkingwith • Host,incollaborationwithNovoNordiskandthe
patientgroups,whichareavailableonourwebsite. WorldDiabetesFoundation(WDF),aLeadership
ForuminAfricatoaddresstheDiabetesepidemic.
Transparencyisfundamentaltosuccessfulpartner-
shipswithpatientgroups.In2009welistedallthe
patientgroupswesupportfinanciallyonourwebsite,
bycountryandwithashortdescriptionoftheactivity
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 102 29012010 00:11:27103
More on the web
• Personalised healthcare:
www.roche.com/phc_in_r_d
• Roche position statements on personalised healthcare, access
to medicines and diagnostics, pricing, neglected diseases, and
working with patient groups:
www.roche.com/policies_guidelines_and_positions
• Access to medicines report
www.roche.com/sust-access.pdf
• Programmes in LDCs:
www.roche.com/programmes_in_least_developed_and_
developed_countries
• Programmes in developed countries:
www.pparx.org
www.GenentechAccessSolutions.com
• Roche trials and patient safety:
www.roche-trials.com
www.roche.com/clinical_trials
www.roche.com/managing_medication_safety
• List of patient groups supported:
www.roche.com/patient-groups
14_L_Roche_AR09_ENG_Corporate Responsibility Part1indd 103 29012010 00:11:27104
Roche Business Report 2009 Corporate Responsibility
People
Foroveracentury,Rochehasstoodforinnovationand isillustratedbyourconsistentrankingasanEmployer
entrepreneurship.Ourhistoryofachievingourbusi- ofChoice(seethetablebelowforaselectionofour
nessgoalsandexcellinginscienceandinnovationis awards).
aresultofconsistentlyemployingthebestpeople.
‘Itrulybelievethatwe’reinthegoldenageofdisease
Wesucceedbecauseofourpeople—peoplewhoare researchanddrugdiscovery.Itisnowpossibleto
passionateaboutmakingadifferencetopatients’ tacklediseasebiologywiththesamerigourasbasic
lives;peoplewholeadanddrivechange;peoplewho biology.Becauseofthisconvergenceofmedicine
liveourcorporatevalues—integrity,courageand andscience,Ican’tthinkofabetterplacetobethan
passion.Wehave81,507employeesbehindourcur- Genentech.Thequalityofthesciencehereison
rentsuccess. parwiththatoftopacademicinstitutions.Itisexhila-
ratingtoexperiencethecombinationofscientific
Wekeepouremployeesengagedandperformingat excellencewithstate-of-the-artresources,enormously
thehighestlevelbycreatingaworkingenvironment talentedcolleaguesandthecultureofrisk-takingwe
inwhicheveryonefeelsvaluedandrespected;where havehere.’
theycandeveloptotheirfullestpotentialandcan
Marc Tessier-Lavigne, Ph.D., Executive Vice President,
maketheirownmark.Ourprogressinachievingthis Research, and Chief Scientific Officer
Employer of choice — Selected external awards (with rankings 1 to 3)
Award Roche site Rank Description
Science Magazine’s Top Employer Genentech 1st Genentech won the Biopharmaceutical
Industry prize for the seventh time
San Francisco Business Times Genentech 1st The rank is based on employee responses
Best Place to Work to a questionnaire and includes
companies in the Bay area with more
than 1,501 employees
Total E-Quality Germany Roche Germany n.a. Total E-Quality awarded for the second
time for Roche’s successful and sustained
equal opportunities commitment
Arizona Bioindustry Association Ventana Medical 1st The award recognised Ventana’s
Bioscience Company of the Year Systems/Roche development and growth
Tissue Diagnostics
Best Places to Work Survey, Roche Denmark 1st Roche was voted Best Pharma/Biotech
Best Pharma/Biotech Company Company in Denmark for the fourth
consecutive year, and second amongst
all sectors
Actualidad Económica Roche Spain 1st Roche ranked 1st in the Pharma Industry
Best Companies to Work For and 5 th overall
Trendence Top Employer Roche Switzerland 3 rd Switzerland’s students voted Roche
the country’s third best employer in its
Technology & Science edition
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 104 29012010 09:4351105
Employees (FTE *) by operating divisions Engaged employees
TheglobalListeningtoYousurvey,conductedinearly
2009 2008 Variance 2009,aimedtomeasuretheeffectivenessofinternal
New Pharma 48,341 47,551 1.7% communicationsandemployees’attitudestothecom-
Chugai 6,632 6,590 0.6% panyandtheirwork.Over30,000employees
Diagnostics 25,967 25,404 2.2% responded.
Other 567 535 6.0%
Total 81,507 80,080 1.8% Overall,91%ofrespondentsexpressedsatisfactionin
theirjobandfelttheywereappropriatelyengaged
* full-time equivalent, FTE.
byRoche.Thevastmajority(89%)feltproudtowork
Employees by contract types forRocheandwouldrecommendtheGrouptoothers
asagoodplacetowork.
2009 2008 Variance
Regular (FTE) 79,631 78,320 1.7% Nearly90%saidtheyhaveaccesstotheinformation
Temporary (FTE) 1,876 1,760 6.6% theyneedtodotheirjobwell.Employeesfeltwell
Headcount 82,428 80,400 2.5% informedaboutourmajorproducts,businessstrategy
Full time (HC) 77,866 76,058 2.4% andfinancialperformance.Wewillcarryoutanother
Part time (HC) 4,562 4,342 5.1% surveyin2011.
Roche Employees worldwide
Employees
Variance2008|2009
Europe | 35, 310
Todayweemploysome
North America | 25, 412 81,500employees,
Asia | 14,169 around2%morethan
in2008.Allofthem
aredrivenbythesame
+2.1 %
spiritandpursuethe
-1.6 % +8.5 %
samegoal:tocreate
newandbetterwaysto
prevent,diagnoseand
Africa | 795 Australia | 891 treatnewdiseases.
Latin America | 4, 930
+6.4 % +0.5 %
-1.2 %
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 105 29012010 09:4351106
Roche Business Report 2009 Corporate Responsibility
DuringtheRoche-Genentechintegration,wepro- certaincandidatesandtodemonstrateprogress
videdrelevantinformationtoemployeesquicklyand towardsgovernmentgoalsforwomenandminorities.
transparentlyusinganintegrationwebportaland
employeeroadshows.Theelectronicplatformallowed Wesponsorandsupportanumberofemployeeaffinity
ustocommunicatemanagementdecisionsinstantly groups,associationsandnetworks.TheGO&E—
andattracted,onaverage,12,000uniquevisitorsper GenentechOut&EqualGroup—aimstopromote
weekbetweenAprilandAugust—mainlyfromthe aworkplaceenvironmentthatembracesallemployees
USandSwitzerland.Weheldroadshowsatallaffected regardlessoftheirsexualorientation.AAIB—
sitesandusedthemtointroducenewmembersof AfricanAmericansinBiotechnology—isdedicated
themanagementteam.Wefilmedtheseeventsand toachievingaculturallydiverseenvironmentwhich
postedthevideosonline.Togetherwithkeypresenta- improvesthedevelopmentofdrugstoaddress
tions,thesevideosprovideddirectinputonstrategic theunmetmedicalneedsofamoreculturallydiverse
directionandothernewsstories.Picturesandper- patientpopulation.
sonalstoriesfromemployeeshelpedpeoplefrom
eachcompanyconnectmoreeasily. TheIntegraprojectatRocheSpainalsoencourages
greaterunderstandingofdisabilityamongemployees
AsurveyatGenentechshowedthatemployeesremain andaimstoincreasethenumberofhireswithdis-
positiveafterthemerger—despitehavingexperi- abilities.InItaly,collaborationwithlocalinstitutions
enceduncertaintyandlossasaresult.Genentech overthelasttwoyearshasenabledustorecruitand
employeesremainproudoftheircultureanditsposi- onboardfiveadditionaldisabledpersons.
tiveimpactonpatients’lives.
Peoplefromover79countries—fromAustralia,
ThesurveyalsoshowedthatGenentech’sfocus UruguaytoSouthAfrica—workforRocheinSwitzer-
onpatientsandcommitmenttoscienceinspiresand land.Intotalmorethan126nationalitiesarerepre-
motivatesemployees.Almostallemployees(93%) sentedworldwideatRoche.
arecommittedtothesuccessofthemergedcompany,
wanttostaywiththecompanyforatleastayear Womenaccountfornearlyhalf(46%)ofemployeesand
(91%),orwanttostayatGenentechforalongtime 37%ofmanagersglobally.Womenalsomakeupmore
(86%). than46%oftheworkforceinover90ofour140affili-
ates.In33,womenaccountformorethan50%ofman-
Fostering diversity agement.ExamplesincludeAustralia,wherewomen
Ourfocusistoensurediversityinourworkforce. accountfor68%ofemployeesand58%ofmanage-
Aninclusiveworkenvironmentallowsustoleverage ment,andHungarywith81%and75%,respectively.
thepotentialofallemployeesirrespectiveofage,
gender,ethnicity,disability,workstyle,experiences, Gender diversity
familysituation,orworkingneeds.
2009 2008 2007
Wedonottoleratediscriminationofanyform,as Women in total
statedinourworldwideemploymentpolicy.We workforce 46% 46% 45%
havemanagementtrainingprogrammesandawide Women in management 37% 37% 32%
rangeofinitiativesataffiliateleveltoencourage Women in senior
andsafeguardemployeediversity.Forexample,our management 28% 29% —
NutleysiteintheUShasadedicateddepartment Women in executive
tomanagediversity.Itsetsannualplanstoevaluate management positions
howemploymentdecisionsmayadverselyaffect i.e. top 120 9% 8% 7%
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 106 29012010 09:4351107
WomenInLeadershipNetwork,BaselandGenentech ‘Genentechchallengesourscientiststodiscovernew
WomenProfessionalsbothaimtoprovideaforum biologyandtotranslatethesefindingsintonovel
forwomenwhichrecognisestheiruniquestrengths medicinestohelppatients.Successrequiresafear-
andtalentsandinwhichexperiencescanbeshared lessnessandwillingnesstoattackthemostdifficult
andleveraged. scientificandclinicalproblemsandnottobedeterred
bythetrialsandtribulationsofscientificdiscovery
Encouraging innovation andunknownsofmedicine.Ifeelfortunatetohavethe
Rocheisaglobal,innovation-ledcompany.Wehave opportunitytoworkalongsideourresearch,develop-
tobalancetheneedforefficiencyandconsistency mentandclinicalscientiststomeetthesechallenges.’
throughstandardisationwithacompetitiveenviron-
Andrew C. Chan, MD, PhD, Senior Vice President, Immunology and
mentinwhichinnovationthrives. Antibody Engineering
Innovationisdrivenbydifferentandoftenconflicting
approaches,ideasandexperiences.Whileensuring Werecogniseinnovationamongouremployeesthrough
thatourmainfunctionalprocessesarealignedacross internalawards.Theseincludeprizesforimproving
theRocheGroup,includingGenentech,wedecided animalwelfareinourtrials,implementinginnovative
tokeeptheresearchanddevelopmentlaboratories informaticssolutionsandproposalsthatimprove
(GenentechResearchandEarlyDevelopment—gRED) patients’lives.TheRochePharmaCEOAwardsrecog-
independenttoensureitsinteractionwithexternal niseteamsthathavepassionatelypursuedinnovative
researchinstitutionswasnotdisrupted.gREDhasits solutionsforpatients,creativelyimprovedtheway
ownbudget,portfoliomanagementandculture—all weworkandpushedscience,marketingandopera-
ofwhicharefundamentaltoinnovation.Wecreated tionstothenextlevel.In2009morethan165teams
aparallelPharmaResearchandEarlyDevelopment fromeveryregion,diseasebiologyareaandfunction
organisation(pRED)comprisingthevariousR&D participatedintheprogramme.Winningteams
centresoutsideGenentechtostimulatethedifferent includedRocheemployeesateverystageintheir
perspectivescriticaltosuccessfulinnovation. careers—fromyoungpost-docstoseniorresearchers
withdecadesofexperience.
Employees FTE by function
OurPostdocFellowshipprogrammeawardsourbest
2009 2008 2007 scientistswithgrantstoconductexploratoryresearch,
Servicing 13,408 12,292 12,215 whichhelpsusreinforceourtalentpipelineinR&D.
Manufacturing &
Logistics 16,395 15,381 14,262 ‘KnowledgeisanessentialaspectinRochethatmulti-
Marketing & plieswhenitissharedandcleverlyused.Thekey
Distribution 28,682 28,426 28,107 istodevelopaparticipatorymanagementstylewhere
Research & teamssharetheirideasanddevelopdifferentways
Development 18,894 18,518 18,580 ofdoingthingsinaframeworkofmutualunderstand-
General & ing.Itisaprivilegetoworkinacompanythatrecog-
Administration 4,128 5,463 5,440 nisestheperformanceandpotentialofitstalents
Total 81,507 80,080 78,604 regardlessoftheirbackgroundandexperienceseven
wherethesemightnotreflectthetraditionalrouteor
theexpectedprofile.Rocheencouragesitsemployees
toriseto,andfaceprofessionalchallengesthus
allowingthemtogrowandreachdifferentpositions.’
María Jesús Alsar, Onco-Hematology Director, Spain
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 107 29012010 09:4352108
Roche Business Report 2009 Corporate Responsibility
Attracting employees Turnover (regular employees) *
Weworkhardtokeepourrecognitionasanemployer
ofchoice.Thisiscriticaltoourabilitytohireand 2009
retainoutstandingpeoplewhoarecommittedtoour Total 7%
goalofimprovingpeople’shealthandqualityoflife. Europe 5.1%
Latin America 13.4%
Roche’sstrongandsustainablebrandenablesus North America 7.8%
toattracttherightpeople.Wehavebuiltalargeand Asia 7.2%
diversepoolofcandidates,dedicatedin-house Australia 10.9%
recruitmentteamsandgloballyalignedrecruitment Africa 18.3%
processes,standardsandtechnology.Ourcareers
* Including non standard temporary contract ends.
websiteexpandedin2009toimprovethelocalvisibility
ofallavailablepositions(includingatGenentech).
Thesitehadsometwomillionuniquevisitorsin2009 Reasons for leaving
andregisteredmorethan388,400spontaneous
applications.WealsocontinuedtorolloutTaleo,our 2009
globale-recruitingplatform.Launchedin2005 Employer-related 40%
injustthreecountries,Taleoisnowavailableinover Employee-related 51%
62countriesworldwide. Neutral* 9%
* Such as temporary contract ends, health issues and retirements.
Wecontinuedtodeployourglobalemployerbrand
in2009—‘Makeyourmark.Improvelives’—toimprove Roche’sturnovershowsastrongdecreasingtrend
awarenessofRocheasanemployerofchoiceand (–30%).Thistrendisconfirmedparticularlybythe
todifferentiateusfromourcompetitors. numberofemployeesleavingoftheirownaccord
(from58%in2006to51%in2009).Over35%ofour
Hiring and retention | Alargeintegrationrequires employeeshavebeenwithRocheformorethan
asharpfocusonretention.Ourdecisiontomaintain tenyears.
Genentech’suniqueresearchoperationswasone
measuretoaidretention,accompaniedbyadditional Developing employees
healthbenefits,outplacementservicesandcash Developmentisapriorityforallemployeesinaninno-
payments.Wehavecontinuedtoattracttopscientists vation-drivenorganisation.Wewantemployeesto
andotherhigh-profiletalentsincethedealwas developtotheirfullestpotentialandsupportthemat
closed.Genentechhired1,364peoplein2009,in- everystageindoingso.
creasingitstotalworkforceby12%.
Performance management | Regularfeedbackand
Staffing rates anopendialoguebetweenemployeesandtheir
managersisacriticalactivityforwhichweholdboth
2009 2008 managersandemployeesaccountable.In2009,92%
Number of vacancies 11,268 13,911 ofouremployeestookpartinperformancemanage-
New hires 8,192 9,169 mentprogrammesand43%informalcareerdevelop-
Internal staffing rate 29.3% 34.5% mentplanning.
External staffing rate 70.6% 65.5%
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 108 29012010 09:4352109
Employee training potentialleaders(3.8%oftotalheadcount),ofwhich
onethirdarewomen.
2009 2008
Total training spend (millions Withinthegloballeadershipportfolio,wehavepro-
CHF) 146 139 grammesaddressingeachcategoryofhigh-potential
Training spend per employee leaders—fromthosewhowillassumeaGlobal
(CHF) 1,794 1,734 leadershippositioninthelongtermtothosewhocan
Total number of training hours succeedakeypositionholderintheshortterm.
(million) 2.16 2.40 In2009theseprogrammestargetedthetop5%of
Average training hours per employeesandincluded:
employee 26 29 • Explorations—includesanassessmentofleader-
Number of postdocs, students shipskills,feedbackandcoachingbysenior
and interns * 429 335 leadersearlyinanemployee’scareer,toenable
themtobuildfocuseddevelopmentplans.
* excluding Genentech and Chugai.
In2009,24employeesparticipated(7women).
Learning | Rocheoffersextensivesupporttoem- • Perspectives—atwo-yearprogrammeinwhich
ployeesforthedevelopmentoffunctional,profes- weprepareearlyhigh-potentialleadersfor
sionalandleadershipskills.OurmajorDiagnostics significantmanagementresponsibilities.Theywork
andEuropeanPharmaaffiliates,accountingfor infourdifferentfunctionsandregions.In2009,
38%ofthetotalRochepopulation,offerednearly 9participantsjoinedforthefirsttime(4women).
13,000coursesin2009throughourcommon • Horizons—givesmid-termhigh-potentialemploy-
CHRISplatform.Over28,000trainingsessions eesanacceleratedglobalandcross-functional
(classroomandweb)tookplaceandweregistered developmentexperienceincriticalareassuchas
closeto552,000bookings. leadership,innovation,risktaking,customer
orientationandchange.In2009,48employees
Succession and talent management | Inanorgani- participated(12women).
sationcharacterisedbychange,leadershipskills • Reflections—providesanassessmentofthemost
areincreasinglyimportant.During2009weensured seniorhigh-potentialemployeesontheirindividual
fullcoverageofourGloballeadershipprogramme strengths,areasofimprovementandpotential
portfolio,providingkeyprogrammesateverystagein basedontheRocheValues&LeadershipCompe-
theleadershipdevelopmentpipeline.In2010Roche’s tencies.In2009,21candidates(3women)took
LearningandDevelopmentdepartmentwillcreate part.
acommonframeworkforleadershipdevelopment,
linkingGloballeadershipprogrammeswithexisting Atatimeofsignificantorganisationalchanges,we
local,regionalandfunctionalinitiatives.Thiswill filledmorethan30%ofouropenpositionsinternally.
giveemployeesandmanagersaccesstoacatalogue
ofleadershipprogrammes. International Mobility | Whilesome7,865vacancies
(70%ofthetotal)arefilledbyexternalcandidates,
High-potentialleadersarepeoplewiththeabilityto weofferprofessionalandpersonaldevelopment
takeoncriticalseniorrolesintheshort,midor opportunitiestoourownemployeesthroughinternal
longterm.Identifyinganddevelopingtheseemployees moves.ThisnotonlyhelpsRocheretainkeypersonnel,
ensureswehavearobustanddiversepoolofcan- itenablesustoleveragepotentialwithintheGroup.
didatesforcriticalpositions.Weidentifyandconfirm Anincreasingamount(over12%)ofthismobility
theseindividualsintalentassessmentsandreviews goesacrossaffiliateandnationalboundaries.Ofour
duringtheyear.In2009weidentified3,119high- 495expatriatesandcross-boundaryemployees,
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 109 29012010 09:4352110
Roche Business Report 2009 Corporate Responsibility
26%arewomen,allofthemrepresenting55different WealsoreviewedcompensationpracticesatRoche
nationalities. andGenentech,andmoved10,653Genentech
employeestoRochelong-termincentives.Thismeans
ToencouragemobilitywithintheGroup,in2009we thatapartfromChugaiemployees,alllong-term
introducedtheIntercompanyTransferandLocal incentivesintheGrouparenowonthesameRoche
ForeignHirePolicy.Thisfacilitatestherecruitmentand Holdingssecurities.MorechangestoalignRoche
relocationofforeignhiresandofpermanentcross- andGenentechcompensationpracticesandthe
bordermoveswithintheGroup.Localmobilityinitia- performancemetricsusedforincentiveswillcome
tivessuchasourLocalPluspolicyinChinahelp intoeffectin2011.
attracttoptalenttoChina,especiallyindividualswho
haveinternationalexperienceandwanttoreturn. Benefits | Throughcompetitivebenefitsprogrammes
wehelptocreateanattractiveworkplace.
Wehavealsorevisedourinternationalassigneespolicy
toimprovetheflexibilityneededtoaddressmarket Over97%ofouraffiliatesofferextensivebenefitsplans.
trends,changingdemographicsandevolvingbusiness Mostgobeyondgovernmentschemesandinclude
needs.Thisrevisionrespondstothefindingsof healthchecksandfreeaccesstoawiderangeof
asurveyof600assigneesandtheirpartners.The medicalservices.Wehavealsointroducedprogrammes
revisedpolicieswillberolledoutin2010. thatencourageahealthylifestylethroughwellness
programmes,healtheducation,fitnesscentres,swim-
Rewarding and recognising employees mingpoolsandrelaxationinitiatives.Wenowhave
Thetotalcompensationpackageweoffermakes Tai-ChiclassesatourBrazilian,ItalianandMexican
asignificantcontributiontoattracting,rewarding, affiliatesandhaveincorporateditinworkshops
recognisingandretainingtherightpeople. appliedbyourLifecycleteams.Wehavebeentrialling
powernappingandareofferinghealthyfoodoptions
Ourtotalremunerationcostsin2009amountedto atourheadquartersinBasel.Wecontinuetooffer
12billionSwissfrancs(anincreaseof8.5%from2008). benefitstoourretireesatseveralofouraffiliates,such
Ourbasepaypackagesrewardindividualperform- asSwitzerland—includingaccesstoemployee
ance,recognisingbothwhatwasachievedandhow restaurants,sportsandleisureactivitiesandtravel
itwasdone.Throughvariablepay,weincentivise checks.
employeeswhocreatenewopportunitiesandstrive
foroutstandingresults.Variablepayisdrivenby Wehaveincreasedourfocusonflexibleworking
individualandteamobjectivesandbytheGroup,divi- arrangements.AftersuccessfulpilotsatourWelwyn
sionalandaffiliateperformance. siteintheUK,ourBaselheadquartersintroduced
apilottoaccommodatedifferentworkingstyles
Wewantouremployeestoshareinoursuccess. orfamilysituationsthroughhomeworkinganddesk
ThroughRocheConnect,employeesinmostcountries sharing.Thepilotaimedtoidentifymoreattractive
canpurchaseRoche’snon-votingequitysecurities andflexibleworkingarrangementsforofficeworkers,
atadiscountofupto20%.In2009,16,604employees aswellastestingefficientandsustainableuseof
in42countries—37%ofthoseeligible—participated officespaceandinfrastructure.
inRocheConnect,1%morethanin2008.Wealso
awardnon-votingequitysecuritiestomanagers,based Genentechintroducedanonlinetoolallowing
ontheirperformance,throughtheRocheLongTerm employeestoassesswhethertheirtasksareeligible
IncentivesPlan.Atotalof3,480managerstookpart forflexibleworkarrangements.
in2009,with589joiningforthefirsttime.
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 110 29012010 09:4352111
Wealsoaimedtoincreasetheconsistencyofour Human rights and labour relations
benefitsprogrammesaroundtheorganisation.Our Rochehasacomprehensiveemploymentpolicy,
goalistoalignbenefitprogrammeswithincountries whichcovershumanrights.TheGroupCompliance
sowecanofferattractivebenefitstoallourem- Officermonitorsthispolicyandservesasacontact
ployees,regardlessofaffiliateordivision,consistently forallemployees.
andefficiently.
Rocherespectstherightofemployeestofreedom
In2009westartedtheharmonisationofthebenefit ofassociationandcollectivebargaining.Morethan
plansofourNorthAmericanaffiliates—coinciding 6,708ofouremployeesareunionmembersand
withtheGenentechintegration.Wewilllaunchthenew over37,713aremembersoforganisationsthatfreely
programmeinOctober2010,anditwillcomeinto representthem(incountrieswherethisislegal).
effecton1January2011.Similarbenefit-harmonisa- TheRocheEuropeForumrepresentsnearly34,900
tionprogrammesareongoinginSwitzerland,Spain, employeesin26countries.Atgloballevel,wehave
FranceandtheUnitedKingdom. recentlyinstalledanEmployeeRelationsofficer.
Asaresultofthefinancialcrisisandthefallinglobal Ourdirectiveontheprotectionofpersonaldatasafe-
equitymarkets,someofourpensionfundsaroundthe guardsinformationaboutemployeesandcomplies
worldfacedchallengesmaintainingahealthyfunding withtherelevantlocallegislation.Whereappropriate,
position.Whereunderfundinghasarisen,Roche wehavenegotiateddataprivacyagreementsbetween
hastakenstepstodevelopappropriatestrategies differentpartsofthebusinessorwithworkscouncils.
inaccordancewiththelocalstatutoryregulations
andpractices,andinconsultationwithemployee More on the web
representatives,includingadditionalcashinjections • Employees: www.roche.com/employees
andrecoveryplans.Someofourmajorpension • Group policies, positions and guidelines:
www.roche.com/policies_guidelines_and_positions
fundshaveremovedearlyretirementincentivesand
• Global careers portal: http://careers.roche.com
haveintroducedmoreflexibleretirementmodels • Employment policy: www.roche.com/employment_policy.pdf
to anticipatetheimpactofanageingworkforce. • Core standards: www.roche.com/commitments
Simplifying and aligning processes in
Human Resources
AllofourHRprocesses(exceptthoseatGenentech
andChugai)nowrunononeCommonHRInformation
Solution(CHRIS).Thisusestransactionalandreport-
ingsystemsandisalignedwithTaleo,ourglobal
e-recruitingsolution.
IntroducedinJuly2009,CHRISreplacesseveral
legacysolutionsandenablesstandardised,streamlined
andsimplifiedHRprocessesacrosstheRocheGroup.
OuraimistoensureconsistentHRservicesand
increasedefficiency.CHRIScovers149affiliatesand
representativeofficesand78%ofRocheemployees.
GenentechandPharmaNorthAmericawillfully
joinin2011.CHRISismanagedbyaglobalsupport
organisationandnetworkofservicinghubs.
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 111 29012010 09:4352112
Roche Business Report 2009 Corporate Responsibility
Society
Oursupportforcommunitiesfocusesonprogrammes Community support in 2009 by area
andareasthatarealignedwithourbusinessmodel.
Webelievewecanenhancetheinnovation,sustainabil- % of total
ityandimpactofourbusinessthroughappropriate Humanitarian and social projects 75%
donations,sponsorshipandemployeevolunteering. Science and education 17%
Thisinspiresandmotivatesourstaffandensures Arts and culture 5%
Rocheremainsacommittedcorporatecitizen. Community and environment 3%
Monitoringtheimpactofourcommunityworkgives Supporting future science
amoreaccurateassessmentofourprogrammes’ Youngscientistsareourfutureemployees.Nurturing
successthanpublishingdetailedfinancialinformation theirtalentensuresRocheremainsaninnovative
aboutourdonations.Forexample,ourGenetics andsuccessfulcompany.Forexample,wehavefoun-
EducationProgrammeforeducatorsinSwitzerland dationstosupportresearchandeducationpro-
andGermanyreachednearly1,250people.With grammesaroundtheworld,includingtheFondation
60teachersenrolledintheworkshops,thesubsequent d’entrepriseRocheinFrance,theglobalRoche
knowledgetransferreachedtheircolleagues,pupils, OrganTransplantationResearchFoundationandthe
andevenfriendsandfamily.Wewillexpanditin GenentechandRocheFoundationsintheUS.
SwitzerlandandneighbouringregionsofGermany
in2010. TheRochePostdocFellowshipProgrammecompleted
itsfirstfullyearin2009.Theprogrammeaims
Allphilanthropicdonationsandnon-commercial toencouragecreativityinscienceandstrengthen
sponsorshipsaremonitoredinternallythroughthe academicnetworksthroughsupportfortalented
FinancialGroupReportingSystem.TheCorporate post-doctoratestudentsontwo-tofour-yearresearch
SustainabilityCommitteeisresponsibleformonitoring projectswithleadingacademicinstitutions.In2009
theirimpact. weoffered19post-doctorates,takingourtotalsince
theprogrammelaunchedin2008to52people.
In2009theRocheGroupapprovedanupdatedCorpo- Weplantoincreasethatnumberto100bytheend
ratePolicyonPhilanthropicDonationsandNon- ofnextyear.
CommercialSponsorship.Thepolicystipulatesthatall
philanthropicprojectsshouldfocusoninnovation, In2009wepilotedtheResearchExchangeScholars
collaboration,qualityandsustainability.Itcomfirms Programme.Theinitiativesupportsscienceeducation
ourpriorityareasashumanitarianandsocial,science bygivinggiftedsecondaryschoolstudentsthechance
andeducation,cultureandarts,andcommunityand togooninternationalexchanges.Thefirstexchange
environment.Ourhumanitarianandsocialprogrammes featuredtwobiotechnologyspecialistschoolsfrom
involvepromotingsustainableaccesstoourmedi- theUSandGermany.Threestudentsfromeach
cinesanddiagnostics.Weonlydonatedrugsindisas- schoolundertookasix-weekinternshipattheother,
terandpandemicsituations. whichincludedindividualmentoringat
alocaluniversity.
Thepolicyalsoensuresourdonationstargeta
focusednumberofnon-governmentalorganisations The2009CongressoftheEuropeanSocietyforMedi-
(NGOs)towhichwecanmakeasignificantdiffer- calOncology(ESMO)awardedRocheinrecognition
ence,ratherthandilutingourdonationsamong ofoursupportforitsYoungOncologistFellowship
alargenumberofNGOs.Weexcludegovernmental, programme.WehavesupportedESMOsinceitwas
politicalandreligiousorganisations. foundedin1975throughclinicalandtransnational
fellowships.Thesehavehelpedyoungoncologistsgain
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 112 29012010 09:4352113
researchexperienceinrenownedEuropeancancer WesetuptheRocheEmployeeActionandCharity
centres.Ourongoingeducationprogrammesinclude Trust(Re&Act)in2006asanindependentcharity
atwo-daybioethicsteachingworkshopforsecondary organisationtomanageemployeedonations.It
schoolteachersintheUSandourpartnershipwith distributesfundstocommunityprojectsanddisaster
theNewJerseyInstituteofTechnologytosupport reliefeffortsaroundtheworld.Sinceanearthquake
aone-dayeducationprogrammeforprimaryand in2007Re&Acthasmaintainedongoingassistance
secondaryteachers. andreconstructioninthetownofChocos,Peru.
In2009theprojectbuiltacommunitycanteenand
Encouraging innovation in the arts 12newhomescapableofwithstandinganother
Wesupportmusicandtheartsbecausethecreativity quake,aswellascompletingthecommunity’sdam.
andinnovationofthosedisciplinesreflectsour
businessmodel.Webelievelessonscanbeshared TheannualRocheChildren’sWalkhasbeengoing
betweenartsandscience.In2009weheldthe since2003.However,itdidnottakeplacein2009as
thirdRocheContinentseventtoencourageartistic ithasbeenmovedfromDecembertoJulytoincrease
involvementamongyoungpeople.Around100future participation.Nonetheless,Re&Act’sworkwith
chemists,biologists,medics,psychologists,musi- theEuropeanCoalitionofPositivePeopleandUNICEF,
cians,setdesigners,recordingengineersandopera Switzerland,whichbothhavelong-termprojects
singersfromuniversitiesalloverEuropeattended tosupportchildrenimpactedbyHIV/AIDSinMalawi,
artandscienceworkshopsandcontemporaryclassical continued.Rocheemployeeswerestillinvitedto
musicperformancesattheSalzburgFestival. donatein2009andweguaranteedfinancialcoverage
toensurethechildrendonotsufferintheinterim.
Roche Commissionsseesussponsoranewmusical Todate,thewalkhasraisedenoughmoneytobuildand
piecebyanoutstandingcontemporarycomposer furnish18newclassrooms,accompanyingteachers’
everytwoyears.ToshioHosokawawillpresenthis officesandsanitationandhygienefacilitiesfornearly
workin2010.Inaddition,Chugaiagainsponsoredthe 1,500primaryschoolchildren.Thesponsoredwalk
StarPhilharmonicChristmasConcertinYokohama, hasalsohelpedfundeducationfor108secondary
Japan,whichsupportsearlycancerdiscoveryand schoolstudentsandfivefurthereducationstudents.
treatment.
InruralSouthAfricathereisjustonedoctorforevery
Supporting our communities 4,000patients.ThePhelophepaHealthCareTrain
Wewantemployeestocontributetotheirlocalcom- aimstoreducetheburdenbyprovidingamobilehealth
munities,soweencouragethemtoidentifythe clinictomorethan45,000people.Wehavesupported
projectsthattheyfeelwouldbemostworthwhile. theservicesinceitbegan15yearsagoandin2009
WhileRochehasarangeofGroupprojects,we additionalfundingfromRochecontributedtoacancer
encouragestafftofundraiseandvolunteeralongside healthawarenessservice.Thenewserviceincludes
theirworkcommitments. cancerscreening,trainingforstaff,communitycancer
awarenessevents,patientcounsellingandeducation
GenentechGoestoTownisacommunityrelations focusedonbreast,cervicalandprostatecancer.
projectsetupin1993.Genentechgivesemployees
25USdollarsworthofvoucherstospendinlocal More on the web
shopsovertwoweeks,encouragingthemtodevelop • Roche social programmes:
localbusinesses.Theprogrammehasspentmore www.roche.com/society
• Roche ’n’ Jazz: www.roche-n-jazz.net
than1.9millionUSdollarsinlocalshopssinceincep-
• Re & Act: http://react.roche.com
tion,withmorethan200businessesparticipating.
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 113 29012010 09:4352114
Roche Business Report 2009 Corporate Responsibility
Safety, security, health
and environmental protection
Safety,security,healthandenvironmentalprotection Wetrainemployeeswhohandlechemicalsaspartof
(SHE)arecriticalforourbusiness.WetakeSHE theirworktousethemproperlyandweprovide
intoconsiderationinallouractivities.TheRocheCor- safetydatasheetsforover1,000specificchemicals
poratePrinciplesandSHEPolicycommitustothe onourwebsite.
highestSHEstandards.In2009weinvested159mil-
lionSwissfrancsinSHEinfrastructureand294million WeholdourECOmpetitioneverythreeyearstoraise
SwissfrancsinSHEoperatingcosts. awarenessofenvironmentalissuesamongemployees
byencouragingthemtosuggestnewwaystoreduce
SHE management ourimpacts.The2009competition—ourfifth—elicited
A36-strongteamcoordinatesSHEwithinRoche.We morethan335proposalsfrom428peopleat46sites.
have680full-timeSHEemployeestoensureour The29winnersincluded:
performance.NewSHEOfficersattendedatraining • RochePaloAlto,US—retrofittingcoolingequip-
weektolearnaboutourSHEPolicy,strategy,Guide- menttoreplacehalogenatedhydrocarbon
linesandprocesses.AttendeesdiscussedRoche’s (HCFC)withhydrocarbonrefrigerants(propane
SHEresponsibilitiesandhowtoaccessrelevant orpropylene)
expertise.Theyalsolearnthowtoestablishandmain- • RocheJacarepaguá,Brazil—recoveringsolutions
tainariskmanagementsystemattheirsites.We fromtubingusingapolystyreneplugratherthan
heldregionalworkshopsforexistingSHEOfficerson waterandnitrogen
topicssuchasenergyefficiency,securityandindus- • ChugaiPharma,Japan—regeneratingemergency
trialhygiene. batteriesinuninterruptedpowersuppliesinstead
ofreplacingthem.
EveryoneatRocheisresponsibleforensuringhealth
andsafetyandforminimisingtheenvironmental TheannualRocheResponsibleCareAwardsencour-
impactsofouroperations.Weneedeveryonetounder- agesitestosuggestenergyefficiencyimprovements.
standourSHEstandards,soweoffersite-specific In2009,50submissionsfrom21sitesstoodout,
training,includinglecturesandpracticalcourses.We including:
havealsobegunabasicone-hourSHEe-learning • RocheBezares,Mexico—Solarboilersinstalled
moduleforallemployees.In2009,60,052employees toprovidehotwater
receivedanaverage2.7hoursofSHEtrainingeach. • RocheDiagnostics,US—Controlledlighting
duringquietperiods
ItisimportanttounderstandSHErisksacrossthe • RocheDiagnostics,India—Aspecialglassfaçade
business,sowecandeveloplocalsafetymeasuresas wasinstalledtosaveenergycosts.
wellasGroup-levelresponses.WelistallSHErisks
onaweb-basedinventoryaccessiblebyallmanagers Security
acrossthebusiness.Individualsitemanagersand WeappointedaCorporateSecurityOfficer(CSO)
SHEOfficersimplementtheSHEPolicyandGuide- in2007.In2009wesetupanetworkofmore
lineslocally.InthePharmaceuticalsandDiagnostics than100SiteSecurityOfficers(SSOs)andissued
Divisions,eco-delegatesraiseawarenessofenviron- aCorporateDirectivetodefinetheirresponsibilities,
mentalissues. aswellasoursecurityprinciplesandgeneral
processes.TheDirectivedescribesminimumstand-
WemonitortheimplementationoftheSHEPolicy ardstoprotectemployees,visitors,physicalassets,
usingregularsiteauditsandweusetheresults productsandbusiness-sensitiveinformation.
toimproveperformance.In2009weconducted
27audits,revealingnomajordeficienciesbut Wealsointroducedaglobalsecurityincident
highlightingtheneedtoupdatesiteriskanalyses. reportingtoolthatallowsSSOsandtheCSOtoanalyse
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 114 29012010 09:4353115
incidentsandestablishcorrectivemeasures.In2009 AGroup-levelbodyinvestigatessignificantSHE
wefocusedoncounterfeitproductsandpreventedthe incidentsandcommunicatestherelevantfindings
saleofsignificantquantitiesoffakeproducts. acrossthecompany,includingforuseintraining
programmes,wheresuitable.
Health and safety
TheRocheAccidentRate(RAR)measuresthe Environmental footprint
numberofworkingdayslostduetooccupational Ourenvironmentalfootprinttakesintoconsideration
accidentsperemployeeperyear. researchandproductionaswellasproductpackag-
ing,distribution,useanddisposal.
In2009theRARwas0.074.Thisrepresentsa5.9%
improvementfrom2008andiscomfortablybelowthe WeusetheSwissAgencyfortheEnvironment’s
0.079Groupgoalfor2010. (BAFU)‘eco-balance’methodtocalculateourenvi-
ronmentalfootprint.Itreflectsresourceuseas
Health and safety wellasemissionsandwaste.In2009oureco-balance
was4.6,animprovementof7.1%from2008.This
2009 2008 2007 reflectssignificantlyreducedemissionstoairand
Roche Accident Rate 0.074 0.078 0.076 organicmaterialsdischargedtowater.Weare
Occupational accidents 392 474 482 currentlyoperatingwithinourtargeteco-balanceof
Occupational illnesses 227 270 311 5.92for2015.
Work-related fatalities 0 0 1
Work-related accidents Wealsomeasureenvironmentalexpenditureinrela-
per million working tiontosalestohelpensurewetargetourinvestment
hours 2.92 3.42 3.46 intheareaswhereitwillhavethemostimpact.
ThecalculationgivesusanEco-EfficiencyRate(EER),
WeexpectcontractorswhoworkonRochepremises asshowninthetablebelow.Thiscombinesdata
tofollowthesamesafetyrulesasemployees. onenergyuse,waste,emissionstoairandwaterwith
Contractorswereinvolvedin152accidentsin2009 expenditureonenvironmentalprotectionandsales
(inadditiontothosereportedforemployees), (adetaileddefinitionisavailableontheRocheGroup
resultinginaninjuryfrequencyrateof1.32(accidents website).In2009ourEERwas84.02,animprove-
per100,000workinghours). mentof7.8%.
Employeessuffered227casesofoccupationalillnesses Eco-efficiency rate
in2009,adecreasefrom270in2008.Thenumber
ofworkingdayslostwas607—thesamelevelasin 2009 2008 2007
2008.Locomotordisorders,especiallyrepetitivestrain Sales (million CHF) 49,051 45,617 46,133
injuries,accountedformorethantwo-thirdsofthe Environmental expend-
total.Weworktoreducetheseinjuriesthroughlocal iture (million CHF) 186 209 232
ergonomicprogrammes,improvedofficeequipment Environmental damage
andindividualassessments.Genentech’sergonomics (millions of environ-
programmeaddressescumulativetraumaand mental damage units) 3,14 2.80 2.96
includesadedicatedtrainingwebsite.TheSouthSan EER 84.02 77.95 67.19
Franciscositehasthreeergonomicsshowrooms
allowingstafftotestproductsfortheoffice,plantand TheRocheEnvironmentalAwarenessinChemical
laboratory. Technology(REACT)programmepromotessustainable
chemistrypracticesinourR&Dlabsaroundtheworld.
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 115 29012010 09:4353116
Roche Business Report 2009 Corporate Responsibility
REACTsetssustainablechemistryguidelinesto Energy use by type | %
measurethebenefits.Forexample,theMassIntensity
Factormeasurestheratioofinputsofrawmaterials Fuel used by 11.1
againstoutputs,whilesolventselectionguidelineshelp company vehicles
employeeschooselessharmfulsolvents.Thepro- Oil 2.1
grammeaimsto:supportRoche’ssustainabilitygoals; Fuel due to business 15.2
sharebestpracticesaroundtheGroup;raise air travel
employeeawareness;increaserecognitionforR&D’s
sustainabilitywork;andreducecosts. Grid electricity 29.2
Energy and climate change
OurpositionpaperonGreenhouseGasesandClimate District heating 3.9
ChangeguidesourGroupstrategyfordecreasing Waste/ 0.9
emissions. Renewable energy
Natural gas 37.6
WeregularlyanalyseRoche’svulnerabilitytothe
changingclimate.Wehavenotidentifiedanysig-
nificantriskstoourbusinessfromclimatechange, sionsfactorsatsomesiteswhoseelectricityproviders
oranyspecificbusinessopportunities. recalculatedthelessemission-intensiveproportionof
theirenergymix.
Roche’senergyandfuelusein2009totalled
13,898terajoules,anincreaseof1.7%from2008.This Greenhouse gas emissions | tonnes CO equivalent
2
ismainlyduetotheinclusionofGenentech’scar
fleetforthefirsttime.Energyuseisapproximately 2009 2008 2007
176gigajoulesperemployee,asmalldecreasesince Total emissions 1,053,118 1,062,114 1,052,407
2008. Total emissions
per million CHF
Energy use | terajoules of sales 21.47 23.28 22.81
2009 2008 2007 The7.8%reductioninemissionsinrelationtosales
Total energy use 13,898 13,662 13,664 showsthatRocheisreducingenergyusewhilethe
Total energy use businessgrows.
per million CHF of sales 0.283 0.299 0.296
Total energy use In2009wedevelopedastandardforintegrating
per employee 0.176 0.178 0.179 energyefficiencymanagementintobuildingprojects.
ThisaccompaniedanewGroup-wideManualon
Ourclimatestrategyfocusesonenergyuse,which EnergyEfficientDesign,whichwillhelpusdesign
accountsformostofourcarbondioxide(CO )emis- futurefacilitiesandrefurbishedbuildingstominimise
2
sions.WeconvertamountsofCO andothergreen- energyuse.
2
housegas(GHG)emissionssuchashalogenated
hydrocarbonsleakingfromrefrigerationequipment Milanhasaproblem—itisoneofthemostpolluted
intoCO-equivalents.In2009weemitted1,053thou- citiesinEurope.Smogisatarecordlevel,farabove
2
sandtonnesofCO-equivalents,anabsolutedecrease EuropeanUnionlimits.RocheMonza(Italy)began
2
of0.8%from2008.Thisreductioncomesdespite aprogrammetoreduceitsenvironmentalimpactsin
increasedenergyconsumptionduetorevisedemis- 2007bymodifyingtransport,increasingrecyclingand
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 116 29012010 09:4353117
Reduce total energy consumption and
greenhouse gas emissions
Energy use by selected types 2009
10% Fuel used by company vehicles
IntroducedanewtargetforourEuropeancom-
panycarfleettoincludeonlyvehiclesproducing
nomorethan120gramsofcarbondioxide(CO)
2
perkilometrebytheendof2011.
15% Fuel due to business air travel
Videoandteleconferencingfacilitieshavebeen
establishedatallsitesandarewidelysupported.
Employeesareencouragedtousetrainsand
toconsolidateseveralbusinesstripsintoone.
30% Grid electricity and natural gas
Ourfirstpriorityistoreduceusageofenergy.
Fortheenergywedousewelookforwaysof
improvingtheefficiency,suchasheatrecovery.
Inadditionweencouragetheuseofgreen
energywhereversensible.Tohelpdrivethisin
2009wereleasedourGroup-wideManual
40%
onEnergyEfficientDesignfortheconstruction
offuturefacilitiesthatminimiseenergyuse.
reducingenergyusethroughsensorlightsand Genentechmetitsown2010GHGemissionsreduction
energy-savinglightbulbs.In2009thesiteincreased goaltwoyearsaheadofschedule.Itwillnowjointhe
itsfocus.Lifegate,anexternalenvironmentalorgani- restofRoche’sUSaffiliatesinpursuinganewgoalof
sationbasedinMonza,nowmonitorsenergyand decreasingemissionsby13%by2013.
wateruse,wastedisposal,logisticsandemployee
transport.Thesitehasalsostartedbuying10%ofits RochehasaGroupdirectiveonenergyconservation
energyfromrenewablesources.Inaddition,aninter- whichpromoteslocalinitiatives.Itincludesenergy
nalawarenesscampaignhasencouragedemployees efficiencystandardsfornewandexistingelectrical
togetinvolvedinenergy-savinginitiatives.Sofar, equipmentandrequiressitestoconductenergy
thesitehasreducedCO emissionsbyaround45%. audits.
2
TheUSEnvironmentalProtectionAgency(EPA)has The2009auditsidentifiedopportunitiestoimprove
commendedourUSaffiliatesformeetingtheirgoalto ourbuildings,utilities,plantsandprocesses,including
reduceGHGemissionsby18%between2001and thoseatGenentech.Theseincludeimprovedmetering
2010aheadoftime.RocheUShaspledgedtoreduce andmonitoring,retro-commissioningbuildings
emissionsbyafurther13%from2008to2013. andadaptinglightingandair-conditioningsystems.
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 117 29012010 09:4355118
Roche Business Report 2009 Corporate Responsibility
Despitethesecentralfunctions,wegivesitesthe Ozone depletion
freedomtodeveloptheirownemissionsreduction ThetargetdateforRoche’sdirectivetophaseout
strategies.Webelievethisapproachimprovesresults halogenatedhydrocarbons(CFCsandHCFCs),which
becausesitesaremorefamiliarwiththeirownneeds damagetheozonelayerandaffecttheclimate,has
andcircumstances.Forexample,RocheShanghai beenextendedfrom2010to2012or2015,depending
hasanongoingprojecttoincreaseenergyefficiency. onthelocalsituation.Thisisduetoalackofaccepted
Theprogrammehasseentheintroductionoftriple alternativesinsomecountries.Genentechhasnot
anddoubleglazing,optimalinsulation,geothermal yetdefinedatargetdate,butiscommittedtophasing
heatingandcooling,low-powerenergysystemsand thesegasesout.
solarwaterheating.
ReplacementsforHCFCsandCFCs,suchasHFCs
Businesstravelaccountsforapproximately15.2%of (hydrofluorocarbons)andPFCs(perfluorinated
ourtotalCO emissionsoverallandourcarfleetis carbons),donotaffecttheozonelayerbuttheycan
2
responsibleforapproximately11.1%.Employeesare contributetoclimatechangeandarepersistentin
encouragedtousetrainswhentravelisnecessary theenvironment,sowedonotconsiderthemalong-
andtoconsolidateseveralbusinesstripsintoone. termalternative.Rochehasatargettophaseout
Videoandteleconferencingfacilitiesalsohelpusmini- HFCsandPFCsby2015.Genentechandotherrecent
misetravel.Forexample,RocheFinlandworkedwith acquisitionswillworktoaseparatedeadline,tobe
WWFFinlandtohosttheAmericanSocietyofClinical definedin2010.Sometechnicalproblemscontinueto
Oncology’sannualmeetingvirtually.InJune2009 preventusfromreplacingtheseinallapplications,
around180customersattendedtheconferencefrom butweareworkingtofindalternativetechnologies.
theirclinics,participatingthroughvideostreaming.
SeveralsitesnowuseTelepresence®systems,which Ozone-depleting chemicals | tonnes
significantlyimprovethequalityofvideoconferencing,
encouragingincreasedusage. 2009 2008 2007
Halogenated
AnewtargetforourEuropeancompanycarfleet hydrocarbons holdings 179.8 144.6 148.2
aimstoensurewewillusevehiclesproducingnomore Halogenated
than120grammesofCO perkilometrebytheend hydrocarbons
2
of2011.ThiswillcutCO emissionsby5,400tonnes emissions 6.5 3.4 4.7
2
andsavetwomillionlitresoffuelperyear.
Roche’shalogenatedhydrocarbonsinventoryincreased
Anumberofsiteshavelaunchedinitiativestoencour- 24.3%in2009duetotheintroductionofGenentech’s
agestaffnottouseprivatecarstocommutetowork. holdingstotheGrouptotal.Withoutthisincrease,
AtGenentech,forexample,thegRideprogrammehas Roche’sholdingswouldhavedecreased6%.
promotedalternativessuchasvanpooling,mass
transit,cycling,walkingandGenenbusshuttlessince Emissions to air
2006.Theshuttleswereupdatedin2009withnewer, Emissionstoairfromouroperationsincludevolatile
moreefficientmodelsthatmeettheUSEPA’s2007 organiccompounds(VOCs),particulates,nitrogen
standardforparticulateemissions.AtRotkreuz, oxides(NO)andsulphurdioxide(SO ).Weaim
x 2
Switzerland,wehaveintroducedanannualbonusof toreducetheseemissions,whichcancontributeto
360Swissfrancsforstaffwhocommutetowork airpollution,smogandacidrain.In2009wereduced
withoutusingacarormotorbike. VOCemissionsby16.9%to177tonnes.Ouremis-
sionsofparticulates,NO andSO were27tonnes,
x 2
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 118 29012010 09:4355119
286tonnes,and9tonnes,respectively.Thesefluctuate Wemonitorlandfillsitestoensureourchemicalwaste
atlowlevelsfromyeartoyear. doesnotposearisktohumanhealthortheenviron-
ment.Somelandfillsneedtobesustainablyremedi-
Emissions to air | tonnes ated.In2009wecompletedaprojecttoremediatethe
HirschackerlandfillinGrenzach,Germany.Roche
2009 2008 2007 voluntarilyfinancedthisproject.In2009wemade
VOCs 177 213 240 availableapproximately247millionSwissfrancsfor
Particulates 27 27 25 othersuchprojects.
Nitrogen oxides 286 193 169
Sulphur dioxide 9 10 12 Water
Weneedcleanwaterformanufacturing,butwe
Waste understandtheneedtoreduceourwateruse.Based
Around96%ofourchemicalwasteisincinerated, ontheGlobalReportingInitiative’sdefinitionof
thedisposalmethodwiththeleastenvironmental waterconsumption(waterusedinproducts,cooling,
impact.In2009weproduced27,605tonnesofchemi- andirrigation),ouruseincreasedby16.3%.We
calwaste,an11.8%decreasefrom2008.Thisdoes used2.8millionm3ofwaterin2009.
notincludewastethatcanbereusedasrawmaterials
byothercompanies.In2009wesoldaround Thewaterweusecanbecontaminatedduringmanu-
4,000tonnes(mostlysolvents)forreuse. facturing,sowetreatwastewatertoensureitis
safeforpeopleandtheenvironment.Wecontinueto
In2008weengagedinsignificantbuildingactiv- developwaystoincreaseourcapacitytotreatwaste-
ity,while2009wascharacterisedbybuilding wateraroundtheGroup.
demolition.Wegenerated53.7%lessgeneralwaste
(19,828tonnes)butourrecyclingratesincreased OneofthewinningsubmissionsofECOmpetition2009
374%,dueto104,817tonnesofbuildingrubblemade camefromRochePenzberg,Germany.Thesubmission
availableforrecycling(mostlymetalsandconcrete outlinesaproposaltouseresidualwaterfromthe
soldtoothercompaniesforreuse).Excludingthis distillationofpurifiedwatertogeneratesteamforthe
buildingrubblewerecycled30,671tonnes,7.3% plant’sboiler.
morethanlastyear.Wedecreasedgeneralwastesent
tolandfillby63.6%.31%ofthetotal19,828twere In2009wedecreasedtheamountoforganicmaterial
incinerated. dischargedintowatercoursesaftertreatmentby
74%to154tonnes.Thisismainlyduetoarecalcula-
Waste | tonnes tionofdatafromtwositesbecauseinvestigationsinto
differencesatsimilarsitesrevealedthattheyhad
2009 2008 2007 over-reportedinpreviousyears.Wealsoreleased
General waste 426kilogramsofheavymetalssuchaschromium,
produced 19,828 42,823 17,480 copperandzinc,21.8%lessthanin2008.
General waste
per million CHF Ournewgoaltoreducetoxicityofdischarged
of sales 0.4 0.94 0.38 wastewaterreflectsthegenerallylowertoxicityof
Chemical waste organicmatterfrombiotechoperationsthanfrom
produced 27,605 31,295 38,167 chemicalproduction.
Chemical waste
per million CHF
of sales 0.56 0.69 0.83
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 119 29012010 09:4355120
Roche Business Report 2009 Corporate Responsibility
Water Compliance and incidents
RochedidnotreceiveanysignificantSHEfinesin2009.
2009 2008 2007 Wemeetalllocallawsorregulationsasaminimum.
Water withdrawn However,ourGrouppoliciesareoftenstricterthan
(million cubic metres) 18.6 21.0 21.0 these.Wecontrolsubstancesthatcouldbemisused
Water used toproducenarcotics,toxinsorchemicalandbio
(million cubic metres) 2.8 2.4 2.3 weapons.Thesesubstances,whichwekeepinsmall
Wastewater discharged supply,areoftenregulatedandweensurecompliance
to treatment plant withallapplicablelegislation.
(million cubic metres) 5.2 7.3 7.1
Organic matter 2010 objectives
discharged to • ReducetheRocheAccidentRateby20%by2010
watercourses fromthe2005baseline
after treatment (tonnes) 154 592 641 • Improvetotaleco-balanceby10%by2015from
Heavy metals 2005baseline(points/employee)
discharged to • Reducetotalenergyconsumptionby10%by2010
watercourses after from2005baseline(gigajoules/employee)
treatment • ReceivenosignificantSHE-relatedfines.
(kilogrammes) 426 545 605
Medium- and long-term objectives
Pharmaceuticals in the environment (PiE) • AveragefourhoursofSHEtrainingperemployee
Tracesofpharmaceuticalproductsendupintheenvi- • ReducetheRocheAccidentRate(RAR)to0.07
ronment,raisingfearsthattheymaylaterbefoundin andwork-relatedaccidentspermillionworking
foodandwatersources.Thisisusuallyduetonormal hourstobelow3by2015
patientuse,althoughmanufacturingandimproper • Improveoureco-balanceby15%by2020,from
disposalalsocontribute.Weofferretailersfinancial a2010baseline
incentivestoreturnunusedoroldproductssowecan • Improveenergyefficiency(measuredasgigajoule
discardthemproperly.Weanalysetheriskofpharma- peremployee)by10%by2014and20%by2019
ceuticalsenteringtheenvironmentinourlife-cycle comparedwith2009
approachtoproductdevelopment,minimising • Increasetheproportionofrenewableenergyused
releaseswherepossible.Manufacturingsitesare to20%by2020
designedandoperatedtoreduceactiveingredients • Reducethetoxicityofdischargedwastewaterby
enteringwastewater. 20%by2020froma2015baseline.
Althoughcurrentevidencesuggestslittlepresenceof More on the web
PiE,werecognisetheneedformoreresearchinto • SHE performance:
long-termeffects.In2009weundertookathorough www.roche.com/she_performance
• Safety, security, health and environmental protection:
riskassessmentoftheactiveingredientoseltamivir
www.roche.com/environment
(Tamiflu)beingexcretedintotheenvironmentduring • Safety, security, health and environmental protection (SHE)
heavypandemicuse.Theassessmentfoundno signifi- Policy:
cantrisk.Our2008positionpaperonPiEdescribes www.roche.com/safety_health_and_environmental_
protection.pdf
ouraimtomonitorrisksandRocheisamemberof
• Group fact sheets, positions, policies and guidelines:
internationalandlocalbodiesstudyingtheimpactsof www.roche.com/policies_guidelines_and_positions
tracechemicalsinsurfaceandgroundwater. • Genentech sustainability report:
www.gene.com/gene/about/environmental/
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 120 29012010 09:4355121
Independent Assurance Report
TotheCorporateSustainabilityCommitteeof TheRocheCorporateSustainabilityCommitteeisresponsible
RocheHoldingLtd,Basel(‘Roche’). forboththesubjectmatterandthecriteria.Ourresponsibilityis
toprovideaconclusiononthesubjectmatterbasedon
Wehaveperformedassuranceprocedurestoprovideassurance ourassuranceproceduresinaccordancewiththeInternational
onthefollowingaspectsofthe2009corporateresponsibility StandardonAssuranceEngagements(ISAE)3000.
reportingofRoche.
Main assurance procedures
Subject matter Ourassuranceproceduresincludedthefollowingwork:
Dataandinformationdisclosedinthecorporateresponsibility • Evaluation of the application of Group guidelines |
reportingofRocheanditsconsolidatedsubsidiaries,excluding ReviewingtheapplicationoftheRocheinternalcorporate
ChugaiPharmaceuticalCo.,Ltd.,forthebusinessyearended responsibilityreportingguidelines;
December31,2009onthefollowingaspects: • Site visits | VisitingselectedsitesofRoche’sPharmaceuti-
• Themanagementandreportingprocesseswithrespectto calsandDiagnosticsDivisionsinSwitzerland,Germany,
thecorporateresponsibilityreportingandtothepreparation France,Spain,ItalyandChina.Theselectionwasbasedon
ofSHEandpeoplekeyfiguresaswellasthecontrol quantitativeandqualitativecriteria;
environmentinrelationtothedataaggregationofthese Interviewingpersonnelresponsibleforcompliancematters,
keyfigures; internalcorporateresponsibilityreportinganddata
• TheSHEkeyfiguresinthetablesonpages114to120and collectionatthesiteswevisitedandattheGrouplevelto
someselectedpeoplekeyfiguresdisclosedonpages104 determinetheunderstandingandapplicationofRoche
to111oftheRocheAnnualReport2009;and internalcorporateresponsibilityguidelines;
• Complianceinformationconcerningthecompliance VisitingthepremisesofPeopleIntouchinAmsterdam.
functions,thecomplianceorganisationandthemanagement InterviewswithPeopleIntouchstaffinvolvedindesign,
ofcasesreportedthroughtheRocheGroupSpeakUpLine, implementationandoperationsoftheSpeakUpsolution.
thelatterwithafocusondataprivacyandprotectionof • Assessment of the key figures | Performingtestson
individual’sanonymityasdisclosedonpage92oftheRoche asamplebasisofevidencesupportingselectedSHEand
AnnualReport2009,excludingethicalincidentdata. peoplekeyfigures(Rocheaccidentrate,energyconsump-
tion,CO emissionsrelatedtoenergyconsumption,release
2
Criteria ofhalogenatedhydrocarbons,useofwater,finesinrelation
• TheRocheGroupinternalcorporateresponsibilityreporting tosafetyandenvironmentalprotection,headcount/FTEdata,
guidelinesbasedontheResponsibleCareprogramme staffturnover,seniormanagementpositionsandlabor
Health,SafetyandEnvironmentalProtectionreporting practicesinformation)concerningcompleteness,accuracy,
guidelinespublishedbytheEuropeanChemicalIndustry adequacyandconsistency;
CouncilCEFICandthe‘SustainabilityReportingGuidelines • Review of the documentation and analysis of relevant
G3’publishedonOctober2006bytheGlobalReporting policies and basic principles | Reviewingtherelevant
Initiative(GRI);and documentationonasamplebasis,includinggroupsustain-
• ThedefinedproceduresbywhichSHEandpeoplekey abilitypolicies,managementandreportingstructuresand
figuresaregathered,collatedandaggregatedinternally. documentation.
• TheRocheGroupbusinessprinciples,theinternalGroup • Assessment of the processes and data con solidation |
SpeakUpguidelinesbasedonthedirectiveonuseof Reviewingtheappropriatenessofthemanagementand
RocheGroupSpeakUpLineandgoodpracticeprocedures reportingprocessesforcorporateresponsibilityreporting;
bywhichcompliancefunctionsandspeakuplinesare andAssessingtheconsolidationprocessofdataatthe
designed,managedandoperated. grouplevel.
• Assessment of speak-up processes and systems
Responsibility and methodology (case management) | Walkthroughthespeakupprocess
Theaccuracyandcompletenessofcorporateresponsibilityindi- byusingapracticalexampleandassessingthefollowing:
catorsaresubjecttoinherentlimitationsgiventheirnatureand protectionagainstunauthorisedaccess;connectionsand
methodsfordetermining,calculatingandestimatingsuchdata. processestoexternalserviceprovidersandexternal
Ourassurancereportshouldthereforebereadinconnection businesspartners;processesinplaceforadministration,
withRoche’sinternalguidelines,definitionsandprocedureson logging,monitoringandbackup/restoreallinrelationtothe
thereportingofitscorporateresponsibilityperformance. dataprivacyandanonymity.
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 121 29012010 09:4355122
Roche Business Report 2009 Independent Assurance Report
Conclusions The Global Reporting
Inouropinion
Initiative sustainability
• Theinternalcorporateresponsibilityreportingguidelinesare
beingappliedproperly; reporting guidelines
• TheinternalreportingsystemtocollectandaggregateSHE
andpeoplekeyfiguresisfunctioningasdesignedand
Withthisyears’AnnualReportwecontinueourapproachof
providesanappropriatebasisforitsdisclosure;and
aligningoursustainabilityreportingtotheguidelinesofthe
• TheRocheGroupSpeakUpLinesystemsandprocessesare
GlobalReportingInitiative(GRI).
designedfollowinggoodpracticeprocedureswithregardto
dataprivacyandanonymity.
Forthethirdtime,RocheisoftheopinionthattheA+level
oftheGRIG3guidelinesappliestoitsAnnualReport2009.
Basedonourworkdescribedinthisreportandtheassessment
ThiswascheckedwithandconfirmedbytheGRI.
ofcriteria,nothinghascometoourattentionthatcausesusto
believethatthedataandinformationmentionedinthesubject
Detailsofhowwereportagainsteachindicatorcanbefound
matteranddisclosedwiththeSustainabilityReportingin
atwww.roche.com/reporting_and_indices
theRocheAnnualReport2009,excludingethicalincidentdata
doesnotgiveafairpictureofRoche’sperformance.
Zurich,19January2010
PricewaterhouseCoopersAG
DrThomasScheiwiller StephanHirschi
SeverinSchwan
15_L_Roche_AR09_ENG_Corporate Responsibility Part2indd 122 29012010 09:4356Published by Cautionary statement regarding forward-looking
F. Hoffmann-La Roche Ltd statements
4070 Basel, Switzerland This Annual Report contains certain forward-looking state-
Tel. +41 (0)61 688 11 11 ments. These forward-looking statements may be identified
Fax +41 (0)61 691 93 91 by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’,
‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar
expressions or by discussion of, among other things, strategy,
Media Office
goals, plans or intentions. Various factors may cause actual
Group Communications
results to differ materially in the future from those reflected in
4070 Basel, Switzerland
forward-looking statements contained in this Annual Report,
Tel. +41 (0)61 688 88 88 among others: (1) pricing and product initiatives of competi-
Fax +41 (0)61 688 27 75 tors; (2) legislative and regulatory developments and eco-
nomic conditions; (3) delay or inability in obtaining regulatory
Investor Relations approvals or bringing products to market; (4) fluctuations in
currency exchange rates and general financial market condi-
4070 Basel, Switzerland
tions; (5) uncertainties in the discovery, development or
Tel. +41 (0)61 688 88 80
marketing of new products or new uses of existing products,
Fax +41 (0)61 691 00 14
including without limitation negative results of clinical trials
or research projects, unexpected side effects of pipeline or
World Wide Web marketed products; (6) increased government pricing pres-
www.roche.com sures; (7) interruptions in production; (8) loss of or inability
to obtain adequate protection for intellectual property rights;
Corporate Sustainability Committee (9) litigation; (10) loss of key executives or other employees;
and (11) adverse publicity and news coverage.
Tel. +41 (0)61 688 40 18
E-mail: corporate.sustainability@roche.com
The statement regarding earnings per share growth is not
a profit forecast and should not be interpreted to mean
To order publications
that Roche’s earnings or earnings per share for 2009 or any
Tel. +41 (0)61 688 83 39 subsequent period will necessarily match or exceed the
Fax +41 (0)61 688 43 43 historical published earnings or earnings per share of Roche.
E-mail: basel.webmaster@roche.com
All trademarks mentioned enjoy legal protection.
Next Annual General Meeting:
Links to third party pages are provided for convenience only.
2 March 2010
We do not express any opinion on the content of any third
party pages and expressly disclaim any liability for all third
party information and the use of it.
The Roche Annual Report is published in German and English.
Printed on non-chlorine bleached, FSC-certified paper.
The Roche Annual Report is issued by
F. Hoffmann-La Roche Ltd, Basel, Group Communications.
The cover photograph shows a ribbon diagram
of rituximab, the therapeutic protein at the
heart of MabThera/Rituxan. This targeted bio-
logic medicine is used to treat non-Hodgkin’s
lymphoma, chronic lymphocytic leukemia and
rheumatoid arthritis.
16_L_Roche_AR09_ENG_Imprint.indd 117 29.01.2010 11:24:507 000 844 E
Roche
|
Annual
Report
2009
10
Key figures
1 Key figures indexed to 2007 = 100. Figures for 2007 as in Annual Report 2008.
2 Before exceptional items. For a full index of Global Reporting Initiative (GRI)
3 Proposed by the Board of Directors. indicators used in the report see:
4 Development phase I to IV. www.roche.com/reporting_and_indices
5 For calculation of the Eco-Efficiency Rate see:
www.roche.com/environment
E
00_L_Roche_AR09_ENG_Key figures.indd 1 29.01.2010 14:20:10
Roche
|
Finance
Report
2009
0 FR1 2H0Y0R9 2E0N0G9 CEoNvGe rC o v2e8r. 1 .2210.170. 2 01079: 4 51 4U:h3r9 USheri t eS e1ite 1
0099
RRoocchhee AFinnnaunacle R Reeppoortrt
F.HoPfufmbalinshn-eLda bRyoche Ltd
4070F .BHaosfefml, aSnwnit-zLear lRanodche Ltd
4070 Basel, Switzerland
© 2010
© 2009
AAllll ttrraaddeemmaarrkkss mareen lteiognaellyd pernojtoeyc lteegda.l protection.
All trademarks mentioned enjoy legal protection.
www.roche.com
Roche Half-Year Report 2009
www.roche.com
Leading in biotechnology.
Improving patient care.
Excellence in Science
70007 8 04060 827
00_Umschlag_ausgeschossen_ENG.indd 1 00_L_Roche_AR09_ENG_Front Cover.indd 1 29.01.2010 14:11:18 29.01.2010 14:20:50